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Pactamycin was isolated in 1961 by the former UpJohn Company and to date is the 
most complex aminocyclopentinol known. This natural metabolite is decorated by six 
contiguous stereocenters, three of which are quaternary, with each position of the 
cyclopentane core functionalized. Biological testing has further revealed that pactamycin 
exhibits activity in every phylogenetic domain.  
Pactamycin’s activity arises from its ability to bind the E-site via a unique pi-stacking 
interaction within the ribosome which precludes protein synthesis and ultimately leads to 
cell death. Generating a less potent pharmacophore could lead to antineoplastic agents, 
antimalarials, and/or antibiotics due to the highly conserved nature of the ribosome. We 
have developed a short modular synthesis predicated upon producing analogs that peturb 
this pi-stacking network. From this sequence we have synthesized the highly complex 
oxygenated core of pactamycin using a diastereoselective epoxide-opening cascade 
reaction in 11 steps and in 4.2% overall yield. Our synthetic sequence further allows us to 
design analogs that contain the requisite di-aryl system by intercepting several advanced 
intermediates.  
Pathogenic bacteria have been responsible for countless infections and deaths. 
Clinicians and researchers alike have developed effective management strategies for these 
infections with the implementation of antibiotics and sterility measures. However, the 
community is facing a new problem with higher incidences of bacterial resistance. 
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Additionally, certain pathogenic colonies can aggregate together and begin to produce 
a protective coating know as a biofilm, consisting of amino acids, polysaccharides, and  
deoxyribonucleic acid (DNA) which safeguards them from perturbation by temperature, 
salinity, pH, and most importantly antibiotics.  
Biofilms have emerged as a new target for infection control. However, killing the 
bacteria associated with the biofilm does not always remove the protective film. The 
resulting nutrient-rich environment provides a surface for additional bacteria to proliferate 
on. We realized that in order to develop an effective antibiofilm antibiotic, the compound 
must act in dual-fold manner, both killing the bacteria and dispersing the associated 
extracellular biofilm matrix.  
We recognized membrane-active antibiotics like daptomycin as a useful platform for 
developing our library. Adding various known polyamino-motif biofilm dispersants to 
these membrane active mimics provided a unique combination which allowed our 
compounds to be active against both planktonic bacteria as well as biofilm-forming species. 
These polyamine-functionalized scaffolds were effective at clearing biofilms generated by 
multiple species of bacteria. To date, the modular construction of these antibiofilm 
antibiotics has allowed us to produce a comprehensive library of over 200 active 
compounds. Furthermore, our efforts have resulted in the generation of several lead 
compounds that are noncytotoxic, nonhemolytic, yet retain competent bactericidal and 
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SYNTHETIC EFFORTS TOWARD THE TOTAL  
SYNTHESIS OF PACTAMYCIN USING A  




Pactamycin (pac) was isolated by scientists at the former Upjohn Company in 1961 
from a fermentation broth of Streptomyces pactum var. pactum.1 Initial structural 
investigation was accomplished using chemical degradation in 1970 which provided 
evidence for the trans C4-C5 diol and cis C1-C2 amines; the structure of pac was further 
verified by X-ray crystallographic analysis in 1972, which revealed and established the 
correct structure and absolute stereochemistry (Figure 1.1).2 In biological tests, pac was 
found to have activity against every phylogenetic domain (archaea, eukaryota, bacteria). 
Nanomolar cytotoxicity was observed in eukaryotic cells (KB, IC50 = 5.3 nM; MCR-5, IC50 
= 53 nM; HCT116 IC50 ≈ 100 nM).3,4 Pac has also shown activity against both Gram-
positive and Gram-negative bacteria and recently was shown active against Plasmodium 
falciparum (IC50 = 14.0 nM) and Trypanosoma brucei (IC50 = 7.0 nM).3 
Elegant X-ray crystallographic studies have determined pac to be an inhibitor of the 
highly conserved ribosomal E-site, the third and final binding site for t-RNA during protein 
synthesis.  Bound  mRNA  occupies  the  pocket  shown  below  (Figure 1.2a)  interacting
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with ribosomal domains H28, H23b, H24a, and the c-terminus of protein S7. However, 
when pac is involved, it can also bind to the E-site facilitated through the pi-stacking of the 
two aromatic subunits (Figure 1.2b), mimicking two nucleotides, which subsequently 
prevents mRNA from entering (Figure 1.2c). This strong interaction prevents mRNA from 
entering the E-site which then causes an inhibition in protein synthesis and eventually leads 
to cell death.5, 6, 7 
Due to its broad spectrum activity, owing to the highly conserved nature of the E-site 
it was once thought the development of pac as an efficacious drug candidate was severely 
limited. However, recent, studies published by the Mahmud group demonstrated that 
biosynthetic analogs of pac specifically TM-025 (2) and TM-026 (3) (Figure 1.3a) have 
diminished eukaryotic cytotoxicity while retaining activity against both chloroquine 
resistant and chloroquine sensitive Plasmodium falciparum. 4 Related natural products 7-
deoxypactamycin (4)8 and jogyamycin (5) (Figure 1.3b) show similar structural changes 
albeit with increased eukaryotic cytotoxicity.9 These studies did not investigate the 
mechanism of action and therefore did not confirm that these analogs were binding the E-
site of the ribosome. However, they did provide evidence that small structural changes to 
the scaffold of this highly complex aminocylopentanol can result in dramatic shifts in 
biological data.  
Architecturally, pac is an exceptionally complex molecule, decorated by three 
quaternary centers, six contiguous stereocenters, and a cyclopentane core with every 
position functionalized. In addition, it contains a salicylate, a urea, an aniline, a 1,2-diol, 
and a 1,2-trans diamine (Figure 1.1). To date, no aminocyclopentanol has been discovered 




Pac’s intriguing and unique structure along with its interesting biological profile has 
attracted several partial and total syntheses’. Chronologically, the Isobe group was the first 
to report a partial synthesis in 2005 culminating with a unique Pauson-Khand reaction to 
produce the cyclopentane core of pac.10 The Knapp group carried out a stereoselective 
partial synthesis in 2007 using a tethered-nitrogen Michael addition to functionalize their 
cyclopentane core.11 In 2011, pac finally succumbed to total synthesis, 50 years after 
discovery, by the Hannensian group in which Hanessian was able to carefully introduce 
the functional groups present on pac through a modular process starting from L-threonine.12  
Alternate semisyntheses were published in 2012 by Looper13 and Johnson.14 In 2013, 
Johnson further demonstrated his interest by publishing the shortest linear synthetic 
sequence to pac in 15 steps with overall yield of 1.9% through which C1, C2, C3, C4, C5, 
and C7 (Figure 1.1) were all prepared simultaneously by an enantioselective Mannich 
reaction.15 
 
1.2 Isobe’s Partial Synthesis of Pac 
The Isobe group was the first to publish chemistry en route to pac. Their synthesis used 
a Pauson Khand reaction, developed by their group, to assemble the five-membered 
cyclopentane ring present in the natural product.16 Starting from diacetone D-glucose 6, 
oxidation of the free alcohol followed by a Wittig/reduction sequence produced the allylic 
alcohol 7 (Scheme 1.1). Attachment of a labile allylic trichloroacetimidate produced 8. A 
subsequent Overman rearrangement afforded 9 as a single product whose structure was 
confirmed by two-dimensional NMR analysis. Ozonolysis of 9 and nucleophilic addition 
with methylmagnesium bromide yielded secondary alcohol 10.10  




natural product through an Albright and Goldman oxidation followed by a Luche reduction 
to afford alcohol 11 (Scheme 1.2). Treatment of 11 with 1,8-diazabicycloundec-7-ene 
(DBU) provided the corresponding oxazolidinone 12. Following benzyl amine formation 
selective deprotection and deoxygenation of the terminal acetonide gave the allyl-acetonide 
14. The remaining internal acetonide was hydrolyzed with TFA to afford the 
correseponding hemi-acetal. Reduction and oxidative cleavage gave the hydroxyl aldehyde 
15.10  
TMS-acetylide mediated alkynylation yielded the enyne 16 (Scheme 1.3) ready for the 
key Pauson-Khand reaction. Unfortunately, attempts at treating enyne 16 with Co2(CO)8 
resulted in an inseparable mixture of diastereomers. To their satisfaction, treatment of the 
crude material 17 with acetic anhydride produced the diacetate 18 as the major product 
which was easily separated by column chromatography. Isobe concluded his synthesis with 
formation of the parent five-membered ring. Highlighted by a very efficacious Pauson-
Khand reaction, the Isobe group developed a unique route to the core of pac from 
diacetone-D-glucose. The final tricycle 18 possessed all the necessary functionalities for 
further functionalization.10 
Isobe was able to construct the core cyclopentane of pac in 20 steps from diacetone D-
glucose. Using a unique Pauson-Khand reaction, the final product possessed the requisite 
chemical information for introduction of the remaining functional groups present on pac.10 
 
1.3 Knapp’s Partial Synthesis of Pac 
In 2007, the Knapp group was able to synthetize a complex oxygenated intermediate 
en route to pac. Their synthetic sequence used a number of stereoelectronic tactics for 




cyclopenten-1-one 19, an enatioselective Corey-Bakshi-Shibata (CBS) reduction afforded 
the alcohol 20 (Scheme 1.4).  Silyl protection with TBS produced the silyl ether 21 which 
was immediately converted to the diol 22 with an osmium-promoted dihydroxylation. 
Subsequent Swern oxidation of the unprotected secondary alcohol gave the highly 
functionalized α-hydroxy-ketone 23 in four trivial steps from 19. A Wittig reaction on the 
pendent ketone 23 produced olefin 24. Peroxy acid oxidation with m-CPBA afforded 
epoxide 25. In a two-step sequence of isomerization (via base-mediated epoxide opening 
to produce diol 26) followed by bezolyation they were able to produce the benzolyated 
olefin 27.11 
With the ene-protected-triol 27 in hand, stereoselective epoxidation would properly 
introduce the requisite stereochemistry at C4. To this end, selective silyl group protection 
of the tertiary alcohol followed by selective deprotection afforded the diol 29 (Scheme 1.5). 
Further peroxy acid oxidation delivered epoxide 30 appropriately via the Hanbest 
interaction with O1. Epoxide 30 was then oxidized under mild basic conditions to produce 
the corresponding α-β unsaturated ketone 31. The epoxide ring was opened during this 
synthetic step to produce to the tertiary alcohol at C4. Delivering the nitrogen to C3 was 
accomplished via a tethered 1,4 addition of 2-nitrobenzenesulfonylisocyanate to enone 31 
which produced oxazolidinone 32 as a single stereoisomer. Installation of the final methine 
carbon on C1 was accomplished via a vinyl-triflate-mediated palladium coupling. To 
generate the precursor, ketone 32 was converted to the vinyl triflate 33, with the addition 
of the hindered phosphazane base 2-tert-Butylimino-2-diethylamino-1,3-
dimethylperhydro-1,3,2-diazaphosphorine (BEMP).  Palladium-assisted coupling of 




hydrolysis of enol ether 34 generated the final oxygenated core 35.11 
Knapp prepared his final oxygenated compound in 16 overall steps from a nonchiral 
starting material using the well precedented Corey-Bakshi-Shibata (CBS) reduction to 
impart chirality.11  
 
1.4 Johnson’s Partial Synthesis of Pac 
Johnson’s partial synthesis envisaged using an advanced acyclic intermediate to 
generate stereochemistry through a modified enantioselective Tsuji-Trost allylation. The 
cyclopentane ring was then to be constructed by a late stage methasis. Starting from 
methylacetoacetate 36, diazo transfer with p-acetamidobenzenesulfonyl azide afforded the 
corresponding diazo-keto-ester 37 (Scheme 1.6). A Rh-catalyzed N-H insertion further 
installed the dimethyl urea on C1 to yield urea 38. Given the low pKa of the α-carbon, 
Johnson could now install the allyl group through modified Tsuji-Trost conditions 
developed by Ito and coworkers. Initially the synthetic design relied on forming the 
racemate of the urea but optimization adopted an enantioselective allylation whereby the 
allyl group was installed to construct keto-ester 39 with an er of 92:8.  Treatment of the 
pendant ketone with L-selectride, followed by TBSOTf afforded methyl ester 40.14 
Conversion of the methyl ester to the methyl ketone 41 was accomplished using 
TMSCH2Li. It should be noted that, although simple in design, this reaction was 
unsuccessful under standard conditions (MeMgBr, MeLi, Cp2TiMe2) due to the presence 
of the adjacent quaternary center, we too had similar problems in producing our methyl 
ketone 90 via this method (see Section 1.7). Activation of ketone 41 with CeCl3 followed 
by isopropenyl Grignard addition smoothly provided the olefin 42. Grubbs second 




the final ring was constructed, nOesy analysis revealed inverted stereochemistry at C5, 
again demonstrating the challenges of this highly congested pentacycle (Scheme 1.7).14 
Given the C5 stereocenter is constructed by two nucleophilic additions (TMSCH2Li 
addition followed by isopropenyl Grignard), Johnson’s group was able to reverse the order 
of these reactions and deliver the correct stereochemical product. In this regard, from 
methyl ester 40 DIBAl-H reduction followed by DMP oxidation provided aldehyde 44. 
Addition of (3-hydroxyprop-1-en-2-yl)lithium produced the corresponding diol 45. The 
primary alcohol was then selectively silylated, followed by DMP oxidation of the 
remaining free alcohol to afford the unsaturated enone 46. Following the same sequence of 
reactions as above (methyl Grignard/Grubbs II methasis) Johnson was able to generate his 
advanced cyclopentane ring 48 with proper stereochemistry at the C5 position, confirmed 
via NOESY analysis (Scheme 1.8).14  
With the correct epimer in hand OsO4 catalyzed dihydroxylation of olefin 48 provided 
diol 49. Swern oxidation of the pendant secondary alcohol afforded the α-hydroxy-ketone 
50 which was further protected with excess 2,2-dimethoxypropane to afford the highly 
substitued bis-dioxolane 51 (Scheme 1.9).14 
Johnson’s semisynthesis, in parallel with Knapp, used nonchiral starting materials 
which were later functionalized. Using an enantioselective Tsuji-Trost reaction Johnson 
was able to report the synthesis of a highly functionalized intermediate en route to pac.14   
 
1.5 Hanessian’s Total Synthesis of Pac 
Finally in 2011, after 50 years, pac succumbed to total synthesis by the Hanessian 
group.  Hanessian’s strategy was to relay stereochemistry around the cyclopentane ring 




is evidenced by the stereochemical information at C1, C2, C7, and C8 mirrored on pac. 
After careful construction of the cyclopentane core around L-threonine the Hanessian 
group was able to adjust a variety of functional groups to meet pac’s stereochemical 
requirements.12  
Starting from L-threonine 52 a three-step sequence provided them the oxazoline 53. 
Subsequent alkylation with O-TBDPS-2-hydroxymethyl acrolein followed by silylation of 
the pendant alcohol afforded the allylic diol 54. Reduction of the benzyl ester with DIBAl-
H and then subsequent methyl Grignard addition provided alcohol 55, which was 
immediately exposed to Swern oxidation conditions to produce methyl-ketone 56. 
Ozonolysis of the olefin provided the ketone which was subjected to a Mukaiyama-type 
intramolecular aldol condensation to provide the diol 57. Β-elimination of the activated 
alcohol at C4 provided the enone 58 which was appropriately set for functionalization at 
C2, C3, C4 (Scheme 1.10).12 
With the cyclopentane ring now intact, base induced expoxidation smoothly provided 
the epoxide 59 as a single diastereomer. Reduction of the C2 ketone using Luche conditions 
delivered the alcohol 60. The alcohol 60 was activated to the triflate ester which was 
secured for inversion via tert-butyl ammonium azide substitution to yield azide 61.  Silyl 
deprotection, followed by periodiate oxidation produced the azido-ketone 62. The proper 
stereochemical information was installed on C5 by methyl Grignard addition to produce 
tertiary alcohol 63. Deprotection of the primary alcohol was accomplished with 
tetrabutylammonium fluoride (TBAF) and upon epoxide activation with Zn(OTf)2 the 
stereochemistry at C4 was inverted to yield triol 64. The acetate group that was 




was then converted to the endocyclic epoxide by triflic anhydride mediated activation to 
yield the epoxy-azide 66. With the help of X-ray crystallographic analysis all the 
stereocenters on the epoxy-cyclopentane 66 were confirmed (Scheme 1.11).12  
The addition of a mild Lewis acid to epoxide 66 in the presence of 3-(prop-1-en-2-
yl)aniline produced the azido-masked trans-diamine 67 (Scheme 1.12). In final preparation 
for the natural compound, the oxazoline was opened with 2N HCl to afford the benzoyl 
protected alcohol 68. Sequential removal of the silyl ether followed by treatment with 2,2-
dimethoxypropane produced the requisite acetonide 69. The dimethyl-urea was to be an 
easily installed functional group, however addition of N,N-dimethylcarbamoyl chloride to 
the amine on C1 (not shown) only produced oxazoline 67. Formation of the urea was 
accomplished using a careful set of conditions whereby the reactive amine was first 
converted to isocyanate in the presence of diphosgene and subsequently reacted with 
dimethylamine to afford urea 70. Conversion of the benzoyl group to the secondary alcohol 
was carried out by addition of DIBAl-H, followed by Johnson-Lemuiex oxidative cleavage 
of the remaining olefin, and acetonide deprotection to yield the azido-triol 71. The 
functionalized ester 72 was procured by the treatment of primary alcohol on C9 with 
cyanomethyl 2-hydroxy-6-methylbenzoate. The remaining azide on C2 was converted to 
the amine in the presence of Lindlar’s catalyst generating pac in 29 linear steps and overall 
3.0% yield (Scheme 1.12).12 
Hanessian’s work demonstrates the challenges to functionalize such a sterically and 
electronically congested molecule. Synthetic construction of this complex 
aminocyclopentanol will allow for targeted SAR studies in order to develop less toxic 




1.6 Johnson’s Total Synthesis of Pac 
Johnson’s efforts toward the complex aminocyclopentanol culminated in 2013. The 
Johnson group recognized the utility of pac in 2012 but were unable to complete their 
synthesis from the initial route. Johnson’s alternative approach detailed below is the 
shortest total synthesis to date, and is accomplished in 15 total steps.15 
Starting from the achiral diketo-urea 73, addition of the cinnamaldehyde imine 74 
under Lewis acid control with cinchonidine produced the highly functionalized Mannich 
adduct 75 in a 98:2 enantiomeric ratio (Scheme 1.12). The utility of this single step was 
demonstrated by the fact that the product possessed all 5 carbons present in the pac core 
and contained the “difficult to install” (as observed in Hanessian’s synthesis) dimethyl 
urea.12 Addition of lithium tri(tert-butoxy)aluminum hydride produced the corresponding 
hydroxyketone which was silylated affording silyl-ether 76. Enolate formation was 
accomplished with lithium diisopropylamide, which was subsequently added to 
formaldehyde to yield alcohol 77. Olefin ozonolysis procured the functionalized keto-
aldehyde 78 for an intramolecular aldol condensation.  Sodium methoxide addition formed 
the 5-membered cyclopentene core 79 (Scheme 1.13).15  
With the cyclopentenone 79 in hand nucleophilic epoxidation afforded the epoxy 
alcohol which was silylated with the robust tert-butyldiphenylsilyl (TBDPS) group to yield 
silyl ether 80 (Scheme 1.14). Methyl Grignard addition to the pendant ketone provided the 
tertiary alcohol 81 at C5 in excellent diastereoselectivity. Upon the addition of a mild Lewis 
acid, the C3-C4 epoxide was opened with 1-(3-aminophenyl)ethan-1-one to produce the 
masked diamine 82. TBAF deprotection of the pendant silylether garnered the free primary 




elucidated by Hanessian to construct di-aryl 84. Treatment of carbamate 84 with palladium 
on carbon produced the final amine, and thus the formation of pac in 15 total steps with an 
overall 1.9% yield.15 
The Johnson group retains the shortest and second total synthesis to date. Their 
ingenuity allowed construction of pac in 15 steps starting from a unique enantioselective 
Mannich reaction. Once more, Johnson’s synthesis demonstrates the necessity in achieving 
this complex aminocyclopentanol in short sequence for analog development.15 
 
1.7 Looper’s Partial Synthesis of Pac 
Our synthetic assault on pac was predicated upon the development of novel analogs 
which modify pac’s pi-stacking interactions (Scheme 1.15). Similarly to Hanessian12 we 
found L-threonine to be a useful chiral synthon containing the chemical information at C1, 
C5, and C7. From L-threonine we could quickly access the alkylated oxazoline methyl 
ester 85. Cyclization of 85 would allow for construction of the functionalized cyclopentene 
86. With the cyclopentene in hand the aldehyde on C4 would act as a handle for 
introduction of an aryl ring. We felt the alternate aryl ring on C3 could be introduced via a 
metal catalyzed N-H insertion on 87, or through the subsequent substitution (after an olefin 
α-halogenation) on halide 88. Either method would provide the requisite bi-aryl system for 
analog development and potential bioactivity. Further analysis suggested that with this 
method we also have the desired chemical information to proceed forward with the 
synthesis of the natural product.  
Starting from L-threonine 52 we first generated the methyl ester, which was then added 





With the oxazoline-methyl ester 89 introduction of C2, C3, and C4 could be 
accomplished through a carefully controlled alkylation. Alkylation at C1 with 1-bromo-5-
pentene under standard conditions, however, provided a complex mixture of products. 
After several failed attempts at alkylation we discovered that rather than the desired 
alkylation, the oxazoline was undergoing β-elimination to afford the linear protonated 
product 87 (Scheme 1.17). We reasoned this undesired product was being formed because 
our electrophile was not strong enough. 
Exchanging the bromide for the iodide provided 1-iodo-5-pentene.18 Subjecting the 
newly formed iodo-pentene to our conditions, resulted in roughly a 3:1 ratio of an 
inseparable mixture of diastereomers, along with a significant amount of the β-eliminated 
product 90. We attributed these unwanted byproducts to two reaction attributes: 1) a poorly 
available nucleophile and 2) unfavorable temperature increases during both enolate 
formation and electrophile addition. To circumvent these problems, we focused on 
solvation of the lithium counterion with the addition of HMPA after LDA formation. In 
conjunction, we also lowered the temperature by submerging the reaction vessel in a 
MeOH/N2 (-85 °C) bath instead of dry ice/acetone (-78 °C). Carefully monitoring the 
temperature via an internal thermocouple after each addition ensured the temperature was 
between -82 and -85 °C, and cleanly yielded the alkylated product 85 as a single 
diastereomer in good yield (Scheme 1.18).19 
Next, we directed our attention to forming the methyl ketone from the methyl ester in 
a two-step process using Weinreb’s amide.20 Both Hanessian and Johnson were unable to 
perform this sequence using the Weinreb amidation and instead resorted to additional steps 




steric bulk adjacent to the methyl ester made this transformation difficult as evidenced by 
both Hanessian’s and Johnson’s stepwise method.21  
Given the proximity of the quaternary center adjacent to the methyl ester we were also 
fearful of having to resort to this sequence. We first attempted to introduce the methyl 
ketone via a two-step process, forming the Weinreb amide and then converting it to the 
ketone via methyl Grignard addition (Scheme 1.19). However, this sequence was 
unreliable due to low yields a consequence of the adjacent quaternary center. In an attempt 
to take advantage of the poor reactivity due to the adjacent quaternary center, we next tried 
to add a single equivalent of methyl Grignard in hopes that the steric bulk of the newly 
formed tetrahedral intermediate would prevent further addition and provide the methyl 
ketone 93. Unfortunately, this reaction proved to be unproductive resulting in starting 
material recovery. 
A report by Grabowiski and coworkers which documented a similar problem, was 
circumvented by slurrying the N,O-dimethylhydroxlamine and methyl ester together first 
for 5 min before adding an excess of methyl Grignard.22 We found these amended 
conditions worked well with our substrate, which afforded the methyl ketone 93 in an 82% 
yield in a single step process (Scheme 1.20).  
With the successful installation of C2, C3, and C4 and methyl addition we turned our 
attention to the formation of the cyclopentane core. The aldehyde was formed through 
oxidative cleavage of the alkene which provided 94 (Scheme 1.21). Reductive workup of 
the molozonide was initially attempted with dimethyl sulfide (DMS), but was amended to 
the use of triphenylphosphine. We found the DMS did not possess the required 




revealed that we had isolated this unstable byproduct. An intramolecular aldol reaction was 
initiated with the addition of SiO2 and Hünigs base at elevated temperature to provide the 
cyclopentene 86 in good yield. These conditions, although simplistic, were serendipitously 
discovered when a basified column was run on the precursor aldehyde 94, which generated 
the cyclized product 86 in situ. 
We now required a suitable method to functionalize C2 and C3. Reduction of the 
aldehyde afforded the alcohol 95 which was followed by epoxidation of the C4-C5 olefin 
to provide the epoxide 96 as a single diastereomer in good yield (Scheme 1.22). We then 
turned our attention to a nitrene insertion reaction which could be directed from the pendant 
alcohol onto C3.23 Upon thorough examination of the reaction, we felt that a cascade 
sequence could install both nitrogens at C3 and C2 (Scheme 1.23). Deprotonation of the 
primary alcohol with sodium hydride followed by addition of sulfamoyl chloride provided 
the corresponding sulfamoyl amide 97. The diastereoselectivity of the above reaction 
sequence was based primarily on the configuration of the C4 stereocenter which was 
determined explicitly by X-ray crystallography (Figure 1.4). 
With the sulfamoyl group properly installed a series of conditions were selected based 
on chemistry by both DuBois24 and He.25 Unfortunately, the nitrene insertion was never 
successful which we attributed partly to the poor solubility of the sulfamoyl ester 95 (Table 
1.1). Thorough evaluation of the reaction sequence led us to attempt this transformation 
with the carbamate 97 instead, which again proved to be unsuccessful (Table 1.1). 
Establishing conditions to properly functionalize C3 proved to be difficult. A report by 
Iwashita and coworkers showed a select example of brominating the alpha position of an 




ene-aldehyde to produce the corresponding brominated derivative. Therefore, olefin 86 
was subjected to halogenation conditions using NBS which provided the subsequent 
bromo-aldehyde 106 in modest yield (Scheme 1.24). To the best of our knowledge this is 
the only α-bromination on an α-β unsaturated aldehyde present in the literature.13 After 
optimization of these reaction conditions it was found that dichloromethane could be 
substituted for carbon tetrachloride as a cheaper and more readily available solvent. An 
exogenous base, in this case K2CO3, also helped prevent unwanted side reactions by 
removing any preformed HBr. Furthermore, bromine was chosen as the bromine radical 
source, over n-bromosuccinimide, as it provided the most consistent yields. Unfortunately, 
the stereochemistry of C3 was unknown and further functionalization was necessary to 
produce a derivative that could be analyzed by crystallographic or spectroscopic means. 
The bromide was displaced with sodium azide, aldehyde reduction with sodium 
borohydride produced the corresponding azido-alcohol 107. Hydrolysis of the oxazoline in 
2N HCl produced the corresponding benzoate. The free amine was then protected with 
PMBzCl to produce amide 108. Peroxy acid oxidation of the olefin, following a similar 
protocol to that developed earlier in our failed nitrene chemistry, produced the epoxide 
109. We felt the stereochemistry at C4/C5 was the same as the sulfamyl epoxide 97 as a 
similar epoxidation protocol was followed.  
In order to properly install the anti-diol at C4 and C5 a cascade reaction was envisioned 
whereby the epoxide on C4/C5 would be opened through an intramolecular process by the 
pendant carbonate group on O7 (Scheme 1.25).27 This could further alleviate any problems 
associated with the incorrect stereocenter present on C7 which would be inverted upon 




Lanthanum triflate was chosen as our Lewis acid catalyst, as it was mild and readily 
available. Unfortunately, addition of lanthanum resulted in only recovered starting 
material.   Use of BF3·OEt2 as the Lewis acid, resulted in the formation of 110. Structural 
analysis, was hindered by a side product 111 which arose from migration of the benzoyl 
group. Global hydrolysis of the mixture of esters 110 and 111 with LiOH afforded 112, 
which proved to be crystalline. From the triol 112 we were able to establish the absolute 
structure of our cyclized product by X-ray crystallography. We confirmed that the 
stereochemistry at C7 was indeed inverted to represent that of the natural product, and the 
cyclization provided the diol as anticipated (Figure 1.5). However, further analysis 
revealed that the azide on C3 was in fact the opposite of what was required for pac (Scheme 
1.26). 
  In order to circumvent the improper C3 stereochemistry, we investigated chemistry 
whereby the stereocenter at C3 could be doubly inverted. After several failed attempts, 
largely due to substrate decomposition when using hydroxide as a nucleophile, we turned 
to a milder oxygen nucleophile. Sodium acetate was chosen and cleanly afforded the C3 
alcohols 113 and 114 under solvolysis conditions. The intermediate acetates were 
presumably cleaved during the reaction. Spectral analysis revealed a 3J splitting pattern for 
113 which was identical to that of the corresponding azide 107. On the other hand, the 
other diastereomer, 114, lacked the same splitting pattern as the azide but was consistent 
with the 3J splitting of the initial bromide 106 indicating it retained the same 
stereochemistry as the starting bromide (Scheme 1.27). 
Given our ability to clearly identify the stereoisomers at C3, we sought a way to 




alternative to acetate as it gave exclusively one diastereomer. Reduction of both ester and 
aldehyde provided diol 116 (Scheme 1.28). The oxazoline was hydrolyzed via the same 
conditions used before to provide the corresponding free amine, which was subjected to 
PMBz protection with PMBzCl to afford the anisole ester 117. As before, epoxidation 
provided 118 as a single diastereomer. Performing the key epoxide opening cascade 
reaction was smoothly accomplished by the addition of BF3·OEt2. Further addition of 
benzoic acid led to the acyl transfer which provided 119 as a single isomer in 90% yield. 
Oxidation of the remaining secondary alcohol was accomplished with the addition of 
(2,2,6,6-Tetramethylpiperidin-1-yl)oxyl (TEMPO) and bis-acetoxy iodobenzene (BAIB) 
to produce the ketone 120. 
The synthesis delineated above represents another powerful sequence in pursuing 
aminocyclopentanols. Although our synthesis is unfinished, obtaining analogs that perturb 
the pi-stacking framework, responsible for pactamycin’s potent activity, should be 
synthetically accessible from bromide 106 as well as ketone 120. Our synthesis introduced 
the trans-C4-C5-diol, and established the correct stereochemistry at C1, C4, C5, and C7. 
We have also demonstrated an unprecedented α-bromination on an ene-aldehyde which 
assisted in the synthesis of the final ketone 120. The utility of our epoxide opening cascade 
as well as the α-bromination could be exploited to produce analogs with varying 
substitution patterns at C4, C5, and C3 and could further help in the development of a 
clinically viable compound.  
 
1.8 Analog Studies  
In order to pursue potential therapeutic leads we intercepted a number of functionalized 




and enzymatic assays (rabbit reticulocyte protein synthesis). We selected intermediates 
based on the similarity to pac’s pi-stacking mechanism of action. In light of this, we 
focused on compounds with at least one pendant aryl ring and contained the requisite 
cyclopentane core. The compounds selected were further decorated with various functional 
groups which could complement binding.  
Three advanced intermediates met these criteria and are shown below (Figure 1.6).  
Unfortunately, the compounds tested lack any viable MIC against MRSA (>64 µg/mL) as 
well as any inhibition in protein synthesis. It is likely that the analogs generated do not 
meet the conformational parameters of the ribosome and thereby are inactive when tested. 
However, iterations on current analogs and other intermediates may produce a more viable 
and active compound.  
 
1.9 Future Aims 
In 12 steps, a significant portion of the highly complex amino cyclopentanol has been 
synthesized. Possible routes to synthesize the natural product are outlined below (Scheme 
1.29). Starting from the ketone α-halogentaion followed by azide displacement should 
produce the requisite nitrogen on C2 to afford azide 124. Although stereochemistry would 
be difficult to control in this transformation, the incorrect isomer could be converted to the 
proper one in a short sequence (not shown). From the azido-ketone 124 removal of the 
oxazoline and dimethyl urea introduction, following Hanessian’s elegant protocols, should 
produce the azido-triol 125. The final ketone could then be reductively aminated with 3-
(prop-1-en-2-yl)aniline and finally azide reduction would provide the natural product.  
Given the parallels between Hanessian’s synthesis and ours we also have the 




using α-halogentaion followed by azide displacement should produce the requisite nitrogen 
on C2 to afford azide 124 again (Scheme 1.30). Reductive amination with 3-(prop-1-en-2-
yl)aniline would provide the masked diamine 126, which with the exception of the robust 
TBDPS group on the oxygen at C9, is identical to Hanessian’s amine 67.  
Although the synthesis of pac has yet to be elucidated by the Looper group the 
highlights of our synthesis include a novel epoxide opening cascade reaction and a short 
synthetic sequence that allows for modularity in designing the desired di-aryl pi stacking 






Table 1.1: Attempted conditions used to achieve the N-H insertion 
Compound Catalyst Additive Solvent Temperature Outcome 
95 Rh2(Oct)4 BAIB, MgO CH2Cl2 rt - 40 °C NR 
95 Rh2(esp)2 BAIB, MgO CH2Cl2 rt - 40 °C NR 
95 Rh2(OAc)4 BAIB, MgO DCE 80 °C NR 
95 Rh2(OAc)4 BAIB, MgO CH2Cl2 rt - 40 °C NR 
97 AgNO3 
BAIB, t-bu-
tripy CH3CN 80 °C NR 
 
 
Figure 1.1: The structure of pac 
 
 
Figure 1.2: Crystallographic analysis of pac’s pi-stacking interaction in the 30s subunit of 














Figure 1.3: (a) Biosynthetic analogs of pac synthesized by the Mahmud laboratory with 
















Figure 1.5: Confirmed X-ray structure of azide 112 with the azide in line with N1 
 
 




















Scheme 1.3: Construction of the final pentacycle via the key Pauson-Khand reaction 
 
 




















Scheme 1.6: Synthesis of the advanced acyclic urea 
 
 






Scheme 1.8: Construction of the key pentacyle with the correct stereochemistry at C5 
 
 





















































































Scheme 1.15: Approach to functionalizing C3 and C4 from L-threonine 
 
 
Scheme 1.16: Formation of the parent oxazoline 
 
 







Scheme 1.18: Successful alkylation of the oxazoline 
 
 
Scheme 1.19: Unsuccessful attempts at generating the methyl ketone 
 
 
Scheme 1.20: Successful use of Grabowiski’s Weinreb amidation to produce the methyl 



















Scheme 1.23: General design of the tethered N-H insertion sequences 
 
 




















Scheme 1.28: Key cascade sequence imparting the correct stereochemistry 
 
 







Scheme 1.30: Proposed formal synthesis to achieve Hanessian’s advanced masked 
diamine 67 
 
1.10 Supporting Information 
1.10.1 General Experimental Conditions 
Unless otherwise noted, materials were obtained from commercial sources and used 
without purification; otherwise, materials were purified according to Purification of 
Laboratory Chemicals.28 All reactions requiring anhydrous conditions were performed 
under a positive pressure of nitrogen using flame-dried glassware. Diisopropylamine, 
triethylamine (NEt3), and N,N-diisopropylethylamine (Hϋnig’s Base) were distilled from 
CaH2 immediately prior to use. Dichloromethane (CH2Cl2), tetrahydrofuran (THF), 
toluene, and acetonitrile (CH3CN) were degassed with nitrogen and passed through a 
solvent purification system (Innovative Technologies Pure Solv). Methanol (MeOH) was 
distilled over magnesium prior to its usage. m-CPBA was used as purchased (77% wt) with 
4-chlorobenzoic acid and H2O impurities. HMPA is considered to be very toxic and should 
be handled with great care when used. 
Yields were calculated for material judged homogeneous by thin-layer chromatography 
and 1H NMR. Thin-layer chromatography was performed on silica plates eluting with the 




performed with slurry-packed silica gel with solvents indicated in glass columns. 1H NMR 
spectra were recorded at 500 MHz as indicated. The chemical shifts (δ) of proton 
resonances are reported relative to the deuterated solvent peak: 7.26 for CDCl3 and 4.87 
for H2O in CD3OD, using the following format: chemical shift [multiplicity (s = singlet, d 
= doublet, t = triplet, q = quartet, m = multiplet, app = apparent), coupling constant(s) (J in 
Hz), integral]. 13C NMR spectra were recorded at 125 MHz. The chemical shifts of carbon 
resonances are reported relative to the deuterated solvent peak: 77.3 (center line) for CDCl3 
and 49.0 (center line) for CD3OD. Infrared spectra were recorded on a Nicolet 380-FT IR 
spectrometer fitted with a Smart Orbit sample system. All absorptions are reported in cm-1 
relative to polystyrene. Mass spectra were obtained by ESI/APCI for LRMS or ESI/APCI-
TOF for HRMS. Melting points were recorded on a Fisher-Johns melting point apparatus 
using a digital thermocouple to determine temperature. Optical rotations were obtained at 
ambient temperature on a Perkin Elmer Model 343 polarimeter (NaD line) using a microcell 
with a 1 decimeter path length. 
 
1.10.2 Experimental Procedures 
 
(4R,5R)-methyl 5-methyl-4-(pent-4-en-1-yl)-2-phenyl-4,5-dihydrooxazole-4-
carboxylate: To a freshly distilled solution of diisopropylamine (57.0 mL, 0.410 mol, 1.45 
equiv.) in THF (2 L) at -78ºC (dry ice/acetone) in a 3 L three neck roundbottomed flask 




added nBuLi (157.0 mL, 2.5M in THF, 0.390 mol, 1.4 equiv.).Following complete addition 
the reaction was taken out of the cold bath and warmed for 30 min or until the reaction 
temperature rose to 0ºC. The reaction was then cooled back to -78ºC and HMPA (200.0 
mL, 1.120 mol, 4 equiv.) was added to the solution quickly. The solution was further cooled 
to -85 ºC (liq. N2/MeOH) and oxazoline 6 (61.2 g, 0.279 mol, 1 equiv.) was added dropwise 
over a period of 35 min The reaction temperature was monitored by a thermocouple and 
never rose above -80 ºC and never below -90 ºC. The solution was then warmed to -78 ºC 
and 5-iodo-1-pentene (109.0 g, 0.560 mol, 2 equiv.) was added over a period of 30 min 
making sure the temperature never rose above -70 ºC. The reaction was allowed to warm 
to rt over a period of 24h. The solvent was removed under reduced pressure. The crude 
material was dissolved in CH2Cl2 (500 mL) and washed with sat. LiCl (3 x 500 mL) to 
yield analytically pure 7 (56.85 g, 71%) as a light yellow oil. Rf= 0.61 (50% ethyl 
acetate/hexanes). [α]20D = +37.4 (c= 0.7, CH2Cl2).1H NMR (500 MHz,CDCl3): 7.99 (d, J 
= 7.5 Hz,2H), 7.48 (t, J = 7.5 Hz, 1H), 7.41 (t, J = 7.0 Hz, 2H), 5.77 (dddd, J = 7.0, 7.0, 
10.0, 17.0 Hz, 1H), 5.02-4.92 (m, 2H) 4.58 (q, J = 7.0 Hz, 1H), 3.75 (s, 3H), 2.14-2.05 (m, 
3H), 1.76-1.62 (m, 2H), 1.46-1.36 (m, 1H), 1.32 (d, J = 6.5 Hz, 3H) ppm. 13C NMR (CDCl3, 
125 MHz): 172.6, 164.3, 138.5, 131.8, 128.7, 128.5, 127.8, 115.0, 83.2, 81.0, 52.3, 39.1, 
33.9, 23.4, 17.1 ppm. IR (neat): 2949 (w),1731, 1646, 1449, 1283, 1148 (all s) cm-1. HRMS 







To a 1 L round bottomed flask containing a magnetic stir bar, oxazoline 7 (10.0 g, 34.8 
mmol, 1 equiv.) in a solution of THF (350 mL) and equipped with a thermocouple under a 
stream of N2 was added N,O-dimethylhydroxlamine hydrochloride (5.10 g, 52.2 mmol, 1.5 
equiv.). The solution was stirred for 5 min until the solids were finely slurried. The solution 
was further cooled to -5 ºC (Acetone/ice/dry ice) and MeMgBr (64.0ml, 3M in THF, 192.0 
mmol, 5.5 equiv.) was added at rate where the temperature never rose above 0 ºC. The 
reaction was left to warm to rt and stirred until TLC analysis showed complete 
consumption of the starting material. The excess MeMgBr was quenched with sat. NH4Cl. 
The crude reaction mixture was then extracted with Et2O (100 ml x 2). The organic layer 
was dried with Na2SO4 and concentrated under reduced pressure. Purification of the 
product was accomplished using flash chromatography eluting with 10% ethyl 
acetate/hexanes. The fractions containing product were concentrated under reduced 
pressure to give the methyl ketone 8 (7.80 g, 82%) as a light yellow oil. Rf= 0.66 (50% 
ethyl acetate/hexanes). [α]20D = +43.2 (c= 0.3, CH2Cl2).1H NMR (500 MHz,CDCl3):8.01(d, 
J = 7.0 Hz, 2H),7.51 (t, J = 7.5 Hz, 1H), 7.46 (t, J = 7.5 Hz, 2H), 5.75 (dddd, J = 7.0, 7.0, 
10.0, 17.0 Hz, 1H), 5.00-4.91 (m, 2H), 4.58 (q, J = 6.5 Hz, 1H), 2.28 (s, 3H), 2.16-1.94 (m, 
3H), 1.68-1.55 (m, 2H), 1.36-1.28 (m, 1H), 1.25 (d, J = 6.5 Hz, 3H) ppm. 13C NMR (125 
MHz,CDCl3,): 218.5, 164.1, 138.5, 131.8, 128.6, 128.0, 115.0, 84.5, 83.5, 39.1, 34.1, 30.4, 
23.1, 17.3 ppm. IR (neat): 2940 (w), 1710 (s), 1644 (s), 1450 (m), 1352 (m), 1150 (s) cm-





4-((4R,5R)-4-acetyl-5-methyl-2-phenyl-4,5-dihydrooxazol-4-yl)butanal: A 250 mL 
flask, open to the atmosphere,  was charged with methyl ketone 8 (9.4 g, 34.8 mmol, 1 
equiv.) and ethyl acetate (175 mL) and cooled to -78°C. Excess O3 was then bubbled 
through the solution until a faint blue color was observed. The reaction was subsequently 
purged of excess O3 by bubbling N2 through the solution. When the blue color disappeared 
N2 was bubbled through for an additional 10 min The reaction was then placed under N2, 
a magnetic stir bar added, and PPh3 (18.2 g, 69.7 mmol, 2 equiv.) added in a single portion. 
The reaction was allowed to warm to rt and further heated to reflux for 8h. The solvent was 
removed under reduced pressure. Purification of the product was accomplished using flash 
chromatography eluting with 10% ethyl acetate/hexanes. The fractions containing product 
were concentrated under reduced pressure to give aldehyde (7.02 g, 79%) as a light yellow 
oil. For fear of instability the product was stored in benzene at -80°C until used. Rf= 0.57 
(50% ethyl acetate/hexanes). [α]20D = +25.8 (c= 1.8, CH2Cl2).1H NMR (500 
MHz,CDCl3):9.73 (t, J = 3 Hz, 1H), 8.00 (d,J = 7.0 Hz, 2H), 7.52 (tt, J = 7.0 Hz, 1H), 7.48 
(t,J = 7.0 Hz, 2H),4.59 (q, J= 6.5 Hz, 1H), 2.45 (td, J = 1.5, 7.5 Hz, 2H), 2.28 (s, 1H), 2.03 
(ddd, J = 4.5, 4.5, 18 Hz, 1H), 1.91-1.84 (m, 1H), 1.65 (td, J = 4, 11.5 Hz, 1H), 1.59-1.52 
(m, 1H), 1.26 (d, J = 7.0 Hz, 3H) ppm. 13C NMR (125 MHz, CDCl3): 212.1, 202.2, 164.6, 
132.0, 128.6, 127.8, 84.3, 83.7, 44.1, 38.5, 30.4, 17.2, 16.7 ppm. IR (neat): 1708 (s), 1644 
(s), 1450 (m), 1352 (m), 1063 (s) cm-1. HRMS (ESI) calculated for C17H21NO2Na m/z 




296.1263 (M+Na), Obsd. 296.1266. 
 
(4R,5S)-4,6-dimethyl-2-phenyl-3-oxa-1-azaspiro[4.4]nona-1,6-diene-7-carbaldehyde: 
To a 250 mL flask containing keto aldehyde(7.50 g, 27.9 mmol, 1.0equiv.) in toluene (200 
mL) was added SiO2 (1.70 g, 28.3 mmol, 1 equiv.). The solution was stirred for 5 min 
followed by the addition of freshly distilled diisopropylethylamine (19.4 mL, 111.6 mmol, 
4 equiv.). The reaction was then heated to 75°C for 48 h or until TLC analysis showed 
complete consumption of the starting material. The solvent was removed under reduced 
pressure to yield a yellow slurry which was filtered through a plug of celite with 
dichloromethane to remove any excess silica. The filtrate was concentrated in vacuo and 
the resultant solid was recrystallized from i-PrOH to yield the cyclopentane 9(6.04 g, 85%) 
as a light yellow solid. Rf =0.58 (50% ethyl acetate/hexanes).mp. 87-89°C. [α]20D 
c= 0.3, CH2Cl2).1H NMR (500 MHz, CDCl3): 10.07 (s, 1H), 7.98 (d, J = 7.5 
Hz, 2H), 7.50 (t, J = 7.5 Hz, 1H), 7.41 (t, J = 7.5 Hz, 2H), 4.64 (q, J = 6.5 Hz, 1H), 2.69-
2.64 (m, 1H), 2.52-2.41 (m, 2H), 2.06 (t, J = 2.0 Hz, 3H), 2.00-1.95 (m, 1H), 1.38 (d, J = 
6.5 Hz, 3H) ppm. 13C NMR (125 MHz,CDCl3):189.2, 164.7, 159.5, 140.0, 132.0, 128.6, 
127.6, 87.5, 85.6, 37.2, 27.4, 16.0, 12.3 ppm. IR (neat): 1667 (s), 1635 (s), 1285 (w), 1059 







carbaldehyde: To a 100 mL flask equipped with a magnetic stirring bar under a stream N2 
containing cyclopentene 9 (1.10 g, 4.31 mmol, 1 equiv.) in a solution of CH2Cl2 (65 mL) 
was added K2CO3 (253 mg, 2.5 mmol, 4equiv.).  Bromine (3.7 g, 21.0 mmol, 5 equiv.) was 
added to the solution followed by AIBN (35 mg, 0.2 mmol, .05 equiv.). The reaction was 
then heated to 40 °C until NMR showed 50-80% consumption of the starting material. The 
excess bromine was quenched with aq. Na2S2O3 (50 mL) and extracted with CH2Cl2 (2 x 
100 mL). The combined organics were dried with Na2SO4. The solvent was removed under 
reduced pressure and the mixture was purified using flash chromatography eluting with 
10% Ethyl acetate/hexanes.9 would co-elute with the product 10 and any attempt to run 
the reaction for longer times would result in substantial decomposition. As such, a mixture 
of the bromide and starting material were carried forward to the next reaction. Rf = 0.58 
(50% ethyl acetate/hexanes).  
 
(4R,5S,7R)-8-formyl-4,9-dimethyl-2-phenyl-3-oxa-1-azaspiro[4.4]nona-1,8-dien-7-yl-




azaspiro[4.4]nona-1,8-dien-7-yl-acetate: A 100 mL flask was charged with a solution of 
bromo aldehyde 10 (90mg, .27 mmol, 1 equiv.) which contained ~40% of the aldehyde 9 
in THF (5 mL). Sodium acetate (710mg, 8.6 mmol, 32 equiv.), and H2O (1 mL) were then 
added and the reaction was stirred for 8 h at reflux. The solvent was evaporated in vacuo. 
Purification of the product was accomplished using flash chromatography eluting with 5% 
ethyl acetate/hexanes followed by 10% ethyl acetate/hexanes. The fractions containing 
product were concentrated under reduced pressure to give acetates 16 (29 mg, 35%) and 
17 (25 mg, 30%) as yellow oils. (16): Rf = .13 (50% Ethyl acetate/Hexanes). [α]20D = -98.2 
(c= 0.6, CH2Cl2). 1H NMR (500 MHz,CDCl3): 10.07 (s, 1H), 7.99 (d, J = 7.5 Hz, 2H), 7.53 
(t, J = 7 Hz, 1H), 7.44 (t, J = 7.5 Hz, 2H), 5.09 (t, J = 6 Hz, 1H), 4.63 (q, J = 7 Hz, 1H),   
2.48 (dd, J = 6.5, 13.5 Hz, 1H), 2.37 (dd, J = 7, 13.5 Hz, 1H), 2.09 (s, 3H), 1.32 (d, J = 7 
Hz, 3H) ppm. 13C NMR (125 MHz,CDCl3): 190.4, 165.1, 161.7, 140.7, 132.2, 128.7, 128.6, 
127.4, 85.5, 84.0, 72.5, 46.5, 15.3, 12.5 ppm.  IR (neat): 3383 (bs), 2935 (w), 1674 (s), 
1637 (s), 1287 (w), 1059 (m) cm-1. HRMS (ESI) (17): Rf = .20 (50% Ethyl 
acetate/Hexanes). [α]20D = -84.1 (c= 0.7, CH2Cl2). 1H NMR (500 MHz,CDCl3): 10.07 (s, 
1H), 7.98 (d, J = 7.5 Hz, 2H), 7.52 (t, J = 6.5 Hz, 1H), 7.44 (t, J = 7.5 Hz, 2H), 5.14 (d, J 
= 7.5 Hz, 1H), 4.74 (d, J = 6.5 Hz, 1H), 2.79 (q, J = 7.0 Hz, 1H), 2.09 (s, 3H), 1.90 (d, J = 
14.5 Hz, 1H), 1.51 (d, J =  7.0 Hz, 3H) ppm. 13C NMR (125 MHz,CDCl3): 189.8, 165.5, 
162.3, 141.3, 132.1, 128.7, 128.6, 127.5, 86.4, 86.1, 72.1, 45.8, 14.8, 12.4 ppm. IR (neat): 






benzoate: A 100 mL flask was charged with a solution of bromo aldehyde 10 (83mg, .25 
mmol, 1 equiv.) which contained ~40% of the aldehyde 9 in THF (5 mL). Sodium benzoate 
(710mg, 5.0 mmol, 20 equiv.), K2CO3 (140mg, 0.9 mmol, 4 equiv.), and H2O (1 mL) were 
then added and the reaction was stirred for 12 h. The solvent was evaporated in vacuo. 
Purification of the product was accomplished using flash chromatography eluting with 5% 
ethyl acetate/hexanes. The fractions containing product were concentrated under reduced 
pressure to give benzoate ester 18 (54 mg, 58%) as a white solid. Rf = .60 (50% Ethyl 
acetate/Hexanes). mp 47-50 °C. [α]20D = -23.1 (c= 1.3, CH2Cl2). 1H NMR (500 
MHz,CDCl3): 10.06 (s, 1H), 8.03 - 7.99 (m, 4H), 7.56 - 7.52 (m, 2H), 7.46 - 7.41 (m, 4H), 
6.27 (t, J = 6.0 Hz, 1H), 4.68 (q, J = 6.5 Hz, 1H), 2.69 - 2.61 (m, 2H), 2.16 (d, J = 1.5 Hz, 
3H), 1.39 (d, J = 6.5 Hz, 3H) ppm. 13C NMR (125 MHz,CDCl3): 188.1, 166.5, 165.4, 161.9, 
137.2, 133.3, 132.3, 130.3, 130.0, 128.8, 128.7, 128.6, 127.3, 95.0, 85.7, 84.7, 74.4, 45.3, 
15.0, 13.0 ppm.  IR (neat): 1715 (s), 1679 (s), 1636 (s), 1450 (w), 1272 (s), 1111 (s), 1096 






1,8-dien-7-ol: A 50 mL flask was charged with 18 (29 mg, .07 mmol, 1 equiv.) and placed 
under N2. THF (5 mL) was then added and the solution cooled to 0 °C. LiAlH4 (15 mg, .40 
mmol, 5 equiv.) was then added in small portions and the reaction stirred for 1h. The 
reaction was quenched by Fieser’s method and concentrated. The resultant material was 
purified by column chromatography eluting with a solution of 4% methanol in 
dichloromethane. The fractions containing product were concentrated to yield 19 (23 mg, 
90%) as an off white solid. Rf = 0.5 (10% MeOH/CH2Cl2). mp 123-126 °C. [α]20D 
(c= .2, CH2Cl2). 1H NMR (500 MHz, CDCl3): 7.96 (d, J = 8.0 Hz, 2H), 7.50 (t, J= 7.0 Hz, 
1H), 7.42, (t, J = 7.5 Hz, 2H), 4.52 (q, J = 6.5 Hz, 1H), 4.45 (1/2ABq, J = 12.5 Hz, 1H), 
4.32 (1/2ABq, J = 12.5 Hz, 1H), 3.36 (bs, 2H), 1.63 (s, 3H), 1.32 (d, J =  7.0 Hz, 3H) 
ppm.13C NMR (125 MHz, CDCl3): 164.0, 141.2, 138.1, 131.9, 128.7, 128.5, 127.7, 85.1, 
83.8, 76.0, 58.6, 47.8, 14.7, 11.8 ppm. IR (neat): 3224 (bs), 2935 (w), 1632 (s), 1450 (w), 
1321 (w), 1295 (w) 1280 (w), 1057 (s), 1014 (m) cm-1. 
 
PMBz Protected Amine: A 50 mL flask was charged with diol 19 (40 mg, .15 mmol, 1 
equiv.) and THF (6 mL). 2N HCl (6 mL) was then added and the reaction was stirred for 3 
d. The reaction mixture was quenched with sat. NaHCO3 (20 mL) and extracted with ethyl 
acetate (3 x 25 mL). The organics were combined and dried with Na2SO4 and concentrated 




with a solution of the crude amine from above (30 mg,0.10 mmol, 1 equiv.) in CH2Cl2 (5 
mL). Para-methoxybenzoyl chloride (26 mg, 0.15mmol, 1.5equiv.) was then added and the 
reaction stirred for 3 h. The reaction was diluted with CH2Cl2 (25 mL) transferred to a 
separatory funnel and washed with 1N NaOH (25 mL). The aqueous layer was extracted 
again with CH2Cl2 (2 x 10 mL). The organics were combined, dried with Na2SO4, and 
concentrated under reduced pressure. Purification of the product was accomplished using 
flash chromatography eluting with 50% ethyl acetate/hexanes followed by 100% ethyl 
acetate. The fractions containing product were concentrated under reduced pressure to give 
PMBz protected amine 20 (30 mg, 48% from diol 19) as a white solid. Rf = 0.07 (5% 
MeOH/CH2Cl2). mp 173 - 175 °C.  [α]20D c= 0.5, CH2Cl2). 1H NMR (500 MHz, 
CDCl3): 8.03 - 8.02 (m, 2H), 7.65 - 7.61 (m, 3H), 7.49 (t, J = 7.5 Hz, 2H), 7.00 (s, 1H), 
6.87 (d, J = 9.0 Hz, 2H), 5.44 (q, J = 6.5 Hz, 1H), 4.82 (d, J = 7.0 Hz, 1H), 4.54 (1/2 ABq, 
J = 13.0 Hz, 1H), 4.35 (1/2 ABq, J = 13.0 Hz, 1H), 3.82 (s, 3H), 2.62 (dd, J = 8.0, 15.0 Hz, 
1H), 2.34 (d, J = 15.5 Hz, 1H), 1.74 (s, 3H), 1.33 (d, J = 6.5 Hz, 3H) ppm. 13C NMR (125 
MHz, CDCl3): 167.1, 166.8, 162.8, 143.1, 134.7, 134.1, 129.9, 129.6, 129.0, 128.9, 126.7, 
114.2, 76.0, 74.8, 71.8, 59.1, 55.7, 45.6, 15.2, 11.3 ppm. IR (neat): 3306 (bs), 1716 (s), 
1647 (m), 1606 (s), 1257 (s), 1176 (w) 1069 (w) cm-1. HRMS (ESI) calculated for 






Epoxide: A 25 mL round bottomed flask was charged with the PMBz protected amine 20 
(20 mg, 50 2Cl2 (2 mL). m-
then added in a single portion along with sat. NaHCO3 (2 mL). The reaction was stirred for 
3 h and then diluted with CH2Cl2 (25 mL), transferred to a separatory funnel and washed 
with H2O (1 x 25 mL). The organics were dried with Na2SO4 and concentrated under 
reduced pressure. Purification of the product was accomplished using flash 
chromatography eluting with 50% ethyl acetate/hexanes followed by 100% ethyl acetate. 
The fractions containing product were concentrated under reduced pressure to give the 
epoxide 21 (15 mg, 75%) as a clear oil. Rf =0.44 (2% MeOH/CH2Cl2). [α]20D 
(c=0.5, CH2Cl2).1H NMR (500 MHz, CD3OD): 8.02 (d, J = 6.5 Hz, d), 7.90 (bd, J = 29.0 
Hz, 1H), 7.70 - 7.67 (m, 2H), 7.62 - 7.58 (m, 1H), 7.49 - 7.46 (m, 3H), 6.94 - 6.90 (m, 2H), 
6.42 (q, J = 6.5 Hz, 1H), 4.63 (t, J = 8.0 Hz, 1H), 3.99 (1/2 ABq, J = 12.0 Hz, 1H), 3.82 (s, 
3H), 3.45 (1/2 ABq, J = 12 Hz, 1H), 2.76 (dd, J = 8.0, 13.5 Hz, 1H) 1.71 (dd, J = 7.5, 14.0 
Hz, 1H), 1.69 (s, 3H), 1.38 (d, J = 6.5 Hz, 3H) ppm. 13C NMR (125 MHz, CD3OD): 170.9, 
167.1, 163.9, 134.3, 133.0, 131.6, 130.7, 130.4, 129.6, 128.6, 114.6, 73.2, 71.8, 70.6, 68.5, 
58.4, 55.9, 39.7, 22.1, 15.8, 13.6 ppm. IR (neat): 3369 (bs), 1716 (s), 1606 (s), 1503 (s), 
1257 (s), 1177 (w), 1069 (w) cm-1. HRMS (ESI) calculated for C24H27NO7Na m/z 464.1685 






Triol: A 50 mL flask was charged with the epoxide 21 (15 mg, 0.03 mmol, 1 equiv.) and 
CH2Cl2. The flask was cooled to 0 °C and BF3•OEt2 (12 mg, 0.09 mmol, 3 equiv.) was 
added. After stirring for 1 h, benzoic acid (37 mg, 0.30 mmol, 10 equiv.) was added and 
the reaction was left to stir for an additional 3 h. The mixture was transferred to a separatory 
funnel and washed with 10% NaOH (3 x 20 mL). The organic layer was dried over Na2SO4 
and concentrated in vacuo. Purification of the product was accomplished using flash 
chromatography eluting with 2% MeOH/CH2Cl2. The fractions containing product were 
concentrated under reduced pressure to give triol 22 (12 mg, 90%) as a clear oil. Rf = .47 
(4% MeOH/CH2Cl2). [α]20D = + 10.0 (c0.3, MeOH). 1H NMR (500 MHz, CD3OD): 8.09 - 
8.07 (m, 2H), 7.85 - 7.83 (m, 2H), 7.61 - 7.57 (m, 1H), 7.49 - 7.45 (m, 2H), 6.99 - 6.97 (m, 
2H), 4.91 (q, J = 6.5 Hz, 1H), 4.59 (1/2 ABq, J = 7.5 Hz, 1H), 4.50 (1/2 ABq, J = 11.5 Hz, 
1H). 4.31 (dd, J = 4, 10 Hz, 1H), 3.84 (s, 3H), 2.72 (dd, J = 9.5, 14 Hz, 1H), 1.64 (dd, J = 
4.5, 15 Hz, 1H), 1.37 (d, J = 6.5 Hz, 3H) ppm.3C NMR (CD3OD, 125 MHz): 168.3, 164.1, 
162.7, 134.2, 131.6, 131.0, 130.7, 129.5, 120.7, 114.9, 84.4, 84.4, 83.9, 79.9, 74.3, 66.8, 
55.9, 40.8, 18.6, 16.9 ppm. IR (neat): 3361 (bs), 2926 (w), 1718 (w), 1645 (s), 1275 (s), 
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INITIAL STUDIES TOWARD GENERATING  
ANTIBIOFILM ANTIBIOTICS 
 
2.1 Background  
In 1928 Alexander Fleming contaminated a Staphylococcus bacteria colony growing 
in a petri dish. This contamination resulted in the serendipitous discovery of the first 
observed bacterial zones of inhibition, thus sparking the advent of antibiotics.1 Antibiotics 
have been one of the most significant advances in medicine in the 20th century and their 
rich history continues to date. The introduction of these antibiotics, however, placed 
pressure on bacteria to develop resistance to them. With antibiotic use rising and drug 
development slowing, bacterial infections because of resistance has become increasingly 
difficult to treat over the past 20 years.2  
The United States Centers for Disease Control and Prevention (CDC) estimates that 
every year approximately 2 million people in the United States contract a severe infection 
from drug-resistant bacteria, and that over 23,000 deaths are a direct result of these 
antibiotic-resistant infections.2  
Numerous reports that outline the current threats of antibiotic resistance have been 
published by the CDC and other health agencies. This list includes, a number of species in 
the categories of urgent and serious threats (Table 2.1), due to their; “clinical impact, 





of effective antibiotics, barriers to prevention.” Although the “golden age” of antibiotic 
discovery has passed, clinicians are in dire need of new antibiotic platforms to treat ever 
evolving bacterial species.2 
 
2.2 Common Current Antibiotic Structures and Functions 
Many of the above bacterial species have a limited window of treatment. The 
antibiotics prescribed to treat these infections are still effective, albeit to a narrow degree. 
Several key antibiotic scaffolds are outlined below as both historical and clinical examples.   
 
2.2.1 β-lactam Antibiotics 
The β-lactam antibiotics represent one of the largest known classes of antibiotics. 
Originally this class was occupied by the penicillins. Over time however, research led to 
development of the cephalosporin β-lactams followed by countless others including 
monocyclic β-lactams, carbapenems, carbacephems, oxapenams, and oxacephems (Figure 
2.1).3,4 Their namesake β-lactam functional group is linked to a variety of side chain 
functionalities in their molecular structure. 
Their mode of action relies on the inhibition of DD-transpeptidases, a series of 
penicillin-binding proteins (PBPs). This irreversible inhibition of PBP’s leads to the 
prevention of cross-linking newly formed peptidoglycans (polymeric mixture that forms 
the bacteria cell wall) thereby arresting the bacterial cell wall synthesis resulting in cell 
death.4 
Unfortunately, given the selective pressure present over the last 75 years bacteria have 
evolved a number of ways to evade this mechanism of action. First and foremost, a 





of cleaving the β-lactam ring before it forms the covalent bond to PBP, rendering it 
ineffective. One method of combating this problem is the introduction of β-lactamase 
inhibitors like clavulanic acid, in conjunction with other β-lactam antibiotics. The 
inhibition of β-lactamase effectively allows standard of care β-lactams to function 
appropriately. However, this resensitization is still a challenging problem and even with 
the introduction of a suicide inhibitor like clavulanic acid; bacteria have evolved to up-
regulate the amount of β-lactamase enzymes present, thereby overwhelming the clavulanic 
acid inside the cell and rendering any antibiotics ineffective.4  
Significant alteration in the primary structure of PBPs has also led to resistant strains 
of bacteria. The most comprehensive example of this phenomena is the mecA(gene) 
present in Methicillin-resistant Staphylococcus aureus (MRSA). The mecA gene prevents 
the β-lactam structure of penicillin and penicillin-like antibiotics from binding to the PBPs. 
The prevention of these interactions allows resistant strains to freely proliferate in the 
presence of a number of β-lactam antibiotics.4 
 
2.2.2 Quinolines and Fluoroquinolines 
The quinolones and fluoroquinolines are another important class of administered 
antibiotics. They consist of a quinolone framework structurally decorated by various 
substitution patterns on N1 and off of the aromatic ring. The first generation drugs like 
Nalidixic acid do not possess the aromatic fluoro substitution on position 6 as shown in 
Figure 2.2. Addition of a fluoro group in second generation analogs like ciprofloxacin 
resulted in a 100-fold enhancement of MIC values and is now a common addition to the 
chemical scaffold.5   





II (1st and 2nd generation compounds like Nalidixic Acid and Ciprofloxacin) or 
topoisomerase IV (3rd and 4th generation compounds like Levofloxacin and Gatifloxacin) 
in bacteria, while sparing the mammalian counterparts of these enzymes. The inhibition of 
either of these enzymes eventually disrupts cell replication by preventing the alleviation of 
overcoiled DNA, leading to cell death.5 
Even given their unique mechanism of action, a significant amount of resistance has 
developed for this scaffold. One of the most prevalent ways for bacteria to remove the 
unwanted bactericide is through efflux, whereby the drug is removed via multidrug-
resistant efflux systems. These active transporters are responsible for exclusion of 
unwanted cellular drug contents yielding a loss in clinical efficacy.5 Moreover, the 
emergence of resistance is also associated with mechanisms that alter the active sites of 
both topoisomerase II and IV. This reduction in the binding affinity of the quinolones 
renders them ineffective.5 
 
2.2.3 Tetracyclines 
The tetracyclines represent another large class of commonly prescribed antibiotics. 
These broad spectrum polyketides were isolated from a Streptomyces genus and all contain 
various functional group modulation on a tetracyclic core, several examples are shown in 
Figure 2.3.6 
The tetracyclines act by inhibiting bacteria protein synthesis. Tetracycline bound to the 
A-site of the ribosomal 30S subunit prevents aminoacyl t-RNA association, effectively 
halting protein synthesis, resulting in cell death.6 
Once again, resistance has occurred through a variety of mechanisms.  Both Gram-





intracellular tetracycline out of the cell, thereby reducing the effective concentration and 
preventing it from binding the A-site of the ribosome. Although a number of the 
tetracyclines (i.e., glycylcycline and minocycline) are still impervious to the efflux 
proteins, laboratory studies have managed to produce resistant strains quite readily and it 
is only a matter of time before they present themselves clinically.6 
Both Gram-negative and Gram-positive stains have also developed nine ribosomal 
protection proteins which effectively prevent tetracycline binding to the ribosome. 
Moreover these ribosomal protection proteins are less specific for the drug itself and more 
specific for the active site targeted, and thus generate a much broader range of resistance.6  
 
2.2.4 Macrolides 
The macrolide antibiotics are another key group of protein synthesis inhibitors. They 
are typically characterized by a large macrocyclic lactone decorated by one or more deoxy 
sugars attached to the parent ring (Figure 2.4). This compound class is mainly represented 
by metabolites isolated from the Streptomyces sp. In contrast to the tetracyclines, 
macrolides bind to the 23s component of the large ribosomal subunit (50S) thus preventing 
elongation.7 
Site-specific methylations in the active site preclude macrolide binding, and in most 
cases are the most relevant resistance mechanism. These methylations reduce the drug’s 
efficacy, and unfortunately in most cases this resistance mechanism is broad spectrum and 
encompasses a number of macrolides.7 Furthermore, Gram-negative bacteria are capable 
of producing a transport system to remove any unwanted material in the cellular contents, 






2.2.5 Lipopeptides, Defensins, and Defensin Mimics 
As resistance becomes more prevalent, the requirement for different antibiotic scaffolds 
is more urgent. In recent years, the lipopeptides like daptomycin and colistan (Figure 2.5) 
have met these demands. These semisynthetic secondary metabolites work by either 
binding the exopolysaccharide of the bacterial outer membrane of Gram-negative strains, 
or binding the lipid-rich membrane in Gram-positive strains. This amphipathic interaction 
causes cellular leaching and rapid cell death. The novelty of these compounds has also 
precluded their over-usage in agricultural, industrial and clinical setting and garnered fewer 
amounts of confirmed resistance. More importantly, the unique mechanism of action 
possessed by these compounds has also been shown to limit resistance. 8 
Further analysis reveals that the unique mechanism of the lipopeptides resembles the 
defensin antimicrobial peptides. These small peptides are β-sheet rich, highly cationic (via 
lysine and arginine residues), and contain six disulphide-linked cysteine residues. More 
importantly, these antimicrobial peptides are present in mammalian cells (thus at 
physiological concentrations are nontoxic) and confer very little known resistance. A 
nontoxic “defensin-mimic” like the lipopeptides demonstrates the ability of the 
pharmaceutical community to develop new and efficacious antibiotics.8 
Unfortunately, these semisynthetic bioanalogs are difficult to make, expensive, and 
susceptible to proteolytic degradation. Moreover performing relevant SAR studies on the 
complex molecules is complicated by their synthesis.8   
 
2.3 The Biofilm Phenotype 
The abundant use of preexisting antibiotics have triggered an evolutionary response by 





themselves by existing primarily in a polymeric matrix-enclosed system more commonly 
referred to as a biofilm. The observation of biofilm forming bacteria was first reported over 
70 years ago by Zobell.9, 10 Scientists first studied bacteria from planktonic or freely 
floating arrangements. However, bacteria rarely exist in this form, and are more commonly 
involved in complex metabolic, structural, and chemical communities.11, 12 
Biofilm bacteria are found on almost every natural and man-made surface and act as a 
direct method to protect themselves from the ever-changing environment they inhabit.11 
Costerton observed biofilms in stream water in the late 1970’s identifying them by their 
encasement in “slime” which anchored the bacteria to the bed surface they lived on. 13  
The complex life cycle of a biofilm begins with attraction to a biological or 
nonbiological surface via weak Van der Waals interactions (Figure 2.6-1). These weak 
interactions lead to more prevalent and stronger associations between the bacteria and the 
surface. Expansion begins when microcolonies occupy the newly formed space via 
replication of the initial attached bacteria (Figure 2.6-2,3). As the microcolonies replicate, 
macrocolonies begin to form and secrete a vast amount of nutrients (including water, 
sugars, and proteins) that enrich the structure and ensure proper maturation of the biofilm 
(Figure 2.6-4).11, 14 This phenotype safeguards the bacteria from external stimuli including 
temperature, salt content, antibiotic content, toxic molecules, and the mammalian immune 
system. When the bacteria have saturated the environment they are in, cell signaling 
pathways disperse the biofilm causing disaggregation, allowing the bacteria to go out and 
find a new hospitable environment (Figure 2.6-5). Cohabitation of the biofilm is possible, 
a phenomena which typically begins with two independent colonies coalescing to form one 





with CF as well as in the oral cavity of patients with dental plaque.16 
The biofilm phenotype is a ubiquitous living structure present on natural and unnatural 
surfaces. Its widespread incidence can be very detrimental in industry and healthcare and 
has been implicated in several disease states. 
  
2.3.1 Biofilms in Industry 
Biofilm formation in industrial settings result in billions of dollars (the complexities of 
these industrial processes prevent an accurate cost analysis) in damages a year through 
destructive process collectively referred to as biofouling which occurs primarily in oil 
pipelines, ship hulls, steel and paper production, the food and beverage industry, water 
desalination and water treatment plants.11a, 17, 18 The aqueous environment of many piping 
and cooling systems serve as an excellent staging area for biofilm growth. These sources 
are typically fed with fresh, nutrient rich, temperate water; variables that promote biofilm 
formation and growth. Unfortunately, even with biocidal agents and the implantation of 
antifouling processes, the inhibition of these unwanted biofilms is only temporary. Even in 
the absolute best case scenarios, that is, use of an antifouling surface, high degree of biocide 
administration, and mechanical debridement of the surface, only several years of biofilm 
free growth are guaranteed.18 Further data has shown that killing the bacteria that reside in 
the biofilm without removing the outer matrix (EPS) results in an optimum medium for the 
next round of biofilm growth. As shown in Figure 2.7, a chemical biocide is administered 
to a mature biofilm. The biocide causes the biofilm to die; however, its structural 
components remain, which can then serve as nutrient rich source for the next biofilm to 
build upon.18 





anodic regions, which promote electron flow and eventually leads to destruction of the 
metal surface. To further complicate the problem of biofouling the presence of iron and 
sulfate reducing species can also lead to the degradation of the steel used in pipelines.19 
Paper production can also be stunted by bacterial growth. Again the high throughput of 
clean, nutrient-rich water results in optimal conditions for biofilm formation. Biofouling in 
this environment can often lead to clogged filters, sheet breaks, and holes in the paper.20 
In order to amend these unwanted effects industries have turned to using toxic biocidal 
agents, like glutaraldehyde for treatment.21 Typically any alternative less toxic approaches, 
that is, dispersants, enzymes, and altering water composition are ineffective.18 The 
unwanted effects of biofilms in industrial media demand the need for novel more effective 
treatment methods. 
 
2.3.2 Biofilm in Medical Devices 
Invasive medical devices, such as catheters, intratracheal tubes, central vein lines, and 
peritoneal dialysis catheters, have advanced the standard of care in the modern clinical 
setting. However, introduction of a foreign object into the body can be met with severe 
reactions. Not only is the body trying to suppress these foreign objects via an autoimmune 
response, these objects can also serve as host for biofilm formation and development. 
According to a 1987 report by Costerton, biofilms were found in the following devices: 
wound drainage tubes, sutures, hemodialysis buttons, intraarterial and intravenous 
catheters, Hickman and silastic cardiac catheters, Swann-Ganz pulmonary artery catheters, 
urinary catheters, ureteral stents, biliary stents, penile prostheses, prosthetic hip joints, 
endotracheal tubes, intrauterine contraceptive devices (IUDs), transparent dressing, 





systems. In most cases no pathogenic infection was associated with the presence of the 
biofilm. This auspicious consequence, however, suggests that the presence of the biofilm 
phenotype is not only undetectable by the body’s own host-defense system but also the 
administration of antibiotics associated with surgical intervention is ineffective at 
destroying these macrocolonies. These sites of growth can also lead to subsequent 
manifestation of dormant bacteria, leading to a chronic pathogenesis.11b 
The inherent microstructure of plastic lends itself as to biofilm growth. Various medical 
devices, including endotracheal tubes have microsurfaces that promote biofilm growth.22 
These engineered surfaces contain a vast amount of troughs and crests which provide an 
ideal environment for the biofilm to not only reside, but also one which it is protected in.22 
The severity of this problem was amplified by the introduction of needleless infusion 
systems, which were implemented in the late 90’s to curtail the transmission of blood-
bourne pathogens including HIV and hepatitis B (previously large bore hollow stainless 
steel hypodermic needles were used).23 These needleless connections, though safer for 
healthcare professionals, have been implicated in several pathogenic outbreaks.23 
In order to solve this problem devices can be coated or impregnated with bactericidal 
agents like chlorohexidene or rifampin.24 Again however, the administration of these agents 
will only curtail infections rates on a short term.  
 
2.3.3 Chronic Infections Related to Biofilm 
Clinicians have developed a number of successful methods for treating acute bacterial 
infections. Acute bacterial infections are characterized by rapid onset, swelling and redness 
at the site of infection, and can be treated by a standard antibiotic regimen. The lack of 





bacteria are in, making them susceptible (albeit depending on their resistance level and 
how quickly the infection has been detected) to modern antibiotics.25  
A chronic infection on the other hand, is often marked by slower progression and is 
difficult, if not impossible, to treat with standard antibiotics. Often, the bacteria responsible 
for infection are observed in a dormant, aggregated state. The bacteria responsible for these 
infections can result in pneumonia in cystic fibrosis patients, chronic wounds, catheter and 
implant associated infections and chronic otitis media (infections of the inner ear).25 Given 
the characteristics of chronic infections the scientific community has suggested that these 
hard to treat bacteria are living in a biofilm or biofilm-like state.  
Cystic fibrosis (CF) is an inherited autosomal recessive disease affecting one out of 
every 20,000 people.26 The cause of CF was recognized in 1989 as mutations in both copies 
of the gene that encodes for the protein cystic fibrosis transmembrane conductance 
regulator (CFTR). The ineffective CFTR results in an ion imbalance leading to excessive 
dehydration of bodily fluids causing sweat, digestive fluids, and mucous to thicken. Most 
CF patients maintain a reasonable quality of life by extensive antibiotic treatment, 
commonly via inhalative Tobramycin therapy.27 Despite an effective and rigorous 
antibiotic program, persons with CF eventually lose their life due to excessive chronic lung 
infections and complications thereof. The constant strain put on the lung tissues through 
multiple pathogenic P. aeruginosa infections as well as administration of large amounts of 
antibiotics eventually leads to tissue destruction by the body’s own immune system. Given 
the conditions of CF, it is firmly believed that the resultant difficult to treat P. aeruginosa 
infections are caused primarily by biofilms.25, 26  





thin section of alveolar material contained cells of P. aeruginosa and what Costerton 
referred to as “microcolonies…enveloped in a fibrous anionic matrix”.28 Further work by 
Davies and coworkers found evidence of clusters of P. aeruginosa enveloped in a thick 
matrix.  Davies was also able to identify two significant quorum sensing signals which 
were in consonance with laboratory biofilm isolates.29 
With the detrimental effects of biofilms in CF patients it is not surprising that biofilms 
are also observed in other chronic infections. An increasing amount of the general populace 
is stricken by diabetes and heart disease. The poor cardiovascular bloodflow as well as the 
myriad of other physiological complications associated with these disease states can lead 
to chronic infections via unnoticed wounds and/or general unhealed lacerations. Although 
these wounds are referred to as chronic, resultant from their delayed repair and healing, 
they have been shown to contain a significant amount of biofilm bacteria. Again the 
presence P. aeruginosa has led a number of researchers and clinicians to conclude that the 
delayed response of heavy antibiotic treatment coupled with persistent wounds are due to 
biofilms clearly associated with these disease states.30 Furthermore, when P. aeruginosa is 
found in the chronic wound, studies have shown the wound to be larger in area compared 
to other examples lacking P. aeruginosa.31  
Given the relevance of the above clinical infections, drug design must not only include 
planktonic data but also move toward a design that addresses biofilm forming species. In 
doing so, the risk for developing chronic biofilm infections may be mitigated.  
 
2.4 Finding a Cellular Target for the Biofilm Phenotype 
Quorum sensing is the mechanism by which bacteria can communicate with each other 





induces a number of quorum sensing factors which are bacterially produced. These quorum 
sensing signals tell the bacteria to go out in search of nutrients, new habitable zones, and 
thus prevent the accumulation of waste products in the biofilm. When these signals are 
released they effectively cause the biofilm to disassemble through several mechanisms, 
including: terminating the synthesis of the extracellular polymeric substance (EPS) matrix, 
breaking down the matrix itself, or disrupting the noncovalent surface adhesion interactions 
which keep the biofilm anchored to its surface.32 
Given the above criteria, these biofilm disassembly methods could be used as targets 
for biofilm dispersal. Moreover, the unique design of a biocidal agent that could influence 
dispersal as well as act as an antibiotic would be highly valued due to the detrimental 
association of biofilms in various media as shown above. 
Losick and Clardy have reported success in this arena, by developing polyamine 
compounds that can disperse Bacillus subtilis, and Staphylococcus aureus biofilms. They 
found several polyamines to be highly interactive with the exopolysaccharide subunit of 
the biofilm causing its degradation. Clardy and Losick show that 25 µm norspermidine, 
prior to inoculation, inhibits biofilm formation without disrupting planktonic growth. 
Further analysis shows that spermidine (one extra methylene unit) is inactive at 
concentrations < 2 mM while the four-nitrogen counterpart of norspermidine, norspermine 
is active at ~50 µM. The authors speculate these results are due to the highly interactive 
nature of norspermidine (and other 3 carbon conjugates) with the EPS causing a weakness 
in the biofilm secondary structure and ultimately biofilm dispersal. However, the seminal 
works of Losick and Clardy have been disputed several times in the community, and 





concentrations reported.33, 34, 35 
The groups of Wall and Michael, as well as Berg, have reported antibiofilm activity by 
norspermidine, however, they reported norspermidine to be 10 times less potent than the 
data reported by Losick and Clardy.35 Unfortunately, it is unknown at this time which data 
is in agreement with the biological activity of these polyamino compounds norspermidine 
and norspermine.  
Due to the sensitivity and reproducibility of the biofilm dispersion data presented above 
there is a need for additional tests to provide a more conclusive analysis as to what effect 
norspermidine and other polyamines have on biofilm production, assembly, and 
disassembly.  
 
2.5 Design and Synthesis of Novel Antibiofilm Antibiotics 
Given the generalized structure of the defensins and the lipopeptide (defensin-like) 
antibiotics (highly polar cationic tails attached to a nonpolar body) we sought to develop 
an antimicrobial that was cheap, easy to make, and highly potent against bacteria. Several 
compound classes in the literature further rigidified our hypothesis for structure 
requirements as they possessed the requisite information to properly mimic the lipopeptides 
and defensins. Furthermore, a number of these compounds contained a polyamine subunit 
which we felt could invoke antibiofilm characteristics in agreement with Clardy and 
Losicks original data.34   
 
2.5.1 Squalamine 
Squalamine (Figure 2.8) is a potent secondary metabolite found in the dogfish shark 





activity, as well as antiprotozoa effects.36 Additionally, this aminosterol has been 
investigated as an anticancer therapeutic for its ability to inhibit angiogenesis in several 
mouse cancer models.37  
When tested, squalamine displayed potent bactericidal activity. Gram-positive strains 
like Staphylococcus aureus showed MIC values of 1-2 µg/mL, while Gram-negative strains 
like E. coli and Pseudomonas aeruginosa showed MIC values of 1-2 µg/mL and 4-8 
µg/mL, respectively.36   
Given the structure of squalamine, we can deduce that the steroidal core provides the 
hydrophobic bulk for the molecule while the polyamine tail gives cationic character. 
Furthermore, given Losick and Clardy’s finding, the pendant polyamine (spermidine) may 
also provide some effect on biofilm antifouling. Although in their examples norspermidine 
(1 methylene unit shorter) was much more effective.33, 34 
 
2.5.2 The Ceragenins 
The ceragenins or cationic steroidal antimicrobials (CSAs) are a class of steroidal 
compounds developed in Paul Savage’s lab at Brigham Young University. The CSAs were 
developed as a complement and mimic of the ever expanding group of lipopeptides. Use 
of synthetic small molecules instead of large polypeptides has a number of benefits as the 
ceragenin’s have no proteolytically cleavable side chains and are obtained from 
commercially available chemical stock thereby eliminating any biosynthesis. Originally 
termed as CSA, the Savage group opted to name their molecules ceragenin’s to avoid any 
stigma associated with the steroid name.38 
The mechanism of action of these molecules is similar to the lipopeptides, as the 





membrane depolarization and ultimately cell death. In Gram-positive bacteria the 
ceragenin’s have been shown to bind to the phospholipids present in the cell membrane 
causing cellular leakage and eventually death. Both membranes are rich in negatively 
charged side-chains (teichoic acid for Gram-positive and lipid A for Gram-negative) and 
thus the association of the cationic ceragenin causes pores leading to cell death.38  
Synthetically (Scheme 2.1), the ceraginins were prepared from cholic acid methyl ester 
(1). Starting from 1, a hydride reduction of the methyl ester followed by trityl chloride 
protection of the pendent alcohol afforded the protected sterol. Subsequent tris-allylation 
of the secondary alcohols produced 2. Hydroboration was accomplished with 9-BBN after 
which the resultant alcohols were mesylated to provide 3. Subsequent azide displacement 
produced tris-azide 4. With the tris-azide in hand, the trityl group was removed and the 
resulting alcohol was activated again with mesyl chloride to yield the mesylate 5. 
Displacement of the activated alcohol with octylamine afforded the desired amine 6. To 
generate the desired ceraginin CSA-13, reduction of the remaining tris-azide was 
accomplished with LiAlH4.38  
In their development of the Ceraginin’s, the Savage group was able to procure several 
effective bactericides.  CSA-13, for example, shows potent activity against resistant strains 
of Staphylococcus aureus with an MIC of 4 µg/mL. Further potency data has revealed 
CSA-13 to be active against protozoa including Leishmania major (LD50 = 4.9 µm) and 
Trypanosoma cruzi (LD50 = 9.0 µm). The synthetic flexibility, novel mechanism of action, 
and lack of proteolytic cleavage make the ceragenins an effective class of antimicrobial 






2.5.3 Looper’s Initial Design Concept   
The above examples showcase an underrepresented class of molecules which have 
broad spectrum activity, are chemically accessible, and more importantly are noncytotoxic 
against mammalian cells. Further, their unique mechanism of action makes these peptide 
membrane-active mimics immune to resistance. These steroidal biocides are governed by 
a simple principle, highly cationic tails are localized on a hydrophobic backbone but lack 
the cleavable amide linkages present in peptide-based antibiotics both natural and 
synthetic. We felt several adjustments could be made in order to expand on this dogma. 
First, a simplified synthetic approach would not only provide more applicable structural 
modularity, but would also favor analog design (Figure 2.9). Second, Clardy and Losick 
have shown various polyamines to have antibiofilm activity (see above).33, 34 Given the 
structure of squalamine (Figure 2.8), we hypothesize that potential antibiofilm activity 
could be observed through polyamine design on a hydrophobic scaffold. With these criteria 
in mind, we constructed a number of compounds in a concise synthetic sequence which 
would allow for modularity aimed at SAR studies. 
Although elegant in design, Savage’s work lacked modularity and synthetic 
accessibility, this is demonstrated in the lengthy synthesis of CSA-13 shown in Scheme 
2.1.38 If the steroidal core was simplified to a smaller, less complex, hydrophobic 
backbone, the synthetic sequence would be significantly shortened.  
 
2.6 Looper’s First Generation Biocide Synthesis 
We felt that the Wieland-Miescher ketone (7) provided us with the requisite chemical 
information to support this process as it met three of the criteria: 1) the ketone was cheap 





adjustments, and 3) the three dimensional structure of the bicycle should be similar to that 
of the steroidal backbone. Starting from racemic Wieland-Miescher ketone (7) 
hydrogenation of the olefin followed by reduction of the pendant ketones afforded the diol 
8. From 8, alkylation with allyl bromide provided diene 10. Unfortunately, the allylation 
required harsh conditions to produce 10 and was low yielding. Also, the remaining SN2 
displacement of the mesylate 11 by nitrogen-nucleophiles required very forcing conditions 
and never produced the desired product 12 (Schemes 2.2 and 2.3).  
Since the Wieland-Miescher ketone approach was unsuccessful in our hands, we turned 
our attention to even simpler backbones. Using the idea of tethering a cationic tail to a 
nonpolar body, benzyl halides were chosen as initial starting materials. We synthesized 
compounds (Figure 2.10) using a displacement reaction with the respective benzyl halide 
and mono-Boc protected diamine and triamines to generate a series analogs with a single 
side chain (Scheme 2.4). We quickly discovered that reductive amination of the requisite 
aldehyde was a cheaper approach compared to the displacement of a benzyl halide and we 
adjusted our synthesis to utilize aldehyde starting materials (Scheme 2.5).  
Based on the MICs of CZ-01-003 through CZ-01-016 (Table 2.2), the single side-chain 
compounds showed limited activity with values ranging from 100 to 1300 µg/mL. 
However, these compounds supported our initial rational design and we felt that the 
simplest and fastest approach to increasing activity would be to add another polyamine side 
chain (Scheme 2.6). This was facilitated through the use of isophthalaldehyde, a starting 
material that is readily accessible and inexpensive. A significant increase in potency 
resulted, as shown in the differences between CZ-01-007 (>800 µg/mL) and CZ-01-025 





studies were strengthened by the addition of several other functional groups to our series, 
including internal and external amides, CZ-01-040 and CZ-01-027 respectively (Figure 
2.11). As well as the tri-methyl conjugate CZ-01-019.  
We were able to gather further empirical biofilm data based on SEM analysis of 
biofilms grown on galvanized steel coupons. CZ-01-025 was the first lead in this series, 
selected due to it bactericide and antibiofilm properties. As shown in Figure 2.12 biofilms 
of Alcanivorax borkumensis were grown on galvanized steel for 48 h and left untreated 
(positive control). The masses of growth can be seen at both 200x and 1000x magnification. 
When these colonies were treated with CZ-01-025 for 2 h, and a significant reduction in 
biofilm is observed (rightmost image) again at both 200x and 1000x magnification. This 
experiential data gave us evidence that not only was CZ-01-025 active in planktonic media 
but also in the biofilm phenotype and CZ-01-025 was responsible for both biofilm dispersal 
and bacterial kill.  
Again, we were able to observe this trend when biofilm were grown in a CDC reactor 
and treated with CZ-01-25. As shown in Figure 2.13, the biofilm was sustained in the water 
but after application of our compound very fine fragments were observed. These fragments 
are indicative of biofilm dispersal.39 These data, albeit qualitative, clearly show proof of 
concept to our compound design. 
We further elected to use a trialdehyde starting material to produce compounds 
containing three side-chains. Although benzene-1,3,5-tricarbaldehyde had to be purchased 
from a specialty chemical supplier, it’s derivatives again showed a similar increase in 
potency as the alteration from one side chain to two. As shown in Table 2.3, CZ-01-52 had 





32 had an MIC of 50 µg/mL whereas the doubly aminated derivative CZ-01-12 had an 
MIC of 100 µg/mL. Again, this trend indicated that first, more cationic character had a 
direct influence on activity, and the norspermidine derivatives were the most potent 
compounds of the group. Several other side chains were used in conjugation with benzene-
1,3,5-tricarbaldehyde including N1,N1-dimethylpropane-1,3-diamine (CZ-01-46), Boc-
norspermidine (CZ-01-54), and nospermine (CZ-01-57), and again their initial MICs were 
higher than CZ-01-52. 
 
2.7 Conclusion and Future Aims 
The first generation series, shown above, provided proof for our initial concept design 
where a simple phenyl ring acted as the hydrophobic backbone and a variety of polyamines 
were selected as the cationic tail(s). With our synthetic method we were able to provide a 
set of carefully constructed compounds in two steps displaying both potent MICs and 
antibiofilm activity. We were able to further conclude norspermidine was the most potent 
side-chain used in analog development and the linkage of it to a hydrophobic backbone 
delivered compounds with antibiofilm properties. The modularity of this first generation 
synthesis was limited by what aldehydes were commercially available, and in order to 
pursue a broader SAR analysis we were pressed to find alternative sources of aldehydes 














Clostridium Difficile (CDIFF) Biggest Threat 
Carbapenem-Resistant Enterobacteriaceae Biggest Threat 
Neisseria gonorrohoeae Biggest Threat 
Multidrug resistant (MDR) Acinetobacter Serious Threat 
MDR Pseudomonas Aeruginosa Serious Threat 
Methicillin-Resistant Staphylococcus Aureus 
(MRSA) Serious Threat 
Drug-Resistant Tuberculosis Serious Threat 
Drug-Resistant Non-Typhodial Salmonella Serious Threat 
Drug-Resistant Shigella Serious Threat 
Extended Spectrum Enterobacteriaceae 
(ESBL) Serious Threat 
 
Table 2.2: The in vitro activity of the initial single side-chain CZ series as MICs against 
MRSA 
 
















Table 2.3: The in vitro activity of the bis and tris polyamine CZ series as MICs against 
MRSA 
 
















Figure 2.1: The structures of various members of the β-lactam family of antibiotics 
 
 







Figure 2.3: Several representative examples from the tetracycline class of antibiotics 
 


































Figure 2.6: Artistic representation of the five stages of biofilm formation from the 
planktonic phenotype (1) to biofilm EPS (hemispherical outer coating) development (2 






Figure 2.7: Artistic representation of antibiotic treatment of a mature single species 



































Figure 2.11: The bis and tris substituted CZ compounds with a variety of cationic 







Figure 2.12: Biofilms of Alcanivorax borkumensis grown for 48 h on galvanized steel and 
then: either left untreated or treated for 2 h with CZ-01-25   
 
 


















































Scheme 2.6: Synthetic analysis for the bi- and tri-substituted phenyl CZ compounds 
 
2.8 Supporting Information 
2.8.1 General Experimental Conditions 
Unless otherwise noted, materials were obtained from commercial sources and used 
without purification; otherwise, materials were purified according to Purification of 
Laboratory Chemicals.40 All reactions requiring anhydrous conditions were performed 
under a positive pressure of nitrogen using flame-dried glassware. Methanol (MeOH) was 
distilled over magnesium prior to its usage. Diaminopropane is highly toxic and should be 
handled with great care. Any volatile polyamine synthesized should also be regarded as 
toxic and should be handled with care and always stored under N2 due to reactivity with 
O2 and CO2. Yields were calculated for material judged homogeneous by thin-layer 





eluting with the solvents indicated and visualized by a 254nm UV lamp. Flash column 
chromatography was performed with slurry-packed silica gel with solvents indicated in 
glass columns. Both the solvent system used for TLC and column chromatography needs 
to be made fresh upon usage due to the volatile nature of NH3 in H2O. 1HNMR spectra 
were recorded at 500 or 300 MHz as indicated. The chemical shifts (δ) of proton resonances 
are reported relative to the deuterated solvent peak: 4.79 ppm for H2O using the following 
format:chemical shift [multiplicity (s = singlet, d = doublet, dd = doublet of doublets, t = 
triplet, q = quartet, pent = pentet, hex = hextet, sept = septet, oct = octet, non = nonet m = 
multiplet),coupling constant(s) (J in Hz), integral]. 13C NMR spectra were recorded at 125 
MHz. Mass spectra were obtained by ESI/APCI for LRMS. Material purity was quantified 
with a Thermo scientific Ultimate 3000 LC system. Certain carbon experiments conducted 
with the VXR500 MHz NMR contain an artifact peak between 170.0-174.0 ppm, which 
has been confirmed by the facility administrator. 
Efficacy profiles of CZ-01-XXX against planktonic MRSA were determined using the 
microdilution minimum inhibitory concentration (MIC) and minimum bactericidal 
concentration (MBC) assays defined by Clinical and Laboratory Standards Institute (CLSI) 
in the M26-A guideline.  For comparison, efficacy profiles were also determined in parallel 
for vancomycin.  In short, to perform MIC analysis, several colonies of freshly-cultured 
MRSA or P. aeruginosa from blood agar were used to adjust a 0.5 McFarland standard 
(equated to ~7.5 x 108 colony forming units (CFU)/mL) in phosphate buffered saline (PBS; 
Fisher Scientific, catalog # BP399-1).  Bacteria were diluted 1:100 in a glass test tube.  In 
a 96-well plate, columns 2-11 were filled with cation adjusted Mueller Hinton broth 





protocol.  In order to fill the wells, liquids were poured into sterile dispensing reservoirs 
(Fisher Scientific, catalog #07-200-127) then pipeted using a multichannel pipet.  This 
process gave a concentration range of antibiotic from 128 µg/mL in column 2 to 0.25 
µg/mL in column 11.  A 96-well plate was covered with a plastic plate cover and incubated 
at 37° C for 24 h after which time the plate was read.  The lowest concentration of antibiotic 
with no growth (no pellet formation) of bacteria was defined as the MIC. 
 
2.8.2 Missing Experimental Data 
Some examples included in the formal report were omitted for clarity, as these 
compounds were synthesized only once and handed off to our biological counterpart 
without full compound characterization. Furthermore, we felt the biological data related to 
these samples did not warrant any additional pursuit.  
 
2.9.3 Experimental Procedures 
 
CZ-01-003: N1-benzylbutane-1,4-diamine, hydrochloride salt: To a solution of 
benzaldehyde (0.50 g, 4.72 mmol, 1.0 equiv.) in MeOH (10 mL) was added tert-butyl (4-
aminobutyl)carbamate (0.88 g, 4.72 mmol, 1.0 equiv.) and the reaction was left to stir for 
16 h. Sodium borohydride (0.71 g, 18.88 mmol, 4 equiv.) was then added portion wise and 
the reaction mixture was left to stir for an additional 1 h. The excess MeOH was evaporated 
and the crude solid was partitioned between EtOAc (50 mL) and 10% NaOH (mL). The 
aqueous layer was then back extracted with EtOAc (1 x 50 mL) dried over Na2SO4 and 





purification. The crude free base was acidified with HCl in MeOH (50 mL) and then placed 
at 0 °C for 1 h to precipitate. The corresponding precipitate was filtered and dried to afford 
the HCl salt as a white solid (48%). 1H NMR (500 MHz, D2O) δ 7.52 (s, 5H), 4.26 (s, 2H), 
3.15 (t, J = 8 Hz, 2H), 3.07 (t, J = 7.5 Hz, 2H), 1.86-1.74 (m, 4H). 13C NMR (125 MHz, 
D2O) 130.6, 129.9, 129.7, 129.2, 51.0, 46.3, 38.8, 23.9, 22.7. LRMS calculated for 
C11H18N2 m/z 179.1 [M+H]+, Obsd. 179.2. 
The following examples were prepared similar to CZ-01-003: 
 
CZ-01-004: N1-Benzylpropane-1,3-diamine, hydrochloride salt: 
1H NMR (500 MHz, D2O) δ 7.49 (quint, J = 3 Hz, 5H), 4.26 (s, 2H), 3.17 (t, J = 8 Hz, 2H), 
3.07 (t, J = 8 Hz, 2H), 2.09 (quint, J = 7.5 Hz, 2H). 13C NMR (125 MHz, D2O) δ 130.6, 
129.9, 129.8, 129.4, 51.4, 44.1, 36.7, 23.9. LRMS calculated for C10H16N2 m/z 165.2 
[M+H]+, Obsd. 165.4. 
 
CZ-01-006: N1-(3-(Benzylamino)propyl)-N3,N3-dimethylpropane-1,3-diamine, 
hydrochloride salt: 1H NMR (500 MHz, D2O) δ 7.41 (s, 5H), 4.18 (s, 2H), 3.20-3.08 (m, 
8 H), 2.83 (s, 6H), 2.15-2.03 (m, 4H). 13C NMR (125 MHz, D2O) 131.0, 130.5, 130.4, 







CZ-01-007: N1-(3-Aminopropyl)-N3-benzylpropane-1,3-diamine, hydrochloride salt:  
1H NMR (500 MHz, D2O) δ 7.49 (s, 5H), 4.25 (s, 2H), 3.20-3.15 (m, 6H), 3.11 (t, J = 8 
Hz, 2H), 2.17-2.07 (m, 4H). 13C NMR (125 MHz, D2O) δ 130.3, 129.8, 129.7, 129.2, 51.2, 
44.6, 44.6, 43.8, 36.5, 23.7, 22.6. LRMS calculated for C13H23N3 m/z 222.2 [M+H]+, Obsd. 
222.2. 
 
CZ-01-011: N1,N12-Dibenzyldodecane-1,12-diamine, hydrochloride salt:  
1H NMR (500 MHz, D2O + CD3OD) δ 7.53 (s, 10H), 4.24 (s, 4H), 3.04 (t, J = 8.5 Hz, 4H), 
1.77-1.70 (m, 4H), 1.42-1.28 (m, 16 H). 13C NMR (125 MHz, D2O + CD3OD) δ 131.0, 
129.8, 129.6, 129.3, 50.9, 47.0, 29.2, 29.1, 28.7, 26.2, 25.7.  
 
CZ-01-013: N1-(3-Methoxybenzyl)dodecane-1,12-diamine, hydrochloride salt: 1H 
NMR (500 MHz, D2O) δ 7.40 (t, J = 8.0 Hz, 1H), 7.06 (s, 1H), 7.05 (s, 1H), 7.03 (s, 1H), 
4.16 (s, 2H), 3.82 (s, 3H), 3.00-2.93 (m, 4H). 1.66-1.58 (m, 4H), 1.32-1.22 (m, 16H). 13C 
NMR (125 MHz, D2O) δ 158.4, 131.5, 129.8, 121.6, 114.5, 114.3, 54.7, 49.8, 46.1, 38.7, 








hydrochloride salt: 1H NMR (500 MHz, D2O) δ 7.49 (s, 5H), 4.27 (s, 2H), 3.51-3.49 (m, 
6H), 3.27-3.14 (m, 6H), 3.12 (t, J = 8.0 Hz, 2H), 2.21-2.10 (m, 4H). 13C NMR (125 MHz, 
D2O) δ 130.5, 130.0, 130.0, 129.5, 51.4, 45.3, 45.2, 43.9, 43.2, 36.6, 27.8, 23.9, 22.8. 
CZ-01-021: N1,N1'-(1,3-Phenylenebis(methylene))bis(dodecane-1,12-diamine), 
hydrochloride salt: 1H NMR (500 MHz, D2O) δ 7.65 (s, 3H), 4.36 (s, 4H), 3.11 (t, J = 8.0 
Hz, 4H), 3.06 (t, J = 7.5 Hz, 4H), 1.77-1.68 (m, 8H), 1.47-1.33 (m, 32H). 13C NMR (125 
MHz, D2O) δ 130.4, 129.9, 129.7, 128.9, 49.0, 45.6, 38.2, 27.3, 27.3, 27.2, 27.1, 26.9, 26.8, 
25.4, 24.4, 24.3, 24.0. Calculated for C32H62N4 m/z 503.5 [M+H]+, Obsd.503.5. 
 
CZ-01-025: N1,N1'-(1,3-phenylenebis(methylene))bis(N3-(3-aminopropyl)propane-
1,3-diamine), hydrochloride salt: 1H NMR (500 MHz, D2O) δ ppm 7.62 (s, 4H), 4.36 (s, 
4H), 3.28-3.21 (m, 12H), 3.15 (t, J = 8.0 Hz, 4H), 2.23-2.11 (m, 8H). 13C NMR (125 MHz, 
D2O) 131.4, 131.3, 131.1, 130.2, 50.8, 44.7, 44.6, 44.1, 36.5, 23.6, 22.6. Calculated for 







diyl))bis(N3,N3-dimethylpropane-1,3-diamine), hydrochloride salt: 1H NMR (500 
MHz, D2O) δ 7.57 (s, 4H), 4.31 (s, 4H), 3.28-3.14 (m, 16H), 2.91 (s, 12H), 2.20-2.10 (m, 
8H). 13C NMR (125 MHz, D2O) δ 132.1, 131.9, 131.8, 130.9, 54.8, 51.5, 45.3, 45.1, 44.8, 
43.5, 23.3, 21.9.  
 
CZ-01-052: N1,N1',N1''-(benzene-1,3,5-triyltris(methylene))tris(N3-(3-
aminopropyl)propane-1,3-diamine), hydrochloride salt:  1H NMR (500 MHz, D2O) δ 
7.74 (s, 3H), 4.41 (s, 6H), 3.30 (t, J = 7.5 Hz, 6H), 3.24 (q, J = 9.0 Hz, 12H), 3.16 (t, J = 
8.0 Hz, 6H), 2.26-2.12 (m, 12H). 13C NMR (125 MHz, D2O) δ 132.7, 132.6, 50.5, 44.7, 









methanol, hydrochloride salt: 1H NMR (500 MHz, D2O) δ 7.57 (s, 2H), 7.55 (s, 1H), 
4.72 (s, 2H), 4.35 (s, 4H), 3.26-3.19 (m,12H), 3.13 (t, J = 7.5 Hz, 4H), 2.21-2.09 (m, 8H). 




aminopropyl)amino)propyl)propane-1,3-diamine), hydrochloride salt: LRMS 
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SYNTHESIS OF N’N’’ ALKYL AND DIALKYL POLYAMINES  
WITH RESPECT TO THEIR APPLICATION  




Polyamines are an important class of organic molecules that contain two or more amine 
functional groups. The polyamines spermidine, spermine, and putrescine (Figure 3.1) play 
an intrinsic role by regulating growth and cellular differentiation.1 It is not surprising that 
upon addition of these polyamines in vitro, a variety of cellular responses are elicited as 
these highly cationic molecules are very promiscuous, binding with nucleic acids, proteins, 
and phospholipids.2  
For years, polyamines have served as clinically relevant molecules and are currently 
being evaluated for use as chemotherapeutics,3 antimalarials,4 biomimetics,5 pesticides,6 
and antihuman immunodeficiency virus (HIV) retrovirals (Figure 3.2).7 Norspermidine, for 
example, has been shown to have significant antiproliferative activity against a number of 
cancer cell lines, not limited to L1210 leukemia, 3LL carcinoma, and EL4 lymphoma.8 
Further investigation has revealed several alkyl-polyamine analogs are effective anti-
neoplastic   agents.   In  particular,  N1,N11-diethylnorspermine  was  selected  to   proceed  





As a ubiquitous source of polyamines, eukaryotic cells have been studied extensively 
to determine the role of polyamines in malignant disease. Elevated levels of polyamines 
have been observed in patients suffering from leukaemias, melanomas, adenocarcinomas 
and lymphomas. Further diagnostic studies have shown that patients in remission had a 
clinically comparable polyamine concentration to normal individuals. Additionally, when 
patients suffered from a tumor recurrence, polyamine levels once again became elevated10.  
Russell and Snyder first observed a connection between increased polyamine synthesis 
and cellular growth in 1968. They reported that with high levels of ornithine decarboxylase 
(ODC), the enzyme responsible for forming the polyamine putrescine (1,4 diamino butane) 
from ornithine, tumor production increased and growth of tissues including rat liver and 
chick embryo were observed.11 In addition, there are a number of exogenous chemical 
promoters of ODC, including UV light and asbestos; these agents are often implicated in 
carcinogenesis.12 
Given the above phenomena one can conclude that there is a link between polyamines 
and cancer. Further investigation of polyamine adducts could have beneficial therapeutic 
results. 
Polyamines are vital for prokaryotic function as well. Recently, polyamines have been 
shown to be important in siderophore biosynthesis, swarming, and biofilm formation. 
Clardy and Losick were able to demonstrate that norspermidine could disrupt biofilm 
formation in Bacillis subtilis; yet minimal changes in the polyamine structure increased the 
minimum biofilm inhibitory concentration (MBIC) 10-100 fold.13 This difference was 
most apparent in the decrease in MBIC by changing the norspermidine to spermidine which 





Polyamines are ubiquitous molecules involved in cellular processes in both prokaryotes 
and eukaryotes. The current polyamine compounds on the market and in the pipeline have 
had impacts on drug discovery in the past 60 years and continue to show promise as 
clinically active compounds. 
 
3.2 DFMO: An Inhibitor of Ornithine Decarboxylase 
The link between heightened levels of polyamine content leading to excessive cellular 
proliferation has been presented in the literature for over 40 years. Researchers used this 
phenomenon to develop a series of ODC inhibitors in the late 1970’s at the Merrell 
Research Institute. At the time, this research was developed in efforts to produce novel, 
viable treatments for cancer and other diseases.  The molecule DFMO (Figure 3.2) was 
prepared by Merrell shortly thereafter.14 
The molecule DFMO has had the most noteworthy impact on polyamine research in 
the past 5 decades. Although clinically DFMO has failed to advance as an anticancer agent, 
its ability to inhibit ornithine decarboxylase (ODC) makes it unique. Over time, DFMO 
has found successful clinical uses as both an antiprotozoal drug and as an active agent in 
reducing excessive facial hair growth on women.15   
DFMO and other ODC inhibitors have been reported to prevent tumor formation and 
growth in experimental models of breast, colon, bladder, and skin carcinogenesis.16 One 
clinical breast cancer study showed that increased ODC activity is loosely linked with 
decreased survival rates.16 Furthermore, a number of studies have shown that high levels 
of ODC activity are observed in several forms of colonic polyps. When left untreated, these 
unwanted cellular growths can develop into colorectal cancer.17 





implicated in a number of carcinogenic polyp cases. In 1993, Gerner and coworkers 
identified a link between ODC activity and colon cancer. When ODC activity and 
polyamine content was examined in 48 benign polyps and 18 malignant colorectal cancers 
(five of which were malignant polyps), they found that these growths had elevated ODC 
activity.17  
Unfortunately, initial clinical studies on DFMO yielded several side effects including 
abdominal pain, diarrhea, moderate anemia, and thrombocytopenia.18 Shortly thereafter, 
American biologist Cyrus Bacchi tested DFMO in a murine trypanosomiasis model and 
found that DFMO cured Trypanosoma brucei without any related acute mouse toxicity.19 
Further clinical trials supported these early results, and in 1990, DFMO was approved for 
its use in the treatment of African sleeping sickness. Currently, DFMO is the only treatment 
for Melarsoprol resistant strains.20,21 
 
3.3 AMD 3100 
The polyamine AMD 3100 (Figure 3.2) was first developed by AnorMED and 
subsequently bought by Genzyme. It is more commonly referred to as Plerixafor. AMD 
3100 was initially valued as an anti-HIV drug but since has been evaluated as an 
immunostimulant after patients receive heavy doses of chemotherapy.22 
In 1985, several polyoxometalates (spherical polyanionic compounds with strong metal 
affinity) were developed to treat HIV by inhibiting cell replication through inhibition of 
reverse transcriptase.23 These compounds had an extremely promising in vitro profile, but 
were never pursued clinically due to their administration protocols (systemic IV). 
However, a number of researchers recognized large organo-porphyrins and porphyrin like 





complexes and could be designed to have a similar mechanism of action as the 
polyoxometalates. The cyclams were chosen as a starting point, given the cyclic 
arrangement of 4 nitrogen atoms and their known affinity for metal ions.  Synthetic 
manipulations were made on a series of cyclam like compounds, including JMS1657 and 
JMS2763, and structure activity relationships led De Clercq to produce AMD3100 
(chronologically labeled as JM3100 as shown in Figure 3.4)  which displayed an excellent 
in vitro profile (EC50 against HIV-1(IIIB) = 3 nM).22, 23 
Unlike most polyamines AMD3100 can be prepared readily from commercially 
available cyclam 1. Phosphonation of three of the four nitrogens afforded the 
phosphorotriamide 2 (Scheme 3.1). The protected cyclam 2 was bis-alkylated with 1,4-
bis(bromomethyl)benzene to produce the protected AMD3100 (3). Hydrolysis with 3M 
HCl then completed the synthesis yielding the HCl salt of AMD3100 in a three-step one-
pot sequence with good yields.24 
Despite its promising in vitro profile, AMD3100 was eventually withdrawn from HIV 
testing due to unforeseen problems that led test subjects to develop cardiac disturbances, 
including rhythm disorders in Phase I trials. Shortly thereafter, subsequent testing revealed 
that AMD3100 was a potent CXCR4 receptor antagonist. This discovery led to the 
development of AMD3100 as an effective recruitment therapy for hematopoetic stem cells. 
Consequently, AMD3100 could be used to mobilize hematopoietic stem cells from the 
bone marrow to the bloodstream after a patient received high-dose myeloablative 
chemotherapy (method of cancer treatment used to kill cells in the bone marrow).22 
The new indication led AMD3100 to another round of clinical trials whereby a more 





in 2008 and is currently used for treating patients undergoing this form of chemotherapy.22 
Given the structure of the polyamine compounds synthetically prepared by the Looper 
group (Chapters 2 and 4) it is worth noting some of the pharmacokinetic data for 
AMD3100. The original clinical study on this molecule showed adverse cardiac effects, 
however, when the dose was limited (40-320 µg/kg) in the haemotopoietic stem cell trial 
no reports of cardiac arrhythmias were noted.22 The active pharmaceutical ingredient (API) 
is cleared at a rate of 4.9 L/h and has a half-life of 3.7-4.7 h. Further analysis revealed that 
the peak plasma concentration is 750-1020 ng/mL and the time required to reach peak 
levels is approximately 1 h. AMD3100 represents a unique class of polycationic molecules 
which are bioavailable with an adequate half-life. Given its unique structure and limited 
toxicity, AMD3100 represents precedence for the Looper group polyamines as they are 
carried forward for animal studies.25 
 
3.4 N1,N11-diethylnorspermine 
The polyamine N1,N11-diethylnorspermine (Figure 3.2) has shown a great deal of 
promise as an active chemotherapeutic agent. Given the rich polyamine pool intrinsic to 
cellular growth, cellular mimics like N1,N11-diethylnorspermine may hold the key to 
impeding cell proliferation. These unnatural polyamines amass inside the cell and decrease 
the amount of natural polyamines in the cell cycle. This cellular imbalance prevents cell 
growth and differentiation and eventually leads to cell death.1b 
When tested clinically, N1,N11-diethylnorspermine was found to have limited toxicity, 
in dogs at doses of 12.5, 25, and 50 mg/kg. Phase I human trials determined IV doses of 
25 mg/m2/day to be safe after five consecutive dosing days.  Furthermore, the maximum 





preliminary phase II clinical trial, the in vivo phase I toxicological data were validated at 
the doses administered but no significant efficacy was seen in a 16 person metastatic breast 
cancer cohort.9 
Despite its setbacks, N1,N11-diethylnorspermine shows very promising in vitro activity 
and a good toxicological profile. Further adjustment of the chemical via structure activity 
relationship studies could provide a more potent and equally safe compound, despite its 
regression in clinical trials. 
 
3.5 Synthesis of Unnatural Polyamines 
Despite their trivial structure, functionalization of any of these polyamines is 
synthetically challenging. Literature searches have revealed several ways to amend this 
problem, however, to the best of our knowledge, methods to produce these synthetically 
modified polyamines are limited and typically protecting group intensive as well as 
impractical for large scale synthesis as they require multiple column chromatography steps 
for purification. 
 
3.5.1 Woster and Casero’s Synthesis of Unnatural Spermine  
Derivatives  
Woster, Casero, and coworkers published an exhaustive protecting group strategy to 
address this problem while constructing norspermine analogs in 1993. Although their 
synthesis demonstrates the tenacity to tackle a challenging problem, they are heavily reliant 
on classical protection and deprotection strategies and limited to purifying intermediates 
via column chromatography as shown in Scheme 3.2. Starting from diaminopropane 4, a 





amine 5.27 Protection of 5 produced the corresponding mesityl diamine 6. Nucleophilic 
addition of the secondary amine onto 3-bromo-propyl-phthalimide yielded the fully 
protected triamine 7, which was subsequently used later in the synthesis. Woster and 
Casero were able to bring in their next piece in a convergent fashion. Starting from 
ethanaminium chloride 8, mesityl protection afforded the sulfone 9. Alkylation with 1,3 
diiodopropane subsequently produced the iodinated alkyl amine 10. Adding 10 to their 
previously constructed triamine 7 they were able to afford fully protected tetraamine 11. 
Hydrogenation conditions removed the benzyl group to yield the phthalimide 12. 
Furnishing the newly formed free amine with another mesityl group afforded 13. Final 
removal of the phthalimide with hydrazine produced the fully protected tetraamine 14 
whereby only the terminal nitrogen was reactive.28 
 
3.5.2 Bergeron’s Synthesis of Unnatural Spermidine Derivatives 
In order to make N1-ethyl-spermidine 20 Raymond Bergeron at the University of 
Florida adopted similar chemistry to that of Woster and Casero. Starting from propylamine 
15, mesityl protection produced the protected primary amine 16. Treatment of the amino-
sulfone with 1,4-dibromobutane afforded the alkylated protected amine 17. Again, 
adopting a convergent approach this alkylated derivative was used after formation of the 
protected diamine 18 from diaminopropane 4. Combining sulfones 18 with 17 under 
displacement conditions produced the fully protected spermidine derivative 19 which was 






3.5.3 Uriac and Sinbandhit’s Resin Based Synthesis of  
Norspermidine Derivatives 
The groups of Uriac and Sinbandhit used resin chemistry to overcome some of the 
protecting group problems present in the previous examples. Starting from the Wang resin 
carbonate 21, mono-Boc-norspermidine (using a three-step procedure) addition mediated 
the release of 4-nitro phenol to produce the carbamate 22. Addition of dansyl chloride 
provided the fully functionalized polyamine 23, which was then activated for solid support 
release. Acid-mediated removal of the carbamate resin as well cleavage of the Boc-
protecting group cleanly afforded the mono-alkylated polyamine 24 (Scheme 3.4).30 
The above examples represent clear indications that a protecting group-free synthesis 
with minimal synthetic steps would be valauble for making various polyamine analogs. 
Also avoiding chromatographic purification would be highly advantageous in order to 
reach industrial process scale.  
 
3.6 Preliminary studies 
We initially investigated norspermidine as a useful bactericidal agent for treatment of 
biofilm forming bacteria. Upon our investigation, we found that norspermidine and several 
other polyamines alone are inactive against most Gram-negative and Gram-positive 
planktonic strains of bacteria; although they disrupted biofilm formation as Clardy had 
shown.13 However, upon attachment of these polyamines to a core structure we were able 
to significantly increase potency of our bactericidal compounds in both planktonic and 
biofilm bacteria with dual-fold activity, killing, and dispersing the biofilm (for more 
information see Chapters 2 and 4).  





utilized in treatment of biofilm related infections (see Chapters 2 and 4). Initial structure 
activity relationship studies showed that norspermidine attached to a linker molecule, in 
our case [1,1'-biphenyl]-3,5-dicarbaldehyde or [1,1'-biphenyl]-3,3',5-tricarbaldehyde, had 
promising activity. The increase in potency was generally tied to an increase in backbone 
hydrophobicity, so we were led to further modulate the polarity of the side chain. As such, 
a general decrease in the side chain polarity was met with a further increase in potency and 
decrease in cytotoxicity (Figure 3.5).  
Furthermore, we felt that the primary terminal amine was a metabolic liability, and 
thus, we turned our attention to a series of alkyl-norspermidines and alkyl-polyamines like 
those present in N1, N11 diethylnorspermine to avoid these problems.  
 
3.7 Looper’s Synthesis of Alkyl Polyamine Derivatives 
When tested, in initial SAR studies, the CZ-analogs with norspermidine as the side-
chain consistently had the lowest MIC. In order to add more hydrophobicity and modularity 
to our CZ-compounds and remove the unwanted terminal primary amine, a series of 
terminally alkylated polyamines were envisioned (for naming see Supporting Information). 
With the precedence outlined above, we felt the synthesis of these compounds, however, 
would be difficult. Moreover, given that the strategy involved selectively altering one 
nitrogen on a substrate with three nearly chemically equivalent amines, purification would 
be inadequate at providing large quantities of research grade material. Initially a Boc-
protection of norspermidine 25 was employed in order to protect the terminal primary 
amine. Excess norspermidine prevented overprotection and yielded the Boc-norspermidine 
26 in moderate yields and moderate purity (Scheme 3.5). The excess norspermidine could 





could be seen (implicitly assigned as di-Boc-norspermidine, mono-Boc-norspermidine, 
and norspermidine). 1H NMR analysis of this mixture, on the other hand, was only sensitive 
enough to display the desired product, mono-Boc-norspermidine. Later studies confirmed 
this fact, and spiking samples with excess byproducts afforded indistinguishable results 
relative to pure material. This crude material, however, was carried forward in order to 
produce the final compound.  
Following a reductive amination of 26, we were able to achieve our alkyl 
norspermidines side chains which required further column purification. Drastic 
fluctuations in our biological assays led us to the conclusion that, although our final CZ-
compounds were empirically pure by NMR, we lacked both the synthetic means and 
analytical data to provide pure compound consistently. This is exemplified in Table 3.1, 
whereby the individual batches of CZ-01-086 (Figure 3.6) yielded significant differences 
in MIC values ranging from sub-micromolar (batch 1) to greater than 25 µg/mL (batch 9) 
against planktonic MRSA. 
We felt that the adjustment of the above method could benefit us in both reaction purity 
and reduction of side products as well as aid in the production novel polyamino 
compounds. With a substantial increase in purity, validation of our biological data could 
then be assured. Given the low cost and availability of norspermidine, several attempts 
were made at adjusting the previous strategy to afford analytically pure material.  
Given that the structure of norspermidine contains only two primary nitrogens we 
rationalized that a controlled reductive amination could produce the desired product with 
a limited amount of side products (Figure 3.7). Fractional vacuum distillation could then 





would have a significantly higher boiling point than its mono-isobutyl counterpart.  When 
attempted this strategy was unsuccessful. Qualitative TLC analysis consistently displayed 
a number of byproducts in roughly equal amounts.  
Exploration of reaction conditions as well as various electrophilic alkyl groups proved 
to be inconsequential (Figure 3.8). After attempting to synthesize the desired product with 
norspermidine and any number of alkyl halogens, a number of byproducts were observed 
both by NMR and TLC. Adjustment of molarity, reaction temperature, and molar 
equivalents was unsuccessful at affording the desired product.  We believed that in both 
cases (alkylation via halide electrophiles and reductive amination) the symmetric terminal 
amines were competing to produce a mixture of bis-alkyl-norspermidine, mono-alkyl-
norspermidine, and unreacted norspermidine and small amounts of other impurities. 
We turned our attention to a linear approach in which each amine was introduced 
selectively, negating the chance of any excess reactivity taking place. 3-amino-1-propanol 
was chosen as a useful starting material for this process as it met three criteria: 1) the 
reagent was cheap and readily available in large quantities (>20 kg), 2) the amine group 
could be synthetically manipulated without effecting the alcohol functionality on the chain. 
3) the hydroxyl group acted as a leaving group synthon whereby it could be activated to 
the bromide, sulfate, or tosylate for displacement. 
After screening conditions we found a reductive amination of the pendent amine to the 
alkylated derivative would provide us with our alkyl amino alcohol. This process is limited 
in the sense that a reductive amination must be used to provide us with pure material. A 






Activation of the alcohol was first attempted via sulfonate formation. Although 
successful, the sulfonate was inactive to our amine nucleophile in the next step under 
standard and elevated temperatures.31 Adjustment of the alcohol to another suitable leaving 
group was achieved through bromination with HBr. The excess water/HBr was then 
distilled off to afford the crude HBr salt which was recrystallized with MeOH/ether or i-
PrOH to yield white crystalline material.32 The scope of this method is shown in Figure 3.7 
where a variety of bromide salts were synthesized. Branched and unbranched alkyl systems 
were used, as well as cyclic and phenyl substituents. If desired this synthesis can work on 
a variety of amino-alcohols, as both two-carbon and three-carbon derivatives were 
produced.  
From the alkylated HBr salt, the substrate was now equipped for the final introduction 
of the remaining diamine. We felt addition of 1,3-diaminopropane to the salt would 
produce the desired norspermidine derivative under carefully controlled reaction 
conditions. We expected the addition of low molar equivalents of 1,3 diaminopropane 
and/or elevated temperatures would produce unwanted byproducts as was observed by 
TLC when this reaction sequence was performed. To circumvent this problems excess (10-
20 equivalents) of 1,3 diaminopropane were used. This worked two-fold, in providing 
enough base to deprotonate the HBr acid salt, and to severely limit any unwanted formation 
of any dialkylated norspermidine. The remaining 1,3-diaminopropane was then easily 
removed by a water wash and vacuum distillation. Vacuum distillation was further 
employed to purify the final product. 
With a successful strategy in hand we chose to make a variety of polyamine derivatives 





SAR studies (Figure 3.10). Functionalities ranged from butyl to octyl and included a variety 
of substituted alkyl derivatives. The diamines were varied to include 1,4-diaminobutane in 
order to generate the respective spermidine analogs 42 and 51. 
To further exemplify the utility of this strategy, we subjected a number of our newly 
formed norspermidine derivatives to a second round of reductive amination (Figure 3.11). 
Both alkyl and aromatic functional aldehydes were chosen. The compounds produced had 
very little bactericidal activity, but nonetheless demonstrate the effectiveness of this 
process. 
 
3.8 Conclusion and Future Aims 
With the above method we have generated an effective way to functionalize these tri-
amine derivatives and are no longer restricted by unsuccessful protecting group strategies 
and inefficient reaction conditions. Our synthesis is amenable to a number of side chains 
and can be completed on large scale (>100 g) with the only purification method being 
distillation and/or recrystallization. 
The difficulty of synthetically deriving these polyamino compounds in high purity is 
evidenced by the examples shown above (Section 3.5). Although the manipulation of these 
compounds seemed trivial, they impart a great deal of synthetic forethought. In our pursuit 
of a large scale synthesis of these alkylated polyamines minor impurities caused variations 
in the MIC of the final product. The synthesis derived from this mitigated these impurities, 
used simple starting materials, and allowed for facile purification by either distillation 
and/or recrystallization. Although the alkylations of amines by substitution reactions on 
alkyl halides are notorious for yielding multiple products and poor yields, we have found 





dialkylated species are purified upon distillation.  
Expansion of this chemistry is of great importance to producing more analogs and 
narrowing down pertinent structure activity relationships. We would further like to explore 
chemistry through several avenues in order to rationally design more functionalized 
molecules.  
Functionalization of the diethylmalonate system would be a useful tool to expand and 
investigate novel systems with different substitution patterns (Scheme 3.6). Starting from 
diethylmalonate, simple di-enolization followed by nucleophilic addition would produce 
the mono (not shown) and dialklyalted products. Reduction of the pendant esters followed 
by an activation/substitution sequence should afford the uniquely substituted 
diaminopropane compound which could be further employed in our current chemistry.   
We realized that our modular approach was somewhat limited in the aldehyde used 
during the initial reductive amination. Literature searches have exposed a limited supply 
of readily available aldehydes, which has significantly hindered SAR studies. A side chain 
synthesis whereby we could tune the functionality of any group terminus as well as adjust 
the overall length could be used in synthesizing a number of analogs. A brief look through 
the literature has led us to chemistry done by the Hrabálek group shown in Scheme 3.7.33 
With this in mind, we can modulate our above synthetic route to bring in aldehydes of 
varying chains lengths and terminal substitution patterns. Scheme 3.7 exemplifies this as 
an n-membered lactone is converted to the corresponding sodium salt. The terminal 
bromide is then replaced with a variety of alkyl Grignard’s reagents, followed by the 
oxidation to produce the fully functionalized aldehyde. 





have shown promising anti-invasive and antiangiogenic activity.34 Given their simple 
structure and biological profile we feel a facile synthesis using the methods described 
above could deliver these compounds in a short synthetic sequence. 
Starting from the amino alcohol, conditions facilitating intramolecular alkylation 
would produce the desired 13-membered ring. Using the bromination chemistry described 
above would yield the HBr salt, which upon treatment with 1,3-diaminopropane would 
afford the natural product, motuporamine A (Scheme 3.8).  
The above examples represent important underexplored problems which the Looper 
lab would like to address in the future. Further amendment of our “side-chain” chemistry 
has the potential to provide more active and safer antimicrobial compounds. The chemistry 
we have developed has allowed us to access a significant number of norspermidine and 
polyamine analogs in a linear sequence with the abolishment of column chromatography. 
These reactions can be completed on kg-scale and are clean, efficient, and high yielding. 
 


























Figure 3.2: Select examples of polyamines used in medical and industrial applications 
 






Figure 3.4: Representative polyamines from the AMD-series 
 
 







Figure 3.6: The structure of biocide CZ-01-086, synthesized with isobutyl norspermidine 
 
 
Figure 3.7: Attempted reductive aminations to produce the desired mono-alkylated amine 
 
 







































Figure 3.11: Dialkylated derivatives shown to demonstrate the versatility of this strategy 
 


















Scheme 3.3: Bergeon’s unnatural norspermidine synthesis 
 
 









Scheme 3.5: Looper’s initial design for alkylated norspermidine 
 
 




Scheme 3.7: Conversion of a variety of lactones to desired long chained alkyl aldehydes 
 
 






3.9 Supporting Information 
3.9.1 General Experimental Conditions 
Unless otherwise noted, materials were obtained from commercial sources and used 
without purification; otherwise, materials were purified according to Purification of 
Laboratory Chemicals.35 All reactions requiring anhydrous conditions were performed 
under a positive pressure of nitrogen using flame-dried glassware. Methanol (MeOH) was 
distilled over magnesium prior to its usage. Diaminopropane is highly toxic and should be 
handled with great care. Any volatile polyamine synthesized should also be regarded as 
toxic and should be handled with care and always stored under N2 due to reactivity with 
O2 and CO2. Distillations were carried out under reduced pressure with a sodium 
bicarbonate (NaHCO3) scrubber for distillations involving HBr and a citric acid scrubber 
for any distillations involving amines. Yields were calculated for material judged 
homogeneous by thin-layer chromatography and 1H NMR. Thin-layer chromatography 
was performed on silica plates eluting with the solvents indicated and visualized by a 
254nm UV lamp or permanganate stain. 1HNMR spectra were recorded at 500 or 300 MHz 
as indicated. The chemical shifts (δ) of proton resonances are reported relative to the 
deuterated solvent peak: 7.26 ppm for CDCl3 and 4.79 ppm for H2O using the following 
format:chemical shift [multiplicity (s = singlet, d = doublet, dd = doublet of doublets, t = 
triplet, q = quartet, pent = pentet, hex = hextet, sept = septet, oct = octet, non = nonet m = 
multiplet),coupling constant(s) (J in Hz), integral]. 13C NMR spectra were recorded at 125 
MHz. The chemical shifts of carbon resonances are reported relative to the deuterated 
solvent peak: 77.0 (first line) for CDCl3. Mass spectra were obtained by ESI/APCI for 





VXR500 MHz NMR contain an artifact peak between 170.0-174.0 ppm, which has been 
confirmed by the facility administrator.  
 
3.9.2 Polyamine Naming 
In the laboratory the utility of naming compounds based on the designated IUPAC 
system is sometimes impractical. We choose a simplified naming system for the polyamine 
side chains we synthesized, based on the principle that we were only interested in 
terminally substituted derivatives.  Hence most derivatives were named as “the side-chain 
present” then the polyamine. For example N1-(3-aminopropyl)-N3-butylpropane-1,3-
diamine the butylated analog would be simplified to n-butyl-norspermidine this same 
principle applies to N1-(3-(isobutylamino)propyl)butane-1,4-diamine which again by our 
naming system would be i-butyl-spermidine and so on.  
 
 
3.9.3 Experimental Procedures 
 
3-(isobutylamino)propan-1-ol: 3-Amino-1-propanol (35.4 g, 0.58 mol, 1 equiv.) was 
placed in a round bottomed flask. The solution was cooled to 0 °C (ice/water) and 
isobutyraldehyde (41.8 g, 0.58 mol, 1 equiv.) was added over the span of 20 min The 
reaction was left to warm and stirred for 8 h. Sodium borohydride (11.0 g, .29 mol, .5 
equiv.) in water (100 mL) was added slowly to the reaction mixture. After bubbling had 





and concentrated under reduced pressure to afford the amino-alcohol as a yellow oil (65.8 
g, 97%). 1H NMR (300 MHz, CDCl3) δ ppm 3.79 (t, J = 5.1 Hz, 2H), 2.84 (t, J = 5.7 Hz, 
2H), 2.40 (d, J = 6.6 Hz, 2H), 1.70-1.62 (m, 3H), 0.88 (d, J = 6.9 Hz, 6H). 13C NMR (125 
MHz, CDCl3) δ ppm 65.0, 58.2, 50.7, 30.8, 28.6, 21.0. 
The other 5 substituted amino alcohols were used without further purification. If desired 
vacuum distillation can be performed on the substituted amino alcohol to ensure purity.   
 
3-bromo-N-isobutylpropan-1-amine, hydrobromide salt: 3-(Isobutylamino)propan-1-
ol (46.0 g, 0.39 mol, 1 equiv.) was placed in a round bottomed flask and cooled to 0 °C 
(ice/water) to this was carefully added HBr (294 mL in H2O). The reaction mixture was 
heated to reflux for 16 h. The remaining HBr in H2O was distilled off at 110 °C to provide 
the crude material as a brown solid which was recrystallized from MeOH/Et2O or i-PrOH 
to afford the pure HBr salt as white crystals (47.9 g, 45% 2nd time 92%, 3rd time 85% from 
3-Amino-1-propanol). 1H NMR (500 MHz, D2O) δ ppm 3.54 (t, J = 6.5 Hz, 2H), 3.21 (t, J 
= 8.0 Hz, 2H), 2.92 (d, J = 7.0 Hz, 2H), 2.30-2.23 (m, 2H), 2.02 (sept, J = 7.0 Hz, 1H), 
0.99 (d, J = 6.5 Hz, 6H). 13C NMR (125 MHz, D2O) 55.0, 46.9, 30.0, 28.5, 25.8, 19.4. 
HRMS (ESI) calculated for C7H16BrN m/z 194.0544 (M+H), Obsd. 194.0546. 








N-(2-bromoethyl)-2-methylpropan-1-amine, hydrobromide salt: 1H NMR (500 MHz, 
D2O) δ ppm 3.73 (t, J = 6.0 Hz, 2H), 3.55 (t, J = 6.0 Hz, 2H), 2.98 (d, J = 7.5 Hz, 2H), 2.06 
(non, J = 7.0 Hz, 1H), 1.01 (d, J = 6.5 Hz, 6H). 13C NMR (125 MHz, D2O) 54.6, 48.9, 25.9, 
25.5, 19.3. HRMS (ESI) calculated for C6H14BrN m/z 180.0388 (M+H), Obsd. 180.0394. 
Yield (12% from 3-Amino-1-propanol). 
 
N-(3-bromopropyl)butan-1-amine, hydrobromide salt: 1H NMR (500 MHz, D2O) δ 
ppm 3.55 (t, J = 6.5 Hz, 2H), 3.22 (t, J = 8.0 Hz, 2H), 3.07 (t, J = 7.5 Hz, 2H), 2.29-2.23 
(m, 2H), 1.70-1.64 (m, 2H), 1.39 (hex, J = 7.5 Hz, 2H), 0.93 (t, J = 7.5 Hz, 3H).  13C NMR 
(125 MHz, CDCl3) δ ppm 48.2, 46.8, 29.8, 28.6, 27.8, 20.1, 13.6. HRMS (ESI) calculated 
for C7H16BrN m/z 194.0544 (M+H), Obsd. 194.0546. Yield (22% from 3-Amino-1-
propanol). 
 
N-(3-bromopropyl)hexan-1-amine, hydrobromide salt: 1H NMR (500 MHz, D2O) δ 
ppm 3.51 (t, J = 6.0 Hz, 2H), 3.18 (t, J = 7.0 Hz, 2H), 3.03 (t, J = 7.5 Hz, 2H), 2.23 (pent, 
J = 6.5 Hz, 2H), 1.65 (pent, J = 8.0 Hz, 2H), 1.36-1.27 (m, 6H), 0.84 (t, J = 7.0 Hz, 3H). 
13C NMR (125 MHz, D2O) δ ppm 48.0, 46.2, 30.6, 29.7, 28.5, 25.6, 25.5, 21.9, 13.4. HRMS 







3-bromo-N-(cyclohexylmethyl)propan-1-amine, hydrobromide salt: 1H NMR (500 
MHz, D2O) δ ppm 3.54 (t, J = 6.0 Hz, 2H), 3.20 (t, J = 7.5 Hz, 2H), 2.92 (d, J = 7.0 Hz, 
2H), 2.28-2.23 (m, 2H), 1.74-1.64 (m, 6H), 1.30-1.13 (m, 3H), 1.04-0.97 (m, 2H).   13C 
NMR (125 MHz, CDCl3) δ ppm 54.2, 47.3, 34.5, 30.9, 29.9, 28.4, 25.8, 25.3. HRMS (ESI) 
calculated for C10H20BrN m/z 234.0857 (M+H), Obsd. 234.0862. Yield (41% from 3-
Amino-1-propanol). 
 
N-(3-bromopropyl)octan-1-amine, hydrobromide salt: 1H NMR (500 MHz, D2O) δ 
ppm 3.53 (t, J = 6.0 Hz, 2H), 3.20 (t, J = 7.5 Hz, 2H), 3.05 (t, J = 8.0 Hz, 2H), 2.27-2.22 
(m, 2H), 1.67 (pent, J = 7.0 Hz, 2H), 1.38-1.27 (m, 10H), 0.85 (t, J = 7.0 Hz, 3H). 13C 
NMR (125 MHz, CDCl3) δ ppm 48.3, 46.6, 31.7, 29.8, 29.1, 29.0, 28.6, 26.8, 25.8, 22.6, 
14.1. HRMS (ESI) calculated for C11H24BrN m/z 250.1170 (M+H), Obsd. 250.1176. Yield 
(21% from 3-Amino-1-propanol). 
 
N-(3-bromopropyl)-2-ethylbutan-1-amine, hydrobromide salt: 1H NMR (500 MHz, 
D2O) δ ppm 3.53 (t, J = 6.0 Hz, 2H), 3.21 (t, J = 7.5 Hz, 2H), 3.00 (d, J = 7.0 Hz, 2H), 
2.29-2.23 (m, 2H), 1.66 (sept, J = 7.0 Hz, 1H), 1.39 (p, J = 7.0 Hz, 4H), 0.87 (t, J = 7.0 Hz, 
6H). 13C NMR (125 MHz, D2O) δ ppm 50.8, 46.8, 37.6, 29.6, 28.1, 22.4, 9.4. HRMS (ESI) 







N-(3-bromopropyl)-2-methylbutan-1-amine, hydrobromide salt: 1H NMR (500 MHz, 
D2O) δ ppm 3.51 (t, J = 6.0 Hz, 2H), 3.18 (t, J = 7.0 Hz, 2H), 3.00(dd, J = 6.5, 12 Hz, 1H), 
2.86 (dd, J = 8.0, 12.5 Hz, 1H), 2.26-2.21 (m, 2H), 1.78 (oct, J = 7.0 Hz, 1H), 1.43-1.35 
(m, 1H), 1.25-1.17 (m, 1H), 0.94 (d, J = 6.5 Hz, 3H), 0.86 (t, J = 7.5 Hz, 3H).  13C NMR 
(125 MHz, D2O) δ ppm 53.3, 46.7, 31.7, 29.7, 28.2, 26.2, 16.1, 10.1. HRMS (ESI) 
calculated for C8H18BrN m/z 208.0701 (M+H), Obsd. 208.0703. Yield (36% from 3-
Amino-1-propanol). 
 
N-(3-bromopropyl)-3-methylbutan-1-amine, hydrobromide salt: : 1H NMR (500 MHz, 
D2O) δ ppm 3.54 (t, J = 6.5 Hz, 2H), 3.20 (t, J = 8.0 Hz, 2H), 3.08 (t, J = 8.0 Hz, 2H), 2.27-
2.22 (m, 2H), 1.66 (non, J = 6.5 Hz, 1H), 1.58-1.54 (m, 2H), 0.91 (d, J = 7.0 Hz, 6H). 13C 
NMR (125 MHz, D2O) δ ppm 46.5, 46.3, 34.4, 29.9, 28.6, 25.4, 21.6. HRMS (ESI) 
calculated for C8H18BrN m/z 208.0701 (M+H), Obsd. 208.0705. Yield (42% from 3-
Amino-1-propanol). 
 
3-bromo-N-(4-(tert-butyl)benzyl)propan-1-amine, hydrobromide salt: 1H NMR (500 
MHz, D2O) δ ppm 7.54 (d, J = 8.5 Hz, 2H), 7.41 (d, J = 7.5 Hz, 2H), 4.20 (s, 2H), 3.66 (t, 





NMR (125 MHz, D2O) δ ppm 153.3, 129.7, 127.7, 126.2, 58.9, 50.5, 44.6, 34.1, 30.4, 27.8. 
HRMS (ESI) calculated for C14H22BrN m/z 284.1014 (M+H), Obsd. 284.1017. Yield (33% 
from 3-Amino-1-propanol) 
  
N1-(3-aminopropyl)-N3-isobutylpropane-1,3-diamine (Iso-butyl norspermidine): A 
round bottomed flask was charged with 1,3 diaminopropane (61.8 g, 0.83 mol, 10 equiv.), 
cooled to 0 °C (ice/water) and to this solution was added 3-bromo-N-isobutylpropan-1-
amine hydrobromide salt (15.5 g, 0.08 mol, 1 equiv.) portionwise over the span of 1.5 h. 
The reaction mixture was left to warm and stirred for 12-16 h. Excess 1,3 diaminopropane 
was removed under reduced pressure, and the remaining semisolid was taken up in 5% 
NaOH (100 mL) and extracted with 85:15 CHCl3/i-PrOH (5 x 100 mL), dried over Na2SO4, 
filtered, and concentrated under reduced pressure. Purification was accomplished by 
fractional distillation (oil bath set at 210 °C, distillate collected at 110 °C) to afford pure 
N1-(3-aminopropyl)-N3-isobutylpropane-1,3-diamine as a clear oil (7.4 g, 50%, best 71%). 
1H NMR (300 MHz, CDCl3) δ ppm 2.76 (t, J = 6.9 Hz, 2H), 2.70-2.63 (m, 6H), 2.39 (d, J 
= 6.9 Hz, 2H), 1.80-1.59 (m, 5H), 1.49 (bs, 4H), 0.89 (d, J = 6.6 Hz, 6H). 13C NMR (125 
MHz, CDCl3) δ ppm 58.4, 49.0, 48.9, 48.2, 40.8, 34.2, 30.7, 28.5, 20.9. HRMS (ESI) 
calculated for C10H25N3 m/z 188.2127 (M+H), Obsd. 188.2123.   
 
N1-(3-aminopropyl)-N3-hexylpropane-1,3-diamine (Hexyl norspermidine): 1H NMR 
(500 MHz, CDCl3) δ ppm 2.75 (t, J = 7.0 Hz, 2H), 2.65 (td, J = 2.5 Hz, 7.0 Hz, 6H), 2.57 





0.87 (t, J = 6.5 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ ppm 50.3, 48.9, 48.8, 48.1, 40.8, 
33.7, 32.0, 30.2, 27.3, 22.8, 14.3. HRMS (ESI) calculated for C12H29N3 m/z 216.2440 
(M+H), Obsd. 216.2443. Yield (55%, 12.74 g). 
 
N1-(3-aminopropyl)-N3-octylpropane-1,3-diamine (Octyl norspermidine): 1H NMR 
(500 MHz, CDCl3) δ ppm 2.75 (t, J = 7.0 Hz, 2H), 2.66 (t, J = 7.0 Hz, 6H), 2.57 (t, J = 7.5 
Hz, 2H), 1.69-1.60 (m, 4H), 1.49-1.42 (m, 2H), 1.27 (s, 10H), 1.04 (bs, 4H), 0.87 (t, J = 
6.5 Hz, 3H). 13C NMR (125 MHz, CDCl3) 50.1, 48.7, 48.6, 47.9, 40.5, 33.6, 31.8, 30.1, 
30.0, 29.5, 29.2, 27.4, 22.6, 14.1. HRMS (ESI) calculated for C14H33N3 m/z 244.2753 
(M+H), Obsd. 244.2756. Yield (43%, 6.70 g). 
 
N1-(3-aminopropyl)-N3-(cyclohexylmethyl)propane-1,3-diamine (cyclohexylmethyl 
norspermidine): 1H NMR (500 MHz, CDCl3) δ ppm 2.75 (t, J = 7.0 Hz, 2H), 2.66-2.61 
(m, 6H), 2.40 (d, J = 7.0 Hz, 2H), 1.72-1.59 (m, 9H), 1.47-1.38 (m, 1H), 1.27-1.03 (m, 
7H), 0.91-0.84 (m, 2H). 13C NMR (125 MHz, CDCl3) δ ppm 57.2, 49.0, 48.2, 40.8, 38.2, 
34.2, 31.7, 30.7, 26.9, 26.3. HRMS (ESI) calculated for C13H29N3 m/z 228.2440 (M+H), 
Obsd. 228.2439. Yield (38%, 3.43 g). 
 
N1-(3-aminopropyl)-N3-butylpropane-1,3-diamine (n-butyl-norspermidine): 1H NMR 
(500 MHz, CDCl3) δ ppm 2.64-2.46 (m, 10H), 1.56-1.49 (m, 4H), 1.37-1.30 (m, 2H), 1.27-





48.1, 40.8, 34.2, 32.5, 30.7, 20.7, 14.0. HRMS (ESI) calculated for C10H25N3 m/z 188.2127 
(M+H), Obsd. 188.2126. Yield (45%, 7.01 g). 
 
N1-(2-(isobutylamino)ethyl)propane-1,3-diamine: 1H NMR (500 MHz, CDCl3) δ ppm 
2.71 (t, J = 7.0 Hz, 2H), 2.64 (s, 4H), 2.62 (t, J = 7.0 Hz, 2H), 2.33 (d, J = 7.0 Hz, 2H), 
1.97 (bs, 4H), 1.66 (sept, J = 6.5 Hz, 1H), 1.58 (pent, J = 7.0 Hz, 2H), 0.82 (d, J = 6.5 Hz, 
6H). 13C NMR (125 MHz, CDCl3) δ ppm 58.1, 49.5, 49.4, 47.9, 40.6, 33.4, 28.4, 20.8. 
HRMS (ESI) calculated for C9H23N3 m/z 174.1970 (M+H), Obsd. 174.1977. Yield (42%, 
4.04 g). 
 
N1-(3-(hexylamino)propyl)butane-1,4-diamine (Hexyl spermidine): 1H NMR (500 
MHz, CDCl3) δ: 2.80 (bs, 4H), 2.65-2.50 (m, 10H), 1.65-1.59 (m, 2H), 1.46-1.38 (m, 6H), 
1.25-1.17 (m, 6H), 0.81 (t, J = 7.0 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ ppm 50.2, 49.9, 
48.6, 42.0, 31.9, 31.3, 30.2, 30.1, 27.4, 27.2, 22.7, 14.2. HRMS (ESI) calculated for 
C13H31N3 m/z 230.2596 (M+H), Obsd. 230.2601. Yield (51%, 4.54 g). 
 
N1-(2-aminoethyl)-N3-hexylpropane-1,3-diamine: 1H NMR (500 MHz, CDCl3) δ: 2.68 
(t, J = 6.0 Hz, 2H), 2.58-2.54 (m, 6H), 2.47 (t, J = 7.0 Hz, 2H), 1.57 (pent, J = 7.0 Hz, 2H), 
1.39-1.31 (m, 2H), 1.22-1.07 (m, 10H), 0.77 (t, J = 7.5 Hz, 3H). 13C NMR  (125 MHz, 
CDCl3) δ ppm 52.7, 50.2, 48.6, 48.4, 41.8, 31.8, 30.5, 30.2, 27.1, 22.6, 14.1. HRMS (ESI) 






N1-(3-(butylamino)propyl)butane-1,4-diamine (Butyl spermidine): 1H NMR (300 
MHz, CDCl3) δ: 2.67-2.51 (m, 10H), 1.62 (pent, J = 7.2 Hz, 2H), 1.52-1.34 (m, 6H), 1.30 
(pent, J = 7.2 Hz, 2H), 0.98 (bs, 4H), 0.86 (t, J = 7.2 Hz, 3H). 13C NMR (75 MHz, CDCl3) 
δ ppm 50.2, 50.1, 48.8, 48.8, 42.4, 32.5, 31.9, 30.8, 27.7, 20.7, 14.2. HRMS (ESI) 
calculated for C11H27N3 m/z 202.2283 (M+H), Obsd. 201.2284. Yield (48%, 5.28 g). 
 
N1-(3-aminopropyl)-N3-(2-ethylbutyl)propane-1,3-diamine (Gem-diethyl 
norspermidine): 1H NMR (300 MHz, CDCl3) δ ppm 2.64 (t, J = 6.9 Hz, 2H), 2.58-2.51 
(m, 6H), 2.36 (d, J = 5.4 Hz, 2H), 1.53 (sept, J = 6.6 Hz, 4H), 1.25-1.15 (m, 5H), 0.97 (bs, 
4H), 0.74 (t, J = 6.9 Hz, 6H). 13C NMR (75 MHz, CDCl3) δ ppm 53.1, 49.1, 49.0, 48.1, 
41.0, 40.7, 34.2, 30.5, 24.2, 11.1. HRMS (ESI) calculated for C12H29N3 m/z 216.2440 
(M+H), Obsd. 216.2439. Yield (56%, 11.92 g). 
 
N1-(3-aminopropyl)-N3-isopentylpropane-1,3-diamine (Iso-amyl norspermidine): 
2.75 (t, J = 6.5 Hz, 2H), 2.66 (t, J = 12.0 Hz, 6H), 2.58 (t, J = 13.0 Hz, 2H), 1.72-1.55 (m, 
5H), 1.39-1.32 (m, 6H), 0.88 (d, J = 11.0 Hz, 6H)  13C NMR (125 MHz, CDCl3) δ ppm 
48.7, 48.2, 47.9, 40.5, 39.2, 33.9, 30.4, 26.1, 22.6. HRMS (ESI) calculated for C11H27N3 






N1-(3-aminopropyl)-N3-(2-methylbutyl)propane-1,3-diamine: 1H NMR (500 MHz, 
CDCl3) δ ppm 2.71 (t, J = 7.0 Hz, 2H), 2.63-2.58 (m, 6H), 2.46 (dd, J = 6.0, 11.5 Hz, 1H), 
2.31 (dd, J = 7.5, 12.0 Hz, 1H),  1.65-1.55 (m, 4H), 1.51-1.42 (m, 1H), 1.39-1.30 (m, 1H), 
1.12-1.05 (m, 5H), 0.85-0.82 (m, 6H). 13C NMR (125 MHz, CDCl3) δ ppm 56.5, 49.0, 48.1, 
40.7, 34.9, 34.2, 30.6, 27.7, 17.8, 11.5. HRMS (ESI) calculated for C11H27N3 m/z 202.2283 
(M+H), Obsd. 202.2287. Yield (51%, 10.06 g). 
 
N1-(3-aminopropyl)-N3-(4-(tert-butyl)benzyl)propane-1,3-diamine (Tert-butyl-benzyl 
norspermidine): 1H NMR (500 MHz, CDCl3) δ ppm 7.34 (d, J = 8.0 Hz, 2H), 7.23 (d, J 
= 8.0 Hz, 2H), 3.74 (s, 2H), 2.75 (t, J = 7.0 Hz, 2H), 2.71-2.64 (m, 6H), 1.70 (pent, J = 7.0 
Hz, 2H), 1.62 (pent, J = 7.0 Hz, 2H), 1.43 (bs, 4H), 1.31 (s, 9H). 13C NMR (125 MHz, 
CDCl3) δ ppm 149.8, 137.2, 127.9, 125.3, 53.6, 48.4, 47.8, 47.7, 40.2, 34.5, 32.8, 31.4, 
29.9. LRMS calculated for C17H31N3 m/z 278.2596 [M+H]+, Obsd. 278.2594. Yield (38%, 
5.16 g). 
 
N1-(3-(isobutylamino)propyl)-2,2-dimethylpropane-1,3-diamine: 1H NMR (500 MHz, 
CDCl3) δ ppm 2.63 (t, J = 7.0 Hz, 4H), 2.50 (s, 2H), 2.39-2.37 (m, 4H), 1.77-1.62 (m, 3H), 
1.02 (bs, 4H), 0.88 (d, J = 7.0 Hz, 6H), 0.84 (s, 6H). 13C NMR (125 MHz, CDCl3) δ ppm 
59.1, 58.5, 51.7, 49.9, 49.0, 35.6, 30.5, 28.5, 23.9, 20.9. HRMS (ESI) calculated for 






N1-(3-(isobutylamino)propyl)butane-1,4-diamine (Iso-butyl spermidine): 1H NMR 
(500 MHz, CDCl3) δ ppm 2.66-2.54 (m, 8H), 2.35-2.33 (m, 2H), 1.70-1.59 (m, 3H), 1.49-
1.40 (m, 4H), 0.98 (bs, 4H), 0.85-0.83 (m, 6H). 13C NMR (125 MHz, CDCl3) δ ppm 58.4, 
50.1, 48.9, 48.9, 42.4, 31.9, 30.6, 28.4, 27.7, 20.8. HRMS (ESI) calculated for C11H27N3 
m/z 202.2283 (M+H), Obsd. 202.2284. Yield (53%, 7.95 g).  
 
N1-benzyl-N3-(3-(isobutylamino)propyl)propane-1,3-diamine, hydrochloride salt: 
Benzaldehyde (0.16 g, 1.56 mmol, 1 equiv.) was added dropwise to a cooled solution (0 
°C) of isobutyl-norspermdine (0.29 g, 1.56 mmol, 1 equiv.) in MeOH (5 mL) and the 
reaction was left to stir for 16 h. Sodium borohydride (.24 g, 6.24 mmol, 4 equiv.) was then 
added portionwise and the reaction mixture was left to stir for an additional 1 h. The excess 
MeOH was evaporated and the crude solid was partitioned between EtOAc (50 mL) and 
10% NaOH (1 x 50 mL). The aqueous layer was then back extracted with EtOAc (1 x 50 
mL) dried over Na2SO4 and evaporated to afford the crude free base which was carried 
forward without further purification. The crude free base was acidified with HCl in MeOH 
(50 mL) and then placed at 0 °C for 1 h to precipitate. The corresponding precipitate was 
filtered and dried to afford the pure HCl salt as a white solid (52%). 1H NMR (500 MHz, 
D2O) δ ppm 7.51 (s, 5 H), 4.28 (s, 2H), 3.23-3.14 (m, 8H), 2.93 (d, J = 6.5 Hz, 2H), 2.19-
2.12 (m, 4H), 2.02 (sept, J = 6.5 Hz, 1H), 1.00 (d, J = 7.0 Hz, 6H). 13C NMR (125 MHz, 





19.3. Yield (52%, 0.31 g). 
The following examples were prepared similar to N1-(benzo[d][1,3]dioxol-5-ylmethyl)-N3-
(3-(butylamino)propyl)propane-1,3-diamine, chloride salt: 
 
N1-benzyl-N3-(3-(butylamino)propyl)propane-1,3-diamine, hydrochloride salt: 1H 
NMR (500 MHz, D2O) δ ppm 7.52-7.49 (m, 5H), 4.28 (s, 2H), 3.22-3.13 (m, 8H), 3.07 (t, 
J = 7.5 Hz, 4H), 2.18-2.09 (m, 4H), 1.66 (pent, J = 7.5 Hz, 2H), 1.39 (hex, J = 7.5 Hz, 2H), 
0.93 (t, J = 7.0 Hz, 3H). 13C NMR (125 MHz, D2O) δ ppm 130.5, 130.0, 130.0, 129.5, 51.4, 
47.8, 44.8, 44.8, 44.4, 44.0, 27.7, 22.8, 19.3, 12.9. HRMS (ESI) calculated for C18H33N3 
m/z 292.2753 (M+H), Obsd. 292.2753. Yield (45%, 0.82 g). 
 
N1-butyl-N3-(3-(isobutylamino)propyl)propane-1,3-diamine, hydrochloride salt: 1H 
NMR (500 MHz, D2O) δ ppm 3.19-3.13 (m, 8H), 3.06 (t, J = 7.5 Hz, 2H), 2.92 (d, J = 7.5 
Hz, 2H), 2.16-2.08 (m, 4H), 2.01 (sept, J = 7.0 Hz, 1H), 1.65 (pent, J = 7.5 Hz, 2H), 1.38 
(hex, J = 7.0 Hz, 2H), 0.98 (d, J = 6.5 Hz, 6H), 0.91 (t, J = 8.0 Hz, 3H). 13C NMR (125 
MHz, D2O) δ ppm 55.1, 47.8, 44.9, 44.8, 44.4, 27.7, 25.8, 22.8, 22.7, 19.3, 19.2, 12.9. 








hydrochloride salt: 1H NMR (500 MHz, D2O) δ ppm 6.98-6.92 (m, 3H), 6.00 (s, 2H), 
4.16 (s, 2H), 3.17-3.11 (m, 8H), 3.05 (t, J = 7.0 Hz, 2H), 2.15-2.08 (m, 4H), 1.64 (pent, J 
= 7.5 Hz, 2H), 1.37 (hex, J = 7.0 Hz, 2H), 0.90 (t, J = 7.5 Hz, 3H). 13C NMR (125 MHz, 
D2O) δ ppm 148.4, 147.9, 124.4, 124.2, 110.1, 109.1, 108.1, 51.2, 47.8, 44.8, 44.8, 43.8, 
27.7m 22.9, 19.3, 12.9. HRMS (ESI) calculated for C18H31N3O2 m/z 322.2511 (M+H), 
Obsd. 322.2494. Yield (55%, 0.17 g). 
 
N1-isobutyl-N3-(3-((4-methoxybenzyl)amino)propyl)propane-1,3-diamine, 
hydrochloride salt: 1H NMR (500 MHz, D2O) δ ppm 7.44 (d, J = 8.0 Hz, 2H), 7.05 (d, J 
= 9.0 Hz, 2H), 4.22 (s, 2H), 3.84 (s, 3H), 3.19-3.14 (m, 8H), 2.93 (d, J = 7.0 Hz, 2H), 2.18-
2.11 (m, 4H), 2.02 (sept, J = 7.0 Hz, 1H), 1.00 (d, J = 7.0 Hz, 6H).  13C NMR (125 MHz, 
D2O) δ ppm 160.0, 131.8, 123.0, 114.8, 55.6, 55.1, 50.9, 45.0, 44.8, 43.8, 25.8, 22.8, 22.7, 
19.3. HRMS (ESI) calculated for C18H33N3O m/z 308.2702 (M+H), Obsd. 308.2702. Yield 
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ADVANCED MEDICINAL CHEMISTRY PROFILE OF  
INITIAL CZ-01 ANTIBIOFILM  
ANTIBIOTIC ANALOGS 
 
4.1 Background  
Looper’s first generation polyamine biocides were simple in design with little 
modularity built into their scaffolds (see Chapter 2). Typically, a known aldehyde was 
reductively aminated to produce the final product in a single step (Scheme 4.1). While the 
facile delivery of large amounts of compound is a benefit of these first generation analogs, 
their potency was not comparable to marketed antibiotics. Structure activity relationship 
studies were also limited by the aldehydes and amines that were commercially available 
(Scheme 4.1). 
Furthermore, initial studies assessed viability through qualitative evaluation of biofilm 
deconstruction after being subjected to the CZ-01 series. In order to have a traditional drug 
discovery program, however, we turned our attention to more quantitative results. To this 
end, the newly designed molecules focused primarily on the MICs of both Gram-positive 
(MRSA) and Gram-negative (P. aeurginosa) strains where biofilm dispersal was 
considered a secondary indication of our compounds efficacy.
To  address SAR limitations, literature searches led us to 5-bromo-isophthalaldehyde 





isophthalaldehyde (Scheme 4.2).1 More importantly, isophthalaldehyde 1, as shown in 
Chapter 2, is readily available and cheap (500g for $216). We felt that the halogen 
substitution on the 5-position would be a synthetic handle for derivatization via both 
Buchwald-Hartwig and Suzuki cross coupling reactions.2, 3 
 
4.2 Looper’s Second Generation Biocide Synthesis 
In order to explore structure activity relationship studies we began our second 
generation synthesis by reacting isophthalaldehyde and NBS in sulfuric acid. Elevated 
temperatures provided the product upon crystallization. With the 5-bromo-
isophthalaldehyde in hand we could investigate a variety of cross coupling reactions, and 
further pursue other structural optimizations with these initial target hits.  
 
4.2.1 Initial Suzuki sp2-sp2 Cross Coupling 
First generation SAR studies led us to conclude that norspermidine was the most potent 
side-chain to date and thus was the polyamine linker used in our initial second generation 
studies. Given the breadth of boronic acids commercially available, we initially focused on 
Suzuki reactions to generate diversified analogs. Treatment of 5-bromo-isophthalaldehyde 
2 with a substituted-phenylboronic acid, palladium tetrakis triphenylphosphine, and cesium 
carbonate in toluene/EtOH/H2O produced the aldehyde 3 in a 45-80% yield as white 
crystalline material. Boc-norspermidine (for non-IUPAC naming see Supporting 
Information) was employed in the reductive amination of our newly formed dialdehyde. 
Methanolic HCl acidification not only cleaved the Boc-groups but also provided the final 
material 4 as the HCl salt (Scheme 4.2). 





Compounds range from ethereal-phenyl-boronic acids to formyl-phenyl-boronic acids but 
are limited to sp2 hybridized boronic acids (Figure 4.1). Attempts at using sp3 adducts 
resulted in recovered starting material. Further analog design via Buchwald-Hartwig 
couplings was unfortunately unsuccessful. Attempts at modifying the Buchwald-Hartwig 
procedure including; ligand selection, solvent degassing, and amine selection was 
unproductive as we tried to make both the pyrimidine derivative 5 as well as the 
morpholino aldehyde 6 (Scheme 4.3).  
The 2nd generation analogs developed were on average more potent than our 1st 
generation analogs (Table 4.1). CZ-01-058, CZ-01-62, CZ-01-65 and CZ-01-66 all had 
MICs less than 10 µg/mL against MRSA. These data suggested that the more hydrophobic 
backbones were beneficial for compound efficacy, and more structural adjustments in 
relation to hydrophobicity would be pertinent for studying bioactivity. 
 
4.2.2 Dimethyl 5-hydroxyisophthalate as a Precursor to Ethereal  
Derivatives 
In addition to exploring cross coupling reactions, we also evaluated another starting 
material, dimethyl 5-hydroxyisophthalate 7, which could be modified at the 5-position of 
the phenyl ring to distribute hydrophobicity. A series of aldehydes were synthesized 
whereby, first the 5-oxy-position was alkylated to produce the substituted ether 8, and then 
the pendant esters were converted to the aldehydes 9 in a two-step reduction/oxidation 
sequence (Scheme 4.4). The oxidation was first carried out with PCC but was amended to 
use MnO2 for ease of workup and purification. Further treatment of the newly formed 
aldehyde with Boc-norspermidine, followed by acidification afforded the polyamino ether 





The ether series gave promising biological data. CZ-01-81 for example, had an MIC 
of 5 µg/mL against MRSA. CZ-01-095 as well, has an MIC of 10 µg/mL (Table 4.2). 
Based on these initial results, we realized that the hydrophobicity of our compounds 
played an important factor in determining efficacy. For example CZ-01-81 was potent 
against both Gram-positive and Gram-negative bacterial strains with MICs of 5 µg/mL and 
8.5 µg/mL, respectively (Table 4.2), and contained the most nonpolar tail (2-ethylhexyl). 
 
4.2.3 Side-Chain Adjustment on Preexisting Scaffolds 
We turned our attention to the adjustment of our polyamine side-chain to improve the 
hydrophobic character of these compounds. Starting from Boc-norspermidine 11, the 
addition of butyl iodide produced n-butyl-norspermidine 12, upon a 
acidification/basification/column purification sequence (Scheme 4.5a). With 12 in hand the 
reductive amination of [1,1'-biphenyl]-3,5-dicarbaldehyde 13 afforded CZ-01-083 
(Scheme 4.5b). Initial biological data for CZ-01-083 was promising with an MIC value 
against MRSA of 5 µg/mL. Further construction of nonpolar side-chains led us to the iso-
butylated norspermidine derivative (isobutyl-norspermidine). Using the same method as 
above, reductive amination of [1,1'-biphenyl]-3,5-dicarbaldehyde produced CZ-01-086. 
Again preliminary test MIC results for CZ-01-086 were favorable (MIC MRSA = 0.9 
µg/mL).  
Unfortunately, the second batch of CZ-01-086 was drastically different by MIC, with 
a value of 15 µg/mL. In order to verify our biological data we remade the material and 
developed an alternate route (Scheme 4.5c). The alternate route benefited us as it was more 
modular in design and allowed for the construction of analogs in a quick and efficient 





in this case isobutyraldehyde, to afford CZ-01-086 after acidification. This batch had a 
much higher MIC than what was initially reported. We felt that significant variables in the 
reaction conditions were attributed to some, if not all, of our inconsistent biological data.  
Unbeknownst to us, these reactions were quite impure and the discrepancies in our 
biological data were a direct result of this (Table 4.3). 1H and 13C NMR analysis had been 
the principal analytical technique used to assess the purity of the CZ-01 series. As shown 
below (Figure 4.3), the NMR spectrum of CZ-01-086 was pristine, and moreover, we felt 
any impurities were negligible in producing drastic biological effects. Qualitative analysis 
by TLC (Figure 4.4) however, provided empirical evidence that our CZ-01 series 
compounds were impure as numerous compound spots were observed. Moreover, NMR 
spectroscopy was not sensitive enough to pick up minute impurities (<5%), and our 
compounds, more than likely, contained various <5% impurities. The active CZ compound 
was then only 60-80% pure, but nondiscernable (from pure material) by NMR analysis.  
The first principle cause of these impurities was reasoned to be the contaminants from 
the side-chain. A linear approach to our norspermidine derivatives would mitigate any 
impurities present and further validate our biological data. Starting from 3-amino-1-
propanol 14 a reductive amination produced the alkylated amine 15 (Scheme 4.6). Treating 
the pendant alcohol with aqueous HBr afforded the brominated acid salt 16, which could 
be recrystallized from i-PrOH or MeOH/Et2O. Construction of the substituted 
norspermidine derivative was accomplished by the addition of the newly formed acid salt 
to neat diaminopropane (8-10 equiv). Vacuum distillation afforded pure material 17. The 
scope of this sequence can be seen in Chapter 3.  





appropriately purified these compounds to a level of 85-95%. Specifically, column 
chromatography with a unique mobile phase (CH2Cl2, MeOH, NH4OH, 250:16:1) was able 
to separate impurities and the CZ-01 compounds. With this in mind, we were able to amend 
our synthesis to not only provide research grade material, but also were now able to 
modulate the side-chain. Unfortunately, LC-MS was unproductive for determining 
compound purity due to the high polar character of these hexa- and nona-HCl salts. 
With an efficient and scalable process now in hand, we augmented our series with a 
great deal of synthetic breadth (Figure 4.5). Given the relative success of CZ-01-086 we 
amended this series to include compounds from the initial scope of reaction shown in 
Chapter 3. Furthermore, no Boc-protection was necessary as the initial aldehyde would 
primarily react with the only primary amine present on norspermidine, and any unwanted 
material was purified by chromatographic means. The biological activity of these analogs 
shows promising data with CZ-01-114 and CZ-01-118 both having low MICs (~1 µg/mL) 
against MRSA (Table 4.4).  
Given the cheap cost and availability of isophthalaldehyde, it was apparent that the 
newly developed substituted norspermidine side-chain chemistry should be applied to this 
series as well. Starting from isophthalaldehyde, reductive aminination with a number of 
the alkylated norspermidine side-chains produced the series shown below (Figure 4.6). The 
compounds CZ-01-097, CZ-01-100, and CZ-01-158 had adequate MICs against both 
Gram-positive and Gram-negative strains (Table 4.5). This was attributed to the 
hydrophobicity of the side-chain as was suggested by our previous SAR studies. We felt it 
was imperative to ascertain preliminary efficacy data on compounds with promising 





100 was tested for cell lysis in an ISO 10993 L929 assay (see Supporting Information). 
Unfortunately, CZ-01-100 exhibited excessive cell lysis at 12.5 µg/mL, which would 
prohibit its use in humans due to cytotoxicity. Furthermore, data suggested that cytotoxicity 
is correlated to Gram-negative activity, which we believe is due to the increased 
hydrophobicity of these molecules which exhibit more broad-spectrum activity.  
The substituted norspermidine side-chain synthesis yielded large amounts of 
substituted amino bromides 16 which we felt were worthy of using as electrophiles with 
dimethyl 5-hydroxyisophthalate 7. A select series of the phenoxy derivatives were made 
(Figure 4.7). At first, we had tried the direct alkylation with a roughly 1:1 ratio of 
electrophile bromide to nucleophile 3,5-bis(methoxycarbonyl)phenolate. Unfortunately all 
attempts were unsuccessful at affording the desired amino-alkylated product (Scheme 4.7). 
We felt the required free amine was too reactive. A Boc-protection was subsequently 
employed to produce the desired bromo-alkylalted carbamate which then was used as a 
successful electrophile to yield the CZ-compound in four known steps (Scheme 4.7). 
This combinatorial process is valued for its modularity, and a significant number of 
analogs could be synthesized in a short sequence (for biological data see Table 4.6). 
However, we chose to focus on a particular subset as they were the strongest lead 
compounds at the time. These include both hexyl, i-butyl, and octyl analogs (Figure 4.7). 
In order to satisfy any missing data in our SAR studies it was imperative that we use 
the substituted norspermidine derivatives for the parent-ether series as well (Scheme 4.4). 
Several CZ-compounds were synthesized primarily using 5-
(cyclohexylmethoxy)isophthalaldehyde as the starting material (Figure 4.8). Again, a 





4.7). The remaining analogs though viable, against Gram-positive strains, showed little to 
no activity against Gram-negative bacteria.  
Concurrently, we began to construct systems with three aldehydes like those used to 
make CZ-01-062, CZ-01-065, CZ-01-066, and CZ-01-069. With our amended side-chain, 
in a combinatorial process, several analogs were made by treating the desired trialdehyde 
with three equivalents of our alkylated norspermidine (Figure 4.9). These tris-derivatives 
again saw an increase in potency in comparison with their bis-counterparts (Table 4.8). 
More importantly, CZ-01-128 had a clinically relevant MIC (3.5 µg/mL) against Gram-
negative bacteria P. aeurginosa. Further analysis revealed that CZ-01-099 had passed 
cytotoxicity testing, on the ISO10993 L929 cytotoxicity assay, at concentrations of 1000 
µg/mL (not causing cell death), meaning its therapeutic window for Gram-positive bacteria 
was roughly 500 times MIC. Unfortunately, the octyl counterpart CZ-01-128 failed at 
every dilution level down to 12.5 µg/mL. This result reinforced our skepticism of the utility 
of the octyl-norspermidine side-chain, as it more than likely possessed inherent 
cytotoxicity, potentially due to its hydrophobicity.  
The above data points allowed us to draw several conclusions about our second 
generation compounds: 1) typically a greater clogp (hydrophobicity) often afforded 
increased potency, 2) the longer alkyl chains (often associated with greater clogp) typically 
resulted in a higher cytotoxicity. From here SAR studies were modified to: 1) increase 
potency levels on both Gram-positive and Gram-negative strains primarily MRSA and P. 
aeurginosa respectively and 2) reduce cytotoxicity in the ISO10993 L929 assay. Given 
that the cytotoxicity of CZ-01-099 was negligible, there was an opportunistic window to 





to meet our demands. 
 
4.2.4 Additional Side-Chain Modifications in Order to Alleviate  
Cytotoxicity 
In order to amend the cytotoxicity issues, additional modifications of the side-chain 
were made. We started with urea functional groups which were made from the 
corresponding amino-bromide and isocyanate (Scheme 4.8). The cytotoxicity of the 
respective analogs from this series could be mitigated by transformation of the terminal 
amine to the urea, while the additional hydrophobicity could still be employed. The 
cyclohexyl phenoxy aldehyde derivative was chosen due to availability at the time. Several 
ureas were synthesized based on this principle (Figure 4.10). Regrettably, these terminal 
ureas possessed very little activity against MRSA and no activity against P. aeruginosa 
(Table 4.9). 
 
4.2.5 Modification of the CZ-01-099 Scaffold 
Chronologically CZ-01-099 was the lead compound of our first and second generation 
CZ-series. In order to identify if any other derivations of this core structure were as potent, 
two additional analogs were made with different substitution patterns and limited to two 
side-chains (Figure 4.11). These arrangements would add support to whether a three-
branched backbone was more efficient than its two-branched counterpart. The three 
branches of CZ-01-099 were essential for any substantial activity of that specific series as 
the MICs for CZ-01-150 and CZ-01-151 were two- to three-fold less potent against MRSA 






4.2.6 Synthesis and Activity of Analogs from an Advanced  
Side-Chain Library 
In attempts to broaden our CZ-library a number of new side-chains were synthesized. 
We felt that long (n > 4) unbranched alkyl chains could be another reason for enhanced 
cytotoxicity. To alleviate this, we made several hydrophobic branched side-chain 
norspermidines including, isoamyl, 2-ethyl butyl, 2-methyl-1-butyl, and 2-ethyl-1-hexyl. 
The large clogp of octyl-norspermidine also led us to synthesize 4-tert-butyl-benzyl-
norspermidine (Figure 4.12).  
We recognized these substituted derivatives as useful leads to investigate the 
relationship between hydrophobicity and potency (Figure 4.13). CZ-01-163 was again the 
most potent of the four compounds synthesized from this series with an MIC of 0.75 µg/mL 
against MRSA and an MIC of 10 µg/mL against P. aeruginosa (Table 4.11). Despite the 
unique side chain CZ-01-163 was also cytotoxic failing at 12.5 µg/mL. 
The tris-aldehyde precursor used to construct CZ-01-099 was chosen as another viable 
substrate for potency analysis for the above alkylated-norspermidine combinations. 
Furthermore, if the new tris-substituted norspermidine analogs were active, cytotoxicity 
testing would follow. In parallel with CZ-01-099 the following compounds, CZ-01-168, 
CZ-01-169, CZ-01-170 and CZ-01-172 (Figure 4.14) were all relatively potent against 
MRSA (values ranging from 2 - 5 µg/mL) but lacked potency against P. aeruginosa (values 








4.2.7 Use of α-helix Mimetics as a Source for CZ-Compound  
Structural Diversity   
During the above syntheses we encountered a unique antimicrobial in the literature, 
brilacidin 21 (Figure 4.15). This guandino pyrimidine was highly active against Gram-
positive (0.5-1 µg/mL against MRSA) and Gram-negative (1-2 µg/mL against E. coli) 
strains and had been approved for phase IIb testing. Brilacidin mimics the action of the 
cationic antimicrobial peptides with two polar guanidine tails bridged by a hydrophobic 
triaryl core.4 
Furthermore, with the knowledge we had of cationic antimicrobial peptides we desired 
to construct a number of α-helices mimics. Andy Hamilton’s lab at Yale University has 
pioneered this research with compounds like 22 and 23 (Figure 4.16), used to inhibit 
protein-protein interactions. In this regard, we began to prepare compounds with the 
terphenyl system constructed from a number di-brominated aromatics (Scheme 4.9).5  
Drawing from Hamilton’s research we envisaged a series of terphenyl systems (26, 27, 
and 28), representative of both brilaciden and the α-helix of cationic antimicrobial peptides 
which could help increase compound potency. To achieve this goal, we started with both 
1,2- and 1,3-dibromobenzene 24 and 25, respectively. In a modular fashion, a series of 
terphenyl aldehydes were assembled with the requisite boronic acid (Scheme 4.8). Under 
standard conditions we were able to synthesize the CZ-series shown below. CZ-01-161 
and CZ-01-166 have both shown promising preliminary results with MICs of 2 and 4 
µg/mL against P. aeruginosa. However, CZ-01-161 was highly cytotoxic failing at 12.5 
µg/mL. When tested for cytotoxicity CZ-01-164 also failed at concentrations as low as 





in order to mitigate cytotoxicity amendments in the core structure are imperative (Table 
4.13). 
We were able to modify the Suzuki reaction to include a terphenyl trialdehyde system. 
Starting from 2,5-dichlorobenzaldehyde 29 the Suzuki reaction with 3-formyl-phenyl 
boronic acid produced the trialdehyde 30 (Scheme 4.10). The low yield was attributed to 
the poor solubility of this compound in organic solvent. The trialdehyde was then used 
under standard protocol to make CZ-01-153 and CZ-01-156 (Figure 4.18). We were 
surprised to see tris-hexyl and tris-isobutyl norserpermidine terphenyl systems with such 
mediocre activity, as the MICs for P. aeruginosa were greater than 50 and 20 µg/mL, 
respectively (Table 4.14). We felt that the substitution patterns on the terphenyl core have 
a direct impact on substrate binding and are pursuing other leads currently.  
The central core of brilaciden (Figure 4.15) contains a unique pyrmidine unit which we 
could also exploit with our synthesis and the presence of the central pyrimidine core may 
alleviate cytotoxicity. We chose to analyze two different substitution patterns on the 
pyrimidine as they were readily available compounds. Starting from either 2,4-
dichloropyrimidine 31 or 4,6-dichloropyrimidine 33 the Suzuki reaction with 4-formyl 
phenylbornic acid produced the desired terphenyl pyrimidines 32 and 34 (Scheme 4.11). 
With these in hand several CZ-analogs were synthesized (Figure 4.19). The potency of 
these analogs against P. aeruginosa was negligible with MICs ranging from 50 µg/mL to 
>40 µg/mL for P. aeruginosa. (Table 4.15). When tested for cytotoxicity CZ-01-174, 
however, passed at 12.5 µg/mL, which is far below its MIC for P. aeruginosa (50 µg/mL).  
The core terphenyl system has the most promising activity but its therapeutic window 





more therapeutically practical compound. The core was adjusted to include a branching 
tert-butyl substituent which we felt could add greater hydrophobic character but limit 
inherent toxicity as it was not attached to the pendant polyamine side-chains. Starting from 
1,3-dibromo-5-(tert-butyl)benzene 35 the Suzuki reaction with either 3-formyl phenyl 
boronic acid or 4-formyl phenyl boronic acid yielded the desired tert-butyl terphenyl 
system 36 or 37 (Scheme 4.11 and 4.12). The new series (Figure 4.20) had favorable 
activity against both Gram-positive and Gram-negative bacteria (Table 4.16). The MICs of 
CZ-01-177, CZ-01-178, CZ-01-179, CZ-01-182, CZ-01-183, and CZ-01-184 were sub 
µM for MRSA and low µM for P. aeurginosa.   These adjustments, however, were 
detrimental to cytotoxicity. To support, our most active compounds to date (CZ-01-178 
and CZ-01-184) both failed cytotoxicity testing at 6.25 µg/mL.  
Unfortunately, the Gram-negative activity of a number of CZ-compounds is often met 
with cytotoxicity. In order to amend the problem continual adjustments must be made for 
further SAR studies. Nonetheless, given the MIC of CZ-01-099 against MRSA coupled 
with its limited cytotoxicity and overall activity profile we felt further biological analysis 
was necessary. 
 
4.3 Biological Studies on CZ-01-099 
In order to ascertain a more comprehensive biological profile for our CZ-series we 
selected CZ-01-099 to move forward in testing, given its amenable cytotoxicity data. The 
preliminary testing was conducted on a topical pig wound model. In this wound model, a 
series of punches were made in the lower back of a pig and subsequently inoculated with 
planktonic MRSA. Topical administration of CZ-01-099 then followed in order to 





however, the positive control showed lack of a bacterial lawn (Figure 4.21a). CZ-01-099 
displayed this same lack of growth (Figure 4.21c). We hypothesized the pig’s immune 
system was robust enough to clear infection regardless of treatment variables as both 
experimental arms showed no bacterial growth.  
In order to confirm that CZ-01-099, was indeed active we repressed the pig’s immune 
response by inoculating with MRSA biofilm instead of planktonic bacteria. Biofilm 
positive controls display MRSA growth in red (Figure 4.21b). On the contrary, when 
treated with CZ-01-099 no or almost no MRSA are observed. 
These data confirm that CZ-01-099 is topically active and possesses the ability to kill 
Gram-positive biofilm bacterial strains like MRSA. Furthermore, no skin structure side 
effects were observed when the CZ-compound was applied giving merit to the compounds 
usage as a commercially available topical antibiotic.  
Serial passage data collected on CZ-01-099 showed limited developed resistance. 
During the course of a 19-passage treatment, CZ-01-099 retained a constant MIC of 6 
µg/mL and further analysis revealed that after 15 passages the MRSA isolate grew at a 
reduced rate. 
In order to determine more comprehensive antibiofilm activity for CZ-01-099, biofilms 
were grown on stainless steel titanium coupons and imaged by scanning electron 
microscopy (SEM). In comparison with glutaraldehyde and vancomycin, CZ-01-099 
cleared biofilms effectively as shown by the lack of any significant amount of grey dots 
(biofilms) upon magnification. In addition, comparison with the negative control shows 
CZ-01-099 to appear similar confirming that CZ-01-099 is indeed an antibiofilm antibiotic 





Concurrently with the CZ-01-099 wound studies, we wanted to perform a good 
laboratory practice (GLP) scale-up of CZ-01-099. To this end, our synthetic method was 
sent to Array BioPharma (now Avista) a contract research organization (CRO). Through 
the work of Array, specific conditions were determined to assess purity and recrystallize 
material. We now possess the ability to quantify the purity of our CZ-compounds via LC-
MS with a C-18 column and 0.1%-0.2% TFA H2O/0.1% TFA CH3CN mobile phase. 
Moreover, our collaboration with Array has enabled us to recrystallize material by using 
an H2O (solvent) i-PrOH (antisolvent) system. To date, CZ-01-099 has been recrystallized 
to 99% purity (judged by LC-MS). It should be noted that not all CZ-compounds possess 
the same physiochemical properties as CZ-01-099 and several, most notably the 
terphenyls, cannot be recrystallized by the above method. 
 
4.4 In vivo Pharmacokinetic Studies and Reselection of Lead  
Compounds 
The in vivo pharmacokinetic (PK) studies conducted on CZ-01-099 had similar 
analytical problems as with initial purity analysis. As such, it proved to be difficult to 
quantify compound levels administered lower than 3 mg/Kg in rat models due to the 
multiple charged states of CZ-01-099. The toxicity of CZ-01-099, however, precluded us 
from administering compound at above this dosage efficaciously.  
 Furthermore, with pure material (>99% judged by LC-MS) in hand the MIC of CZ-
01-099 was tested ad nauseam. Unfortunately, testing revealed (not reported in Table 4.8) 
an increase in MIC (~12 µg/mL), most likely related to material purity. As a result, we 
looked toward developing a new lead compound. 





requirements for a lead compound. CZ-01-114 had a low MIC against MRSA (~1 µg/mL) 
and against P. aeurginosa (~10 µg/mL). CZ-01-114 was synthesized, purified by 
recrystallization and quantified by LC-MS. With compound purity established at 98%, 
MICs were determined and our as follows: MRSA (1 µg/mL), P. aeruginosa (64 µg/mL), 
and CRE (16 µg/mL). Given the low MIC against MRSA, CZ-01-114 was selected as a 
candidate for additional biological testing. Cytotoxicity tests revealed that CZ-01-114 does 
not cause cell death below 50 µg/mL. More importantly, the promising profile of CZ-01-
114 would allow us to employ the compound in PK studies in hopes that the general toxicity 
of CZ-01-114 will not preclude dosing at higher concentrations. These dosages should then 
enable us to observe appreciable levels in blood plasma and to obtain accurate PK data. 
Currently we are using CZ-01-114 in our lead optimization process and tailoring the 
general structure to mitigate cytotoxicity while increase potency in both Gram-negative 
and Gram-positive strains.  
 
4.5 Conclusion and Future Aims 
The CZ-compounds presented confirm the importance of both side-chain and backbone 
modulation. The promising cytotoxicity profiles of CZ-01-099 and CZ-01-114 indicate 
that minimal adjustments in structure mitigate mammalian cell toxicity while retaining 
bactericidal activity. In addition, we have discovered compounds that possess surfactant-
like characteristics but are noncytotoxic and nonhemolytic against mammalian cells. The 
stigma associated with these polyamino compounds, due to their promiscuous binding, and 
multiple charged states is often associated with our CZ-compounds. Furthermore 
membrane active surfactants possess little specificity for bacterial cell membranes over 





displayed that through judicious SAR studies can exhibit selectivity for bacterial cell 
membranes and can be synthetically derived in high yield and good purity with effective 
techniques including distillation and recrystallization.  
In our SAR profile we were restricted by available aldehydes but amended our 
synthesis to more modular starting materials (i.e., 5-bromo-isophthalaldehyde and 5-
alkoxyisophthalaldehyde) thereby giving us the ability to adjust hydrophobicity in the 
backbone. In attempts to further diversify our synthesis we have also adjusted the 
norspermidine side-chain to again tailor hydrophobicity into our final compound. The side-
chain modulation also alleviated issues with purity as the linear sequence developed 
prevented and/or purified unwanted alkylations. The influence of these minor impurities 
on MIC is evidenced by the data for CZ-01-086 and CZ-01-099. To date, the synthetic 
method used to construct CZ-compounds is modular, scalable to the requisite quantities for 
animal testing, and high throughput with facile purification techniques including 
recrystallization which has been used to provide final compounds with up to 99% purity.  
A significant portion of the data presented however, is preliminary and requires an 
analysis of overall purity via the described LC-MS. In addition, a number of aldehyde 
scaffolds were synthesized prior to their alkylated norspermidine counterparts, and in order 
to ascertain reasonable SAR leads a number of compounds need to be added to the CZ-01-
series and are described below. 
The substituted ether series (Figure 4.23) showed promising initial data with MIC 
values as low as 5 for MRSA. However, the purity of these compounds was only 
determined qualitatively and was not investigated by LC-MS. This series is also hampered 





following compounds below are to be synthesized in the future by our method. 
With the recently acquired data for CZ-01-114 the same structural analysis will be 
applied to a number of biphenyl analogs not limited to what is hypothesized below (Figure 
4.24). The basis of this series is three-fold: 1) addition of more polar side-chains to increase 
potency, 2) addition of more polar functionalization on the biphenyl system to increase 
potency, and 3) general SAR modifications based on readily available substituted phenyl 
boronic acids.  
The advanced SAR profile of the CZ-series has revealed a number of the requirements 
to possess an active noncytotoxic analog. However, preliminary data indicated that 
compound purity and polarity is extremely important in dictating activity. Furthermore, 
additional studies, not limited to what is described above must be carried out in order to 
ascertain a full profile on our CZ-analogs. 
The modularity of this synthetic method described above has allowed us to construct a 
diversified library of first in class antibiofilm antibiotics. Purification of the final CZ-
compounds by recrystallization has ensured adequate and reliable MIC data and is further 
applicable to the scale required for animal testing. With the lack of available methods for 
construction of alkylated polyamines our synthesis further mandated the development of a 
linear sequence to afford our side-chain which has now been used to enhance our current 
library and substantiate SAR studies. The continuation of this chemistry is paramount in 








Table 4.1: The in vitro activity of the initial second generation CZ series as MICs against 







CZ-01-058 7.3 (n=9) 50 
CZ-01-061 >5 >20 
CZ-01-062 4.64 18 
CZ-01-063 >5 >20 
CZ-01-065 2 14.5 
CZ-01-066 5.1 19.3 
CZ-01-067 NA NA 
CZ-01-068 NA NA 
CZ-01-069 >10 >20 
CZ-01-070 >5 20 
CZ-01-071 >10 >100 
CZ-01-075 >5 20 
 
 
Table 4.2: The in vitro activity of the substituted phenoxy second generation CZ series as 







CZ-01-076 >10 >50 
CZ-01-081 5 8.5 
CZ-01-090 5 >25 





















Table 4.4: The in vitro activity of the substituted alkylated-norspermidine CZ series using 
[1,1'-biphenyl]-3,5-dicarbaldehyde, as MICs against Gram-positive MRSA and Gram-







CZ-01-092 2 10 
CZ-01-096 2 30 
CZ-01-111 5 10 
CZ-01-112 10 >30 
CZ-01-114 1 10 
CZ-01-118 1 10 
CZ-01-137 NA >25 
CZ-01-141 NA 20 
CZ-01-142 5 20 
 
 
Table 4.5: The in vitro activity of the substituted alkylated-norspermidine CZ series using 








CZ-01-097 1 12 
CZ-01-100 2.5 15 
CZ-01-108 5 >40 
CZ-01-113 5 >25 





Table 4.6: The in vitro activity of the amino-ethereal CZ-series, as MICs against Gram-







CZ-01-107 >15 >50 
CZ-01-110 2 20 
CZ-01-121 5 30 
CZ-01-122 5 >50 
 
Table 4.7: The in vitro activity of the substituted norspermidine ethereal CZ-series as 







CZ-01-091 15 >15 
CZ-01-103 5 10 
CZ-01-124 5 >50 
CZ-01-125 5 >50 
 
Table 4.8: The in vitro activity of the substituted tris norspermidine CZ-series, as MICs 







CZ-01-099 5.8 200 
CZ-01-126 10 >40 
CZ-01-127 3 18 
CZ-01-128 2 3.5 
CZ-01-140 2 40 
 
 
Table 4.9: The in vitro activity of the substituted urea CZ-series, as MICs against Gram-







CZ-01-129 >15 >30 
CZ-01-130 8 >50 







Table 4.10: The in vitro activity of the modified CZ-01-099 analogs as MICs against 







CZ-01-150 30 NA 
CZ-01-151 20 NA 
 
Table 4.11:  The in vitro activity of the altered norspermidine side chain CZ-series, as 







CZ-01-159 10 15 
CZ-01-160 10 15 
CZ-01-163 0.75 10 
CZ-01-165 4 >50 
CZ-01-167 10 >20 
 
Table 4.12: The in vitro activity of the altered norspermidine side chain CZ-series with 








CZ-01-168 5 >20 
CZ-01-169 5 >20 
CZ-01-170 3 >50 







Table 4.13: The in vitro activity of the dialdehyde terphenyl CZ-series, as MICs against 
Gram-positive MRSA and Gram-negative Pseudomonas aeruginosa 
 
Cmpd MIC-MRSA (µg/mL) 
MIC-P. aeurginosa 
(µg/mL) 
CZ-01-152 10 30 
CZ-01-154 2.7 20 
CZ-01-155 10 15 
CZ-01-157 3 15 
CZ-01-161 1 2 
CZ-01-164 0.75 10 
CZ-01-166 1 4 
CZ-01-180 NA (due to solubility) NA (due to solubility) 
 
Table 4.14: The in vitro activity of the trialdehyde terphenyl CZ-series, as MICs against 







CZ-01-153 10 >50 
CZ-01-156 2 20 
 
Table 4.15: The in vitro activity of the pyrimidine terphenyl CZ-series, as MICs against 







CZ-01-174 7 50 
CZ-01-176 20 >40 
 
 
Table 4.16: The in vitro activity of the tert-butyl terphenyl CZ-series, as MICs against 







CZ-01-177 0.75 1 
CZ-01-178 0.75 1 
CZ-01-179 0.5 4 
CZ-01-182 0.25 4 
CZ-01-183 0.5 8 







Figure 4.1: Initial second generation CZ-compounds made via the Suzuki coupling with a 
variety of sp2 boronic acids, followed by Boc-norspermidine reductive amination, with 






Figure 4.2: Ethereal CZ compounds constructed from dimethyl 5-hydroxyisophthalate, 
with the pendent alkylated phenol shown in red. 
 
 





















Figure 4.5: Structure profile of the initial alkylated(shown in red)-norspermidine analogs 















Figure 4.6: Structure profile of the initial alkylated(shown in red)-norspermidine analogs 







Figure 4.7: Amino-ethereal derivatives with the amended 5-positon in red with side-chain 
modifications in blue 
 
 
Figure 4.8: Alkylated phenoxy derivatives shown in red, with the requisite norspermidine 
















Figure 4.10: Terminally functionalized urea (shown in blue) analogs with the tris-




Figure 4.11: Truncated CZ-01-099 analogs both of which contain the i-butyl alkylated 

















































Figure 4.17: Initial terphenyl CZ-compounds with the modulated norspermidine side-







Figure 4.18: The structures of the CZ-compounds generated from the terphenyl 
trialdehyde with the modulated norspermidine side-chain shown in red 
 
 
Figure 4.19: Structures of the pyrimidine anlalogs with the modulated norspermidine 
















Figure 4.20: Structures of the tert-butyl terphenyl analogs with the modulated 











Figure 4.22: Qualitative biofilm dispersion data of CZ-01-099 in conjunction with 

























Figure 4.24: (a) Desired aldehydes used for additional SAR studies (b) Desired CZ-01-






Scheme 4.1: Reiteration of the general synthesis of the first generation CZ compounds, 
specifically CZ-01-01 to CZ-01-57 (certain substituted derivatives are left out for clarity) 
 
 
Scheme 4.2: General forward synthesis for second generation CZ compounds starting 
with the formation of 5-bromoisophthalaldehyde from isophthalaldehyde followed by the 












Scheme 4.4: Second generation phenoxy CZ analogs made via the substituted phenoxy 









Scheme 4.5: Approach to substituted norspermidine CZ-analogs, prepared from the Boc-
norspermdine (a and b) and the requisite free base (c) with the supplemental side-chain 




Scheme 4.6: Representative example of the construction of terminally substituted 
polyamines from the amino alcohol an alkylated norspermidine, with the alkyl side-chain 










Scheme 4.7: Unsuccessful and successful use of the substituted amino bromide salts to 
generate novel amino ethereal analogs with the ameded norspermidine side-chain shown 




Scheme 4.8: Synthesis of the urea norspermidine side chains 
 
 







Scheme 4.10: Synthesis of the terphenyl trialdehyde 
 
 
Scheme 4.11: Synthesis of pyrimidine terphenyl aldehydes 
 
 










4.6 Supporting Information 
4.6.1 General Experimental Conditions 
Unless otherwise noted, materials were obtained from commercial sources and used 
without purification; otherwise, materials were purified according to Purification of 
Laboratory Chemicals.6 All reactions requiring anhydrous conditions were performed 
under a positive pressure of nitrogen using flame-dried glassware. Methanol (MeOH) was 
distilled over magnesium prior to its usage. Diaminopropane is highly toxic and should be 
handled with great care. Any volatile polyamine synthesized should also be regarded as 
toxic and should be handled with care and always stored under N2 due to reactivity with 
O2 and CO2. Yields were calculated for material judged homogeneous by thin-layer 
chromatography and 1H NMR. Thin-layer chromatography was performed on silica plates 
eluting with the solvents indicated and visualized by a 254nm UV lamp. Flash column 
chromatography was performed with slurry-packed silica gel with solvents indicated in 
glass columns. Both the solvent system used for TLC and column chromatography needs 
to be made fresh upon usage due to the volatile nature of NH3 in H2O. 1HNMR spectra 
were recorded at 500 or 300 MHz as indicated. The chemical shifts (δ) of proton resonances 
are reported relative to the deuterated solvent peak: 4.79 for H2O using the following 
format:chemical shift [multiplicity (s = singlet, bs = broad singlet, d = doublet, dd = doublet 
of doublets, t = triplet, tt = triplet of triplets, q = quartet, pent = pentet, hex = hextet, sept = 
septet, oct = octet, non = nonet m = multiplet),coupling constant(s) (J in Hz), integral]. 13C 
NMR spectra were recorded at 125 MHz. Mass spectra were obtained by ESI/APCI for 
LRMS. Material purity was quantified with a Thermo scientific Ultimate 3000 LC system. 





peak between 170.0-174.0 ppm, which has been confirmed by the facility administrator. 
Efficacy profiles of CZ-01-XXX against planktonic MRSA were determined using the 
microdilution minimum inhibitory concentration (MIC) and minimum bactericidal 
concentration (MBC) assays defined by Clinical and Laboratory Standards Institute (CLSI) 
in the M26-A guideline.  For comparison, efficacy profiles were also determined in parallel 
for vancomycin.  In short, to perform MIC analysis, several colonies of freshly-cultured 
MRSA or P. aeruginosa from blood agar were used to adjust a 0.5 McFarland standard 
(equated to ~7.5 x 108 colony forming units (CFU)/mL) in phosphate buffered saline (PBS; 
Fisher Scientific, catalog # BP399-1).  Bacteria were diluted 1:100 in a glass test tube.  In 
a 96-well plate, columns 2-11 were filled with cation adjusted Mueller Hinton broth 
(CAMHB; Fisher Scientific, catalog #B12322), antibiotic solution and MRSA as per the 
protocol.  In order to fill the wells, liquids were poured into sterile dispensing reservoirs 
(Fisher Scientific, catalog #07-200-127) then pipeted using a multichannel pipet.  This 
process gave a concentration range of antibiotic from 128 µg/mL in column 2 to 0.25 
µg/mL in column 11.  A 96-well plate was covered with a plastic plate cover and incubated 
at 37° C for 24 h after which time the plate was read.  The lowest concentration of antibiotic 
with no growth (no pellet formation) of bacteria was defined as the MIC. 
 
4.6.2 Missing Experimental Data 
Some examples included in the formal report were omitted for clarity or lack full 
characterization, as these compounds were synthesized only once and handed off to our 
biological counterpart without full compound characterization. Furthermore, we felt the 






4.6.3 ISO 10993 Assay 
The ISO 10993 assay is used to determine qualitative cytotoxicity against the L929 cell 
line. Data is given as a score of 0-4 at varying dilution levels. A score of between and 
including 0-2 refers to a “pass” or noncytotoxic compound, while a score of 3-4 refers to 
considerable cell death and is deemed cytotoxic.  
 
4.6.4 Experimental Procedures 
 
1-(3-((3-aminopropyl)amino)propyl)-3-isopropylurea: A flame dried flask was charged 
with 3-bromopropan-1-amine-hydrobromide (1.02 g, 4.66 mmol, 1.0 equiv.), NEt3 (0.78 
mL, 5.59 mol, 1.2 equiv.), and CH2Cl2 (20 mL) and placed under N2. To this was added 
isopropyl-isocyanate (0.45 mL, 4.66 mmol, 1.0 equiv.) and the reaction was left to stir for 
2.5 h. The excess solvent was evaporated and the crude material was placed directly on a 
column and purified with EtOAc. The above purified material was added to a stirring 
solution of diaminopropane (7.8 mL, 93.2 mmol, 20.0 equiv.) at 0 °C over the span of 1.5 
h. The reaction mixture was left to warm and stirred for 12-16 h. Excess 1,3 
diaminopropane was removed under reduced pressure, and the remaining semisolid was 
taken up in 5% NaOH (100 mL) and extracted with 85:15 CHCl3/i-PrOH (5 x 20 mL), 
dried over Na2SO4, filtered, and concentrated under reduced pressure. Purification was 
accomplished by column chromatography eluting with 100:75:20 
(CH2Cl2:MeOH:NH4OH) to afford the material as a pure semisolid (21%). 1H NMR (500 
MHz, CDCl3) δ ppm  5.38 (s, 1H), 4.99 (d, J = 7.5 Hz), 3.79 (oct, J = 6.5 Hz, 1H) 3.19(d, 





J = 7.0 Hz, 4H), 1.09 (d, J = 6.5 Hz, 6H). 13C NMR (125 MHz, CDCl3) δ ppm 158.7, 47.9, 
47.6, 42.2, 40.5, 38.7, 33.1, 30.1, 23.6. 
The following example was prepared similar to 1-(3-((3-aminopropyl)amino)propyl)-3-
isopropylurea: 
 
1-(3-((3-aminopropyl)amino)propyl)-3-(tert-butyl)urea : 1H NMR (500 MHz, CDCl3) δ 
ppm 5.54 (s, 1H), 5.22 (s, 1H), 3.07 (q, J = 6.0 Hz, 2H), 2.68 (t, J = 7.0 Hz, 2H), 2.55 (q, 
J = 8.0 Hz, 4H), 1.58-1.51 (m, 4H), 1.20 (s, 9H). ). 13C NMR (125 MHz, CDCl3) δ ppm 
158.7, 49.7, 47.7, 47.2, 40.3, 37.8, 32.7, 30.2, 29.6. 
 
N1-(3-aminopropyl)-N3-(2-ethylhexyl)propane-1,3-diamine: Was prepared similar to 
iso-butyl norspermidine, however, during the final step column chromatography (40:8:1 
CH2Cl2:MeOH:NH4OH) was used to afford the product as 1a yellow oil (Yield 16% 3 
steps). 1H NMR (500 MHz, CDCl3) δ ppm 3.33-3.02 (m, 5H), 2.81-2.62 (m, 6H), 2.50-
2.44 (m, 2H), 1.76-1.63 (m, 4H), 1.45-1.35 (m, 1H), 1.33-1.20 (m, 8H), 0.87-0.80 (m, 
6H). 13C NMR (125 MHz, CDCl3) δ ppm 53.3, 49.1, 48.8, 48.0, 40.6, 39.2, 39.1, 31.5, 






5-butoxyisophthalaldehyde: Dimethyl 5-hydroxyisophthalate (0.40 g, 1.90 mmol, 1.0 
equiv.), cesium carbonate (1.30 g, 3.80 mmol, 2.0 equiv.) and CH3CN (12 mL) were added 
to a round bottom flask and stirred for 15-30 min Iodobutane (0.42 g, 2.28 mmol, 1.2 
equiv.) was added and the reaction was stirred for 16 h. The solvent was concentrated under 
reduced pressure and the reaction mixture was partitioned between EtOAc (50 mL) and 
H2O (50 mL). The organic layer was separated and the aqueous layer extracted with EtOAc 
(50 mL). The combined organics were dried over Na2SO4, filtered, and concentrated under 
reduced pressure to afford the desired product which was used without further purification. 
To a solution of dimethyl 5-butoxyisophthalate, the product from above, (0.51 g, 1.90 
mmol, 1.0 equiv.) in THF (16 mL) was slowly added LiAlH4 (0.40 g, 10.5 mmol, 5.5 
equiv.) and the reaction mixture was stirred for 8 h. The reaction was quenched by the 
addition of 2N HCl (5 mL). The mixture was extracted with Et2O (2 x 25 mL) and EtOAc 
(2 x 25 mL), the organics layers combined, dried over Na2SO4, filtered, and concentrated 
under reduced pressure to afford the desired product (0.24 g) as an oil,  which was used 
without further purification. (5-Butoxy-1,3-phenylene)dimethanol, the product from 
above, (0.24 g, 1.15 mmol, 1.0 equiv.) and CH3CN (20 mL) were added to a round bottom 
flask. To the solution was added MnO2 (1.97 g, 23.0 mmol, 20.0 equiv.) and the reaction 





reduced pressure. Purification by column chromatography (90% Hexanes/EtOAc) afforded 
the desired product (0.18 g, 44%, 3 steps) as a white semisolid. 1H NMR (300 MHz, 
CDCl3) δ ppm 9.99 (s, 2H), 7.89 (s, 1H), 7.58 (s, 2H), 4.03 (t, J = 6.6 Hz, 2H), 1.77 (quint, 
J = 6.6 Hz, 2H), 1.47 (sext, J = 7.2 Hz, 2H), 0.94 (t, J = 7.5 Hz, 3H). 13C NMR (75 MHz, 
CDCl3) δ ppm 191.3, 160.6, 138.6, 124.2, 120.1, 68.9, 31.3, 19.4, 14.1. 
The following example were prepared similar to 5-butoxyisophthalaldehyde: 
 
5-(Cyclohexylmethoxy)isophthalaldehyde: 1H NMR (300 MHz, CDCl3) δ ppm 10.02 (s, 
2H), 7.91 (s, 1H), 7.61 (s, 2H), 3.84 (d, J = 6.0 Hz, 2H), 1.87-1.67 (m, 6H), 1.31-1.03 (m, 
5H). 13C NMR (75 MHz, CDCl3) δ ppm 191.4, 160.9, 138.6, 124.3, 120.2, 74.6, 37.9, 30.1, 
26.7, 26.0. White solid (45%, 3 steps). 
 
5-(2-Ethylbutoxy)isophthalaldehyde: 1H NMR (500 MHz, CDCl3) δ ppm 10.01 (s, 2H), 
7.90 (s, 1H), 7.62 (s, 2H), 3.94 (d, J = 5.5 Hz, 2H), 1.68 (hept, J = 6.5 Hz, 1H), 1.46 (dec, 
J = 6.5 Hz, 4H), 0.91 (t, J = 7.5 Hz, 6H). 13C NMR (125 MHz, CDCl3) δ ppm 191.1, 160.7, 






5-(Hydroxymethyl)isophthalaldehyde: 1H NMR (500 MHz, CDCl3) δ ppm 10.09 (s, 2H), 
8.27 (s, 1H), 8.15 (s, 2H), 4.88 (s, 2H), 2.54 (br s, 1H). 13C NMR (125 MHz, CDCl3) δ ppm 
191.4, 143.7, 137.4, 132.8, 130.3, 63.9. White solid (34%). 
 
[1,1'-biphenyl]-3,5-dicarbaldehyde: A solution of 5-bromoisophthaldehyde (40.0 g, 
187.8 mmol, 1.0 equiv.), phenylboronic acid (22.9 g, 187.8 mmol, 1.0 equiv.) and 
potassium carbonate (64.8 g, 469.5 mmol, 2.5 equiv.) in DME/H2O (5:1, 600 mL) was 
purged with N2 for 5 min Tetrakispalladium triphenylphosphine (1.1 g, 0.9 mmol) was 
added and the reaction mixture heated to 90 °C and stirred for 16 h. The reaction mixture 
was cooled to rt, filtered through a pad of celite and the solvent evaporated under reduced 
pressure. Purification by column chromatography (10% EtOAc/hexanes) afforded the 
desired product (74%, 29.1 g) as an off-white solid. 1H NMR (300 MHz, CDCl3) δ ppm 
10.18 (s, 2H), 8.37 (d, J = 1.2 Hz, 2H), 8.35 (t, J = 1.5 Hz, 1H), 7.70-7.66 (m, 2H), 7.55-
7.43 (m, 3H). 13C NMR (125 MHz, CDCl3) δ ppm 191.0, 143.2, 138.2, 137.5, 132.8, 129.6, 
129.2, 128.7, 127.1.  







[1,1'-biphenyl]-3,3',5-tricarbaldehyde: 1H NMR (300 MHz, CDCl3) δ ppm 10.20 (s, 2H), 
10.10 (s, 1H), 8.42 (s, 3H), 8.21 (s, 1H), 7.98 (t, J = 5.4 Hz, 2H), 7.72 (t, J = 5.4 Hz, 2H).13C 
NMR (125 MHz, CDCl3) δ ppm 192.0, 191.0, 142.1, 139.6, 138.0, 137.5, 133.1, 133.0, 
130.7, 130.5, 130.3, 128.1. Off-white solid (64-90%).  
 
[1,1'-biphenyl]-3,4'-dicarbaldehyde: 1H NMR (500 MHz, CDCl3) δ ppm 10.10 (s, 2H), 
8.13 (t, J = 2.0 Hz, 2H), 7.91-7.88 (m, 4H), 7.65 (t, J = 7.5 Hz, 2H). 13C NMR (125 MHz, 







[1,1'-biphenyl]-4,4'-dicarbaldehyde: 1H NMR (500 MHz, CDCl3) δ ppm 10.06 (s, 2H), 
7.97 (d, J = 7.5 Hz, 4H), 7.77 (d, J = 8.5 Hz, 4H). 13C NMR (125 MHz, CDCl3) δ ppm 
191.8, 145.7, 136.2, 130.5, 128.2. Off white solid (67%) 
 
[1,1':2',1''-terphenyl]-3,3''-dicarbaldehyde: 1H NMR (500 MHz, CDCl3) δ ppm 9.90 (s, 
2H), 7.73-7.70 (m, 4H), 7.50-7.46 (m, 4H), 7.36-7.31 (m, 4H). 13C NMR (125 MHz, 
CDCl3) δ ppm 192.2, 142.3, 139.4, 136.7, 136.2, 131.2, 130.8, 128.9, 128.6, 128.3. Yellow 
solid (68%) 
 
[1,1':4',1''-terphenyl]-2',3,3''-tricarbaldehyde: 1H NMR (500 MHz, CDCl3) δ ppm 
10.11-10.10 (m, 2H), 9.99 (s, 1H), 8.18-8.15 (m, 1H), 8.00-7.93 (m, 2H), 7.82-7.81 (m, 
1H), 7.71-7.57 (m, 6H), 7.50-7.47 (m, 1H).  13C NMR (125 MHz, CDCl3) δ ppm 192.1, 
191.9, 191.2, 145.1, 140.5, 138.9, 137.3, 136.9, 136.0, 133.4, 130.8, 130.4, 130.1, 130.0, 






[1,1':3',1''-terphenyl]-4,4''-dicarbaldehyde: 1H NMR (500 MHz, CDCl3) δ ppm 10.06 
(s, 2H), 7.97 (d, J = 8.0 Hz, 4H), 7.86 (t, J = 2.0 Hz, 1H), 7.79 (d, J = 8.0 Hz, 4H), 7.68-
7.66 (m, 2H), 7.60-7.57 (m, 1H). 13C NMR (125 MHz, CDCl3) δ ppm 192.1, 146.9, 140.8, 
135.7, 130.6, 130.0, 128.1, 127.7, 126.7. Off-white solid (37-50%). 
 
4,4'-(pyrimidine-2,4-diyl)dibenzaldehyde: 1H NMR (500 MHz, CDCl3) δ ppm 10.10 (s, 
1H), 10.07 (s, 1H), 8.71 (d, J = 4.5 Hz, 1H), 8.25 (d, J = 8.0 Hz, 2H), 8.10 (d, J = 8.0 Hz, 
2H), 7.98 (d, J = 8.0 Hz, 2H), 7.78 (d, J = 8.0 Hz, 2H), 7.71 (d, J = 5.5 Hz, 1H). 13C NMR 
(125 MHz, CDCl3) δ ppm 191.9, 191.7, 165.9, 160.6, 140.5, 138.6, 136.2, 130.5, 130.4, 






5'-(tert-butyl)-[1,1':3',1''-terphenyl]-3,3''-dicarbaldehyde: 1H NMR (500 MHz, CDCl3) 
δ 10.12 (s, 2H), 8.16 (s, 2H), 7.94-7.89 (m, 4H), 7.67-7.65 (m, 5H), 1.46 (s, 9H).  13C NMR 
(125 MHz, CDCl3) δ ppm 192.5, 153.1, 142.7, 140.7, 137.2, 133.6, 129.8, 129.2, 128.5, 
124.3, 123.8, 35.3, 31.7. Yellow solid (47%). 
For fully characterized compounds (1H NMR, 13C NMR, IR, mp, and LCMS) See: CZ-01-
086, CZ-01-096, CZ-01-097, CZ-01-099, CZ-01-100, CZ-01-108, CZ-01-114, CZ-01-
166, CZ-01-168, CZ-01-170, CZ-01-179, and CZ-01-182. All the respective CZ-




aminopropyl)propane-1,3-diamine), hydrochloride salt: To a solution of [1,1'-
biphenyl]-3,5-dicarbaldehyde () in MeOH was added Boc-norspermidine () and the 
reaction was left to stir for 16 h. Sodium borohydride (4 equiv.) was then added portion 
wise and the reaction mixture was left to stir for an additional 1 h. The excess MeOH was 
evaporated and the crude solid was partitioned between EtOAc (50 mL) and 10% NaOH 
(mL). The aqueous layer was then back extracted with EtOAc (1 x 50 mL) dried over 
Na2SO4 and evaporated to afford the crude free base. If desired column chromatography 
can be performed using gradient conditions starting at (300:16:1 CH2Cl2:MeOH:NH4OH). 





precipitate. The corresponding precipitate was filtered and dried to afford the pure HCl salt 
as a white solid (25-52%).  1H NMR (D2O, 500 MHz) δ ppm 7.85 (s, 2H), 7.74 (d, J = 7.5 
Hz, 2H), 7.59-7.56 (m, 3H), 7.50-7.49 (m, 1H), 4.38 (s, 4H), 3.29 (t, J =8.0 Hz, 4H), 3.23 
(q, J = 5.0 Hz, 8H), 3.14 (t, J = 8.0 Hz, 4H), 2.25-2.19 (m, 4H), 2.17-2.11 (m, 4H). 13C 
NMR (125 MHz, D2O) 142.3, 138.8, 132.1, 130.0, 129.5, 129.2, 128.4, 127.0, 50.8, 44.7, 
44.6, 44.2, 36.5, 23.7, 22.7. LRMS calculated for C26H44N6 m/z 441.4 [M+H]+, Obsd. 
441.4. 
The following example were prepared similar to CZ-01-058, in later cases the alkylated 




chloride: 1H NMR (500 MHz, D2O) δ 7.72 (s, 2H), 7.49 (s, 1H), 7.15 (s, 2H), 6.93 (d, J = 
8.5 Hz, 1H), 5.95 (s, 2H), 4.30 (s, 4H), 3.21-3.12 (m, 8H), 3.05 (t, J = 8.0 Hz, 4H), 2.17-
2.02 (m, 8H). 13C NMR (125 MHz, D2O) δ 148.1, 147.6, 142.3, 133.3, 132.2, 130.8, 129.7, 








aminopropyl)propane-1,3-diamine), hydrohydrochloride salt: 1H NMR (400 MHz, 
D2O) δ 7.96 (s, 2H), 7.93-7.85 (m, 2H), 7.71-7.61 (m, J = 8.5 Hz, 3H), 4.47 (s, 4H), 4.44 
(s, 2H), 3.36-3.23 (m, 18H), 3.17 (t, J = 8.0 Hz, 6H), 2.30-2.22 (m, 6H), 2.20-2.13 (m, 6H). 
LRMS calculated for C33H61N9 m/z 584.5 [M+H]+, Obsd. 584.5.   
 
CZ-01-063: N1,N1'-((2'-Methyl-[1,1'-biphenyl]-3,5-diyl)bis(methylene))bis(N3-(3-
aminopropyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 MHz, D2O) δ 
7.59 (s, 1H), 7.56 (d, J = 1.0 Hz, 2H), 7.41-7.40 (m, 2H), 7.38-7.35 (m, 1H), 7.32-7.31 (m, 
1H), 4.38 (s, 4H), 3.25 (t, J =7.5 Hz, 4H), 3.20-3.18 (m, 8H), 3.11 (t, J = 8.0 Hz, 4H), 2.25 
(m, 3H), 2.20-2.15 (m, 4H), 2.14-2.07 (m, 4H) ). 13C NMR (125 MHz, D2O) δ 143.3, 139.9, 





36.6, 23.7, 22.7. LRMS calculated for C27H46N6 m/z 455.4 [M+H]+, Obsd. 455.4. 
 
CZ-01-065: N1,N1',N1''-([1,1'-Biphenyl]-3,4',5-triyltris(methylene))tris(N3-(3-
aminopropyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 MHz, D2O) δ 
7.92 (s, 2H), 7.84 (d, J = 8.5 Hz, 2H), 7.65 (d, J = 8.5 Hz, 3H), 4.43 (s, 4H), 4.37 (s, 2H), 
3.31-3.28 (m, 6H), 3.26-3.20 (m, 12H), 3.14 (t, J = 8.0 Hz, 6H), 2.25-2.17 (m, 6H), 2.16-
2.10 (m, 6H). 13C NMR (125 MHz, D2O) δ 141.6, 140.1, 132.2, 130.6, 130.6, 130.4, 129.7, 
127.8, 50.8, 44.7, 44.6, 44.2, 36.5, 23.7, 22.7, 22.6. LRMS calculated for C33H61N9 m/z 









salt: 1H NMR (500 MHz, D2O) δ 7.93 (s, 2H), 7.88-7.82 (m, 2H), 7.65 (s, 1H), 7.35 (d, J 
= 9.0 Hz, 1H), 4.94-4.87 (m, 1H), 4.47 (s, 4H), 4.43 (s, 2H), 3.39-3.28 (m, 18H), 3.22 (t, J 
= 8.0 Hz, 6H), 2.33-2.18 (m, 12H), 1.48 (d, J = 6.5 Hz, 6H). 13C NMR (125 MHz, D2O) δ 
158.9, 143.9, 134.8, 133.8, 132.9, 132.6, 132.3, 131.8, 122.7, 117.0, 84.4, 74.5, 53.5, 49.6, 
47.3, 47.3, 47.0, 46.9, 46.7, 39.2, 26.3, 25.3, 25.2, 23.9. LRMS calculated for C36H67N9O 
m/z 642.5 [M+H]+, Obsd. 642.5. 
 
CZ-01-067: N1,N1'-((4'-Isopropoxy-[1,1'-biphenyl]-3,5-diyl)bis(methylene))bis(N3-(3-
aminopropyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 MHz, D2O) δ 
7.81 (s, 2H), 7.68 (d, J = 8.5 Hz, 2H), 7.54 (s, 1H), 7.12 (d, J = 8.5 Hz, 2H), 4.78-4.72 (m, 
1H), 4.37 (s, 4H), 3.28 (t, J = 8.0 Hz, 4H), 3.24-3.19 (m, 8H), 3.13 (t, J = 8.0 Hz, 4H), 
2.24-2.19 (m, 4H), 2.17-2.09 (m, 4H), 1.35 (d, J = 6.0 Hz, 6H). 13C NMR (125 MHz, D2O) 
δ 157.0, 141.8, 132.0, 131.8, 129.4, 129.0, 128.3, 116.8, 71.6, 50.8, 44.6, 44.6, 44.1, 36.4, 







aminopropyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 MHz, D2O) δ 
7.90 (s, 2H), 7.83 (t, J = 1.0 Hz, 1H), 7.63-7.61 (m, 1H), 7.60-7.57 (m, 1H), 7.53 (s, 1H), 
4.38 (s, 4H), 3.27 (t, J = 8.0 Hz, 4H), 3.23-3.19 (m, 8H), 3.13 (t, J = 8.0 Hz, 4H), 2.23-2.17 
(m, 4H), 2.15-2.09 (m, 4H). 13C NMR (125 MHz, D2O) δ 139.9, 137.1, 132.2, 129.6, 128.7, 
127.7, 125.9, 122.3, 50.8, 44.7, 44.6, 44.1, 36.5, 23.7, 22.6. LRMS calculated for 













salt: 1H NMR (500 MHz, D2O) δ 8.20 (s, 2H), 8.07 (s, 1H), 7.91 (s, 2H), 7.69 (s, 1H), 4.41 
(s, 4H), 3.30 (t, J = 7.5 Hz, 4H), 3.26-3.21 (m, 8H), 3.14 (t, J = 8.0 Hz, 4H), 2.23-2.19 (m, 
4H), 2.17-2.10 (m, 4H). 13C NMR (125 MHz, D2O) δ 140.6, 139.7, 132.4, 131.5, 131.2, 
129.9, 127.5, 124.4, 122.2, 50.7, 44.7, 44.6, 44.3, 36.5, 23.7, 22.6. LRMS calculated for 
C28H42F6N6 m/z 577.3 [M+H]+, Obsd. 577.3.  
 
CZ-01-071: N1,N1'-((5-(Pyridin-4-yl)-1,3-phenylene)bis(methylene))bis(N3-(3-
aminopropyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 MHz, D2O) δ 
8.87 (d, J = 6.0 Hz, 2H), 8.39 (d, J = 6.5 Hz,, 2H), 8.15 (s, 2H), 7.88 (s, 1H), 4.47 (s, 4H), 
3.30 (t, J = 8.0 Hz, 4H), 3.24-3.19(m, 8H), 3.12 (t, J = 8.0 Hz, 4H), 2.24-2.19 (m, 4H), 
2.15-2.08 (m, 4H). 13C NMR (125 MHz, D2O) δ 156.6, 141.6, 136.8, 134.4, 133.2, 131.0, 





[M+H]+, Obsd. 442.4. 
 
CZ-01-075: N1,N1'-((4'-Fluoro-[1,1'-biphenyl]-3,5-diyl)bis(methylene))bis(N3-(3-
aminopropyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 MHz, D2O) δ 
7.80 (s, 2H), 7.71-7.68 (m, 2H), 7.56 (s, 1H), 7.25 (t, J = 9.0 Hz, 2H), 4.37 (s, 4H), 3.26 (t, 
J = 8.0 Hz, 4H), 3.19 (q, J = 8.0 Hz, 8H), 3.11 (t, J = 7.5 Hz, 4H), 2.22-2.07 (m, 8H). 13C 
NMR (125 MHz, D2O) δ 162.9 (d, 244 Hz), 135.3(d, 3 Hz), 132.3, 130.1, 129.7, 129.1 (d, 
8 Hz), 116.1 (d, 21 Hz), 51.1, 44.9, 44.8, 44.4, 36.7, 23.9, 22.9. LRMS calculated for 
C26H43FN6 m/z 459.4 [M+H]+, Obsd. 459.4. 
 
CZ-01-076: N1,N1'-((5-Butoxy-1,3-phenylene)bis(methylene))bis(N3-(3-
aminopropyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 MHz, D2O) δ 
ppm 7.20 (s, 3H), 4.30 (s, 4H), 4.15 (t, J = 6.5 Hz, 2H), 3.26-3.20 (m, 12H), 3.14 (t, J = 
7.5 Hz, 4H), 2.22-2.10 (m, 8H), 1.79 (quint, J = 6.5 Hz, 2H), 1.48 (sext, J = 7.5 Hz, 2H), 
0.96 (t, J = 7.0 Hz, 3H). 13C NMR (125 MHz, D2O) 159.2, 132.9, 123.5, 117.3, 68.8, 50.8, 





437.4 [M+H]+, Obsd. 437.4. 
 
CZ-01-081: N1,N1'-((5-((2-Ethylhexyl)oxy)-1,3-phenylene)bis(methylene))bis(N3-(3-
aminopropyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 MHz, D2O) δ . 
13C NMR (125 MHz, D2O) 159.9, 133.2, 123.7, 117.7, 72.0, 51.1, 44.9, 44.6, 44.4, 38.8, 
36.8, 29.9, 28.5, 24.0, 23.4, 22.9, 22.7, 13.7, 10.6.  LRMS calculated for C28H56N6O m/z 
493.5 [M+H]+, Obsd. 493.5. 
 
CZ-01-083: N1,N1'-([1,1'-biphenyl]-3,5-diylbis(methylene))bis(N3-(3-
(butylamino)propyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 MHz, 
D2O) δ 7.83 (s, 2H), 7.71 (d, J = 7.5 Hz, 2H), 7.55-7.52 (m, 3H), 7.49-7.45 (m, 1H), 4.35 
(s, 4H), 3.26 (t, J = 7.5 Hz, 4H), 3.21-3.16 (m, 8H), 3.14 (t, J = 8.0 Hz, 4H), 3.05 (t, J = 
8.0 Hz, 4H), 2.21-2.10 (m, 8H), 1.65 (quint, J = 7.0 Hz, 4H), 1.37 (sext, J = 8.0 Hz, 4H), 
0.91 (t, J = 7.0 Hz, 6H). 13C NMR (125 MHz, D2O) δ 142.5, 138.9, 132.3, 130.3, 129.8, 





calculated for C34H60N6 m/z 553.5 [M+H]+, Obsd. 553.5. 
 
CZ-01-086: N1,N1'-([1,1'-biphenyl]-3,5-diylbis(methylene))bis(N3-(3-
(isobutylamino)propyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 MHz, 
D2O) δ 7.87 (s, 2H), 7.75(d, J = 7.5, 2H), 7.59-7.48 (m, 4H), 4.39 (s, 4H), 3.26 (t, J = 8.0 
Hz, 4H), 3.21-3.12 (m, 12H), 2.92 (d, J = 7.0 Hz, 4H), 2.21-2.10 (m, 8H), 2.01 (sept, J = 
7.0 Hz, 2H), 0.99 (d, J = 7.0 Hz, 12H). 13C NMR (125 MHz, D2O) δ 142.8, 139.1, 132.4, 
130.1, 129.8, 129.5, 128.7, 127.3, 55.1, 51.1, 44.9, 44.8, 44.4, 25.8, 22.8, 22.7, 19.2. IR 
(neat): 3400 (bs), 2961, 2765 (all s) cm-1. mp decomposition (202-204 °C).  LRMS 
calculated for C34H60N6 m/z 553.5 [M+H]+, Obsd. 553.5. 
 
CZ-01-088: (3',5'-Bis(((3-((3-aminopropyl)amino)propyl)amino)methyl)-[1,1'-
biphenyl]-4-yl)(piperidin-1-yl)methanone, hydrochloride salt: 1H NMR (300 MHz, 
D2O) δ 7.87 (s, 2H), 7.78 (d, J = 8.4 Hz, 2H), 7.58 (s, 1H), 7.54-7.49 (m, 2H), 4.37 (s, 4H), 





(m, 8H), 1.71-1.64 (m, 4H), 1.58-1.49 (m, 4H). LRMS calculated for C32H53N7O m/z 552.4 
[M+H]+, Obsd. 552.4. 
 
CZ-01-089: 1,1'-((([1,1'-Biphenyl]-3,5diylbis(methylene))bis(azanediyl))bis(propane-
3,1-diyl))bis(tetrahydropyrimidin-2(1H)-one), hydrochloride salt:  1H NMR (300 
MHz, D2O) δ 7.80 (d, J = 6.5 Hz, 2H), 7.71-7.68 (m, 2H), 7.56-7.45 (m, 4H), 4.30 (s, 4H), 
3.34 (t, J = 6.6 Hz, 4H), 3.21 (t, J = 6.0 Hz, 4H), 3.11 (t, J = 6.0 Hz, 4H), 3.04 (t, J = 7.2 
Hz, 4H), 1.97-1.88 (m, 4H), 1.78 (p, J = 6.0 Hz, 4H) . LRMS [M+H]+ 493.4. 
 
CZ-01-090: N1,N1'-((5-(2-Ethylbutoxy)-1,3-phenylene)bis(methylene))bis(N3-(3-
aminopropyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 MHz, D2O) δ 
7.23 (s, 2H), 7.22 (s, 1H), 4.32 (s, 4H), 4.06 (t, J = 7.0 Hz, 2H), 3.27-3.18 (m, 12H), 3.15 
(t, J = 8.0 Hz, 4H), 2.24-2.12 (m, 8H), 1.72 (m , J = 6.0 Hz, 1H), 1.52-1.44 (m, 4H), 0.94-
0.91 (m, 6H). 13C NMR (125 MHz, D2O) δ 159.6, 132.9, 123.5, 117.5, 71.43, 50.8, 44.7, 
44.6, 44.1, 40.1, 36.5, 23.7, 22.6, 10.3. LRMS calculated for C25H52N6O m/z 465.4 







(isobutylamino)propyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 MHz, 
D2O) δ 7.20 (s, 2H), 7.18 (s, 1H), 4.29 (s, 4H), 4.05 (d, J = 6.0 Hz, 2H), 3.25-3.15 (m, 
16H), 2.94 (d, J = 7.0 Hz, 2H), 2.21-2.12 (m, 8H), 2.07-1.99 (m, 2H), 1.72 (quint, J = 6.5 
Hz, 1H), 1.50-1.43 (m, 4H), 1.00 (d, J = 7.0 Hz, 12H), 0.92 (t, J = 6.0 Hz, 6H). 13C NMR 
(125 MHz, D2O) δ 159.6, 132.9, 123.4, 117.4, 71.4, 54.8, 50.8, 44.7, 44.6, 44.6, 44.1, 40.1, 




(octylamino)propyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 MHz, 





(s, 4H), 3.26 (t, J = 8.0 Hz, 4H), 3.21-3.16 (m, 12H), 3.14 (t, J = 8.0 Hz, 4H), 3.06 (t, J = 
8.0 Hz, 4H), 2.21-2.09 (m, 4H), 1.69-1.65 (m, 4H), 1.38-1.28 (m, 20H), 0.86 (t, J = 6.0 Hz, 
6H). 13C NMR (125 MHz, D2O) δ 142.5, 138.8, 132.2, 129.9, 129.5, 129.3, 128.5, 127.0, 
50.8, 47.8, 44.6, 44.1, 30.9, 28.1, 28.0, 25.6, 25.4, 22.7, 22.6, 21.9, 13.3. LRMS calculated 
for C42H76N6 m/z 665.6 [M+H]+, Obsd. 333.3 [M+H]/2+. 
  
CZ-01-093: N1,N1'-((5-isoPropoxy-1,3-phenylene)bis(methylene))bis(N3-(3-
aminopropyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (300 MHz, D2O) δ 
7.13 (s, 3H), 4.78-4.72 (m, 1H), 4.23 (s, 4H), 3.27-3.18 (m, 12H), 3.13 (t, J = 7.8 Hz, 4H), 
2.23-2.18 (m, 4H), 2.18-2.10 (m, 4H), 1.36 (d, J = 10.2Hz, 6H). 
 
CZ-01-094: N1,N1'-([1,1'-Biphenyl]-3,5-diylbis(methylene))bis(N3-(3-





D2O) δ 7.84 (s, 2H), 7.74-7.70 (m, 2H), 7.58-7.50 (m, 4H), 7.47 (s, 10H), 4.37 (s, 4H), 4.24 
(s, 4H), 3.26-3.11 (m, 16H), 2.20-2.05 (m, 8H).     
 
CZ-01-095: N1,N1'-((5-(Benzyloxy)-1,3-phenylene)bis(methylene))bis(N3-(3-
aminopropyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 MHz, D2O) δ 
7.52 (d, J = 7.0 Hz, 2H), 7.49-7.41 (m, 3H), 7.23 (s, 2H), 7.20 (s, 1H), 5.23 (s, 2H), 4.29 
(s, 4H), 3.22-3.15 (m, 12H), 3.13 (t, J = 8.0 Hz, 4H), 2.20-2.09 (m, 8H). 13C NMR (125 
MHz, D2O) δ 158.7, 136.0, 133.0, 132.5, 128.5, 128.0, 123.9, 117.7, 70.4, 50.7, 44.3, 44.0, 
36.5, 23.7, 22.6 LRMS calculated for C27H46N6O m/z 471.4 [M+H]+, Obsd. 471.4. 
 
CZ-01-096: N1,N1'-([1,1'-Biphenyl]-3,5-diylbis(methylene))bis(N3-(3-
((cyclohexylmethyl)amino)propyl)propane-1,3-diamine), hydrochloride salt: 1H 
NMR (500 MHz, D2O) δ 7.87 (s, 2H), 7.75 (d, J = 7.5 Hz, 2H), 7.59-7.56(m, 3H), 7.51-





4H), 2.93 (d, J = 7.0 Hz, 4H), 2.24-2.12 (m, 8H), 1.74-1.60 (m, 12H), 1.30-1.14 (m, 6H), 
1.05-0.98 (m, 4H). 13C NMR (125 MHz, D2O) δ 142.4, 138.8, 132.1, 130.0, 129.6, 129.3, 
128.5, 127.0, 53.7, 50.8, 44.7, 44.6, 44.2, 34.5, 29.7, 25.4, 24.9, 22.6, 22.5. IR (neat): 3386 
(bs), 2921, 2739, 1453 (all s) cm-1. mp decomposition (235-237 °C).  LRMS calculated for 
C40H68N6 m/z 633.6 [M+H]+, Obsd. 633.5. 
 
CZ-01-097: N1,N1'-(1,3-phenylenebis(methylene))bis(N3-(3-
((cyclohexylmethyl)amino)propyl)propane-1,3-diamine), hydrochloride salt: 1H 
NMR (500 MHz, D2O) δ 7.57 (s, 4H), 4.30 (s, 4H), 3.22 (t, J = 7.5 Hz, 4H), 3.18-3.15 (m, 
8H), 3.12 (t, J = 8.0 Hz, 4H), 2.91 (d, J = 7.0 Hz, 4H), 2.18-2.08 (m, 8H), 1.72-1.62 (m, 
12H), 1.28-1.11 (m, 6H), 1.03-0.96 (m, 4H). 13C NMR (125 MHz, D2O) δ 131.4, 131.2, 
131.0, 130.2, 53.7, 50.8, 48.8, 44.7, 44.6, 44.0, 34.5, 29.7, 25.3, 24.8, 22.6, 22.5. IR (neat): 
3330 (bs), 2971, 2936, 2831, 1455 (all s) cm-1. mp decomposition (250-251 °C). LRMS 







(isobutylamino)propyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 MHz, 
D2O) δ ppm 7.91 (s, 1H), 7.85-7.82 (m, 3H), 7.65-7.56 (m, 3H), 4.42 (s, 4H), 4.39 (s, 2H), 
3.29-3.16 (m, 24H), 2.93 (d, J = 6.0 Hz, 6H), 2.20-2.13 (m, 12H), 2.07-2.00 (m, 3H), 0.99 
(d, J = 6.0 Hz, 18H). 13CNMR (125 MHz, D2O) δ ppm 141.6, 139.8, 132.2, 131.3, 130.4, 
130.3, 129.7, 129.5, 128.6, 128.4, 54.8, 54.8, 51.1, 50.8, 44.7, 44.6, 44.2, 44.0, 25.5, 22.7, 
22.5, 19.0. IR (neat): 3381 (bs), 2950, 2755, 1447 (all s) cm-1. mp decomposition (248-250 
°C).  LRMS calculated for C45H85N9 m/z 752.7 [M+H]+, Obsd. 376.8 [M+H]+/2. 
 
CZ-01-100: N1,N1'-(1,3-Phenylenebis(methylene))bis(N3-(3-(octylamino)propyl) 
(propane-1,3-diamine), hydrochloride salt: 1H NMR (500 MHz, D2O) δ 7.58 (s, 4H), 
4.32 (s, 4H), 3.10-2.98 (m, 16H), 2.91 (t, J = 8.0 Hz, 4H), 2.05-1.95 (m, 8H), 1.53 (quint, 





δ 131.4, 131.2, 131.1, 130.2, 50.8, 47.9, 44.6, 44.6, 44.2, 44.1, 30.9, 28.1, 28.1, 25.6, 25.4, 
22.6, 21.9, 13.3. IR (neat): 3326 (bs), 2942, 2831, 1457 (all s) cm-1. mp decomposition 
(254-255 °C).  LRMS calculated for C36H72N6 m/z 589.6 [M+H]+, Obsd. 589.5. 
 
CZ-01-101: N1,N1'-((5-(Cyclohexylmethoxy)-1,3-phenylene)bis(methylene)) 
bis(N3-(3-aminopropyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 MHz, 
D2O) δ 7.16 (d, J = 7.5 Hz 3H), 4.27 (s, 4H), 3.93 (t, J = 6.0 Hz, 2H), 3.23-3.09 (m, 16H), 
2.19-2.07 (m, 8H), 1.83-1.66 (m, 6H), 1.31-1.17 (m, 3H), 1.10-1.05 (m, 2H). 13C NMR 
(125 MHz, D2O) δ 131.4, 131.2, 131.1, 130.2, 50.8, 47.9, 44.6, 44.6, 44.2, 44.1, 30.9, 28.1, 




hydrochloride salt: 1H NMR (300 MHz, D2O) δ 7.75-7.69 (m, 4H), 6.60 (d, J = 2.1 Hz, 
2H), 4.38 (s, 4H), 3.92 (s, 3H), 3.27-3.09 (m, 16H), 2.89 (d, J = 7.2 Hz, 4H), 2.21-2.06 (m, 





(m, 4H), 6.60 (d, J = 2.1 Hz, 2H), 4.38 (s, 4H), 3.92 (s, 3H), 3.27-3.09 (m, 16H), 2.89 (d, J 
= 7.2 Hz, 4H), 2.21-2.06 (m, 8H), 2.03-1.94 (m, 2H), 0.97 (d, J = 6.9 Hz, 12H). 
 
CZ-01-103: N1,N1'-((5-(Cyclohexylmethoxy)-1,3-phenylene)bis(methylene))bis(N3-(3-
(octylamino)propyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 MHz, 
D2O) δ 7.18 (s, 3H), 4.28 (s, 4H), 3.95 (s, 2H) 3.20-3.14 (m, 16H), 3.06 (t, J = 7.5 Hz, 4H), 
2.22-2.10 (m, 8H), 1.88-1.80 (m, 3H), 1.76-1.64 (m 8H), 1.41-1.20 (m, 22H), 1.12-1.03 
(m, 2H), 0.89-0.83 (m, 6H). 13C NMR (125 MHz, D2O) δ 159.5, 133.0, 123.4, 117.3, 74.4, 
50.8, 47.8, 44.6, 44.6, 44.2, 44.1, 36.8, 30.9, 29.1, 28.1, 28.0, 25.9, 25.6, 25.4, 25.2, 22.6, 
22.6, 21.9, 13.3. LRMS calculated for C43H84N6O m/z 701.7 [M+H]+, Obsd. 701.7. 
 
CZ-01-104: N1,N1'-((5-(Cyclohexyloxy)-1,3-phenylene)bis(methylene))bis(N3-(3-





D2O) δ 7.60 (s, 2H), 7.53 (s, 1H), 4.73 (t, J = 1.2 Hz, 1H), 4.42 (s, 4H), 3.26-3.13 (m, 16H), 
2.84 (d, J = 6.9 Hz, 2H), 2.23-2.08 (m, 8H), 2.06-1.96 (m, 2H), 1.87-1.78 (m, 4H), 1.65-
1.36 (m, 6H), 0.99 (d, J = 6.6 Hz, 12H). LRMS calculated for C34H66N6O m/z 575.5 
[M+H]+, Obsd. 575.5. 
 
CZ-01-105: N1,N1'-((5-(cyclohexyloxy)-1,3-phenylene)bis(methylene))bis(N3-(3-
aminopropyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (300 MHz, D2O) δ 
7.22 (s, 2H), 7.18 (s, 1H), 4.68 (t, J = 1.2 Hz, 1H), 4.30 (s, 4H), 3.28-3.18 (m, 12H), 3.14 
(t, J = 7.8 Hz, 4H), 2.21-2.06 (m, 8H), 1.84-1.75 (m, 4H), 1.63-1.34 (m, 6H). LRMS 
calculated for C26H50N6O m/z 463.4 [M+H]+, Obsd. 463.5. 
 
CZ-01-106: N1,N1'-((5-(Benzyloxy)-1,3-phenylene)bis(methylene))bis(N3-(3-
(isobutylamino)propyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (400 MHz, 
D2O) δ 7.55 (s, 1H), 7.52 (d, J = 2.1 Hz, 2H), 7.49 (s, 2H), 7.26 (s, 3H), 5.29 (s, 2H), 4.31 









hydrochloride salt: 1H NMR (500 MHz, D2O) δ ppm 7.21 (s, 1H), 7.19 (s, 2H), 4.30 (s, 
4H), 4.23 (t, J = 5.5 Hz, 2H), 3.29 (t, J = 7.0 Hz, 2H), 3.25-3.19 (m, 12H), 3.12 (t, J = 7.5 
Hz, 4H), 2.95 (d, J = 7.0 Hz, 2H), 2.25-2.03 (m, 13H), 1.01 (d, J = 7.5 Hz, 6H). 13C NMR 
(125 MHz, D2O) 158.9, 133.0, 123.7, 117.1, 65.8, 54.8, 50.7, 45.7, 44.7, 44.6, 44.2, 36.7, 




propane-1,3-diamine), hydrochloride salt: 1H NMR (300 MHz, D2O) δ 7.54 (s, 4H), 4.28 





2H), 0.95 (d, J = 6.9 Hz, 12H). 13C NMR (125 MHz, D2O) δ 131.6, 131.5, 131.3, 130.4, 
55.1, 51.1, 45.0, 44.9, 44.8, 44.3, 25.8, 22.8, 22.7, 19.3. IR (neat): 3451 (bs), 2763, 1457 
(all s) cm-1. mp decomposition (250-251 °C). LRMS calculated for C28H56N6 m/z 477.5 
[M+H]+, Obsd. 477.4. 
 
CZ-01-109: N1,N1'-((5-Bromo-1,3-phenylene)bis(methylene))bis(N3-(3-
(isobutylamino)propyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (300 MHz, 
D2O) δ 7.76 (s, 2H), 7.51 (s, 1H), 4.27 (s, 4H), 3.21-3.08 (m, 16H), 2.88 (d, J = 7.5 Hz, 
4H), 2.16-2.06 (m, 8H), 2.02-1.93 (m, 2H), 0.96 (d, J = 6.6 Hz, 12H). . LRMS calculated 









4.24 (t, J = 5.0 Hz, 2H), 3.30 (t, J = 7.0 Hz, 2H), 3.26-3.14 (m, 16H), 3.07 (t, J = 7.0 Hz, 
4H), 2.96 (d, J = 7.5 Hz, 2H), 2.26-2.03 (m, 11H), 1.69 (quint, J = 6.5 Hz, 4H), 1.38-1.28 
(m, 20H), 1.02 (d, J = 6.5 Hz, 6H), 0.87 (t, J = 5.5 Hz, 6H). 13C NMR (125 MHz, D2O) δ 
158.9, 133.0, 123.7, 117.1, 65.8, 54.8, 50.8, 47.9, 45.7, 44.6, 44.6, 44.2, 44.1, 30.9, 28.1, 
28.1, 25.6, 25.5, 25.4, 25.2, 22.6, 22.6, 19.1, 13.4. 
 
CZ-01-111: N1,N1'-([1,1'-Biphenyl]-3,5-diylbis(methylene))bis(N4-(3-
(isobutylamino)propyl)butane-1,4-diamine), hydrochloride salt: 1H NMR (500 MHz, 
D2O) δ 7.86 (s, 2H), 7.75 (d, J = 7.5 Hz, 2H), 7.58 (t, J = 8.0 Hz, 3H), 7.50 (t, J = 7.5 Hz, 
1H), 4.37 (s, 4H), 3.20-3.11 (m, 16H), 2.92 (d, J = 7.5 Hz, 4H), 2.16-2.10 (m, 4H), 2.06-
1.97 (m, 2H), 1.88-1.80 (m, 8H), 0.99 (d, J = 6.5 Hz, 12H). 13C NMR (125 MHz, D2O) δ 
142.7, 139.1, 132.6, 130.1, 129.7, 129.5, 128.7, 127.7, 55.1, 50.9, 47.2, 46.7, 44.5, 44.7, 








(isobutylamino)propyl)-2,2-dimethylpropane-1,3-diamine), hydrochloride salt: 1H 
NMR (500 MHz, D2O) δ 7.89 (s, 2H), 7.71 (d, J = 7.5 Hz, 2H), 7.62 (s, 1H), 7.52 (t, J = 
7.5 Hz, 2H), 7.44 (t, J = 7.5 Hz, 1H), 4.39 (s, 4H), 3.19-3.01 (m, 16H), 2.89 (d, J = 7.5 Hz, 
4H), 2.21-2.15 (m, 4H), 2.03-1.96 (m, 2H), 1.18 (s, 12H), 0.97 (d, J = 6.5 Hz, 12H). 13C 
NMR (125 MHz, D2O) δ 142.2, 138.8, 131.7, 131.4, 130.2, 129.5, 128.7, 127.2, 55.6, 55.1, 
52.1, 46.3, 45.0, 33.2, 25.8, 22.5, 22.4, 21.9, 19.3. LRMS calculated for C38H68N6 m/z 
609.6 [M+H]+, Obsd. 609.5. 
 
CZ-01-113: N1,N1'-(1,3-Phenylenebis(methylene))bis(N3-(3-
(hexylamino)propyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 MHz, 
D2O) δ 7.58 (s, 4H), 4.32 (s, 4H), 3.24-3.13 (m, 16H), 3.05 (t, J = 8.0 Hz, 4H), 2.20-2.09 
(m, 8H), 1.68-1.63 (m, 4H), 1.38-1.33 (m, 4H), 1.32-1.26 (m, 8H), 0.85 (t, J = 7.5 Hz, 6H). 









(hexylamino)propyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 MHz, 
D2O) δ 7.83 (s, 2H), 7.71 (d, J = 7.5 Hz, 2H), 7.55-7.53 (m, 3H), 7.47 (t, J = 6.5 Hz, 1H), 
4.34 (s, 4H), 3.25 (t, J = 8.0 Hz, 4H), 3.19 (q, J = 8.0 Hz, 8H), 3.13 (t, J = 8.0 Hz, 4H), 
3.04 (t, J = 8.5 Hz, 4H), 2.22-2.09 (m, 8H), 1.66 (quint, J = 7.5 Hz, 4H), 1.36-1.31 (m, 4H), 
1.28-1.27 (m, 8H), 0.85 (t, J = 7 Hz, 6H). 13C NMR (125 MHz, D2O) δ 142.5, 139.0, 132.3, 
130.3, 129.8, 129.5, 128.7, 127.3, 51.0, 48.1, 44.9, 44.4, 44.4, 30.6, 25.6, 25.5, 22.9, 22.8, 
21.9, 13.5. IR (neat): 3404 (bs), 2947, 2762, 1738, 1712 (all s) cm-1. mp decomposition 








(hexylamino)propyl)butane-1,4-diamine), hydrochloride salt: 1H NMR (500 MHz, 
D2O) δ 7.87 (s, 2H), 7.76 (d, J = 7.5 Hz, 2H), 7.58 (t, J = 8.0 Hz, 3H), 7.51 (t, J = 7.5 Hz, 
1H), 4.37 (s, 4H), 3.21-3.14 (m, 12H), 3.07 (t, J = 7.0 Hz, 4H), 2.16-2.09 (m, 4H), 1.90-
1.77 (m, 10H), 1.69 (quint, J = 7.0 Hz, 4H), 1.39-1.37 (m, 4H), 1.32-1.31 (m, 10H), 0.86 
(t, J = 7.0 Hz, 6H). 13C NMR (125 MHz, D2O) δ 142.6, 139.1, 132.6, 130.2, 129.7, 129.5, 
128.7, 127.3, 50.9, 48.1, 47.2, 46.7, 44.7, 44.5, 30.6, 25.6, 25.5, 23.0, 23.0, 22.8, 21.9, 13.4. 
LRMS calculated for C40H72N6 m/z 637.6 [M+H]+, Obsd. 637.6. 
 
CZ-01-119: N1,N1'-(1,3-Phenylenebis(methylene))bis(N4-(3-
(hexylamino)propyl)butane-1,4-diamine), hydrochloride salt: 1H NMR (500 MHz, 
D2O) δ 7.65 (s, 4H), 4.37 (s, 4H), 3.26-3.19 (m, 16H), 3.14 (t, J = 7.5 Hz, 4H), 2.20 (quint, 
J = 8.0 Hz, 4H), 1.88 (br s, 8H), 1.75 (quint, J = 8.0 Hz, 4H), 1.46-1.42 (m, 4H), 1.39-1.36 
(m, 8H), 0.94 (t, J = 6.5 Hz, 6H). 13C NMR (125 MHz, D2O) δ 134.2, 133.7, 133.5, 132.7, 
53.3, 50.4, 49.6, 49.1, 47.1, 46.8, 32.9, 27.9, 27.8, 25.4, 25.3, 25.2, 24.2, 15.8. LRMS 









hydrochloride salt: 1H NMR (500 MHz, D2O) δ ppm 7.05 (s, 1H), 7.03 (s, 2H), 4.13 (s, 
4H), 4.07 (t, J = 6.0 Hz, 2H), 3.15-2.97 (m, 18H), 2.90 (t, J = 8.0 Hz, 4H), 2.78 (d, J = 6.5 
Hz, 2H), 2.09-1.94 (m, 10H), 1.88 (sept, J = 7.0 Hz, 1H), 1.51 (pent, J = 7.5 Hz, 4H), 1.23-
1.08 (m, 12H), 0.84 (d, J = 6.0 Hz, 6H), 0.70 (t, J = 7.0 Hz, 6H). 13C NMR (125 MHz, 
D2O) δ 159.0, 133.1, 124.0, 117.4, 66.1, 55.0, 50.9, 49.0, 48.0, 45.9, 44.8, 44.4, 44.3, 30.5, 
25.7, 25.5, 25.4 25.4, 22.8, 21.8, 19.3, 13.4. LRMS calculated for C39H79N7O m/z 662.6 
[M+H]+, Obsd. 662.4. 
 
CZ-122: N1,N1'-((5-(3-(hexylamino)propoxy)-1,3-phenylene)bis(methylene))bis(N3-





D2O) δ ppm 7.20 (s, 1H), 7.18 (s, 2H), 4.28 (s, 4H), 4.21 (t, J = 5.5 Hz, 2H), 3.28-3.12 (m, 
18H), 3.08-3.03 (m, 6H), 2.22-2.09 (m, 10H), 1.72-1.63 (m, 6H), 1.38-1.24 (m, 18H), 0.85 
(t, J = 6.0 Hz, 9H). 13C NMR (125 MHz, D2O) δ 159.1, 133.2, 124.0, 117.4, 66.0, 51.0, 
48.1, 45.4, 44.9, 44.8, 44.4, 44.4, 30.6, 30.6, 25.6, 25.6, 25.6, 25.5, 25.5, 22.8, 21.9, 21.9, 
13.4, 13.4.  
 
CZ-01-124: N1,N1'-((5-(cyclohexylmethoxy)-1,3-phenylene)bis(methylene))bis(N3-(3-
(butylamino)propyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 MHz, 
D2O) δ ppm 7.16 (s, 3H), 4.27 (s, 4H), 3.93 (d, J = 6.0 Hz, 2H), 3.22-3.12 (m, 16H), 3.05 
(t, J = 8.0 Hz, 4H), 2.18-2.07 (m, 8H), 1.82-1.71 (m, 5H), 1.65 (pent, J = 7.5 Hz, 4H), 1.37 
(hex, J = 7.5 Hz, 4H), 1.30-1.01 (m, 6H), 0.91 (t, J = 7.0 Hz, 6H). 13C NMR (125 MHz, 
D2O) δ 159.7, 133.2, 123.6, 117.6, 74.6, 51.0, 47.8, 44.8, 44.4, 44.3, 37.1, 29.4, 27.7, 26.2, 









(isobutylamino)propyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 MHz, 
D2O) δ ppm 7.16 (s, 3H), 4.27 (s, 4H), 3.93 (d, J = 6.0 Hz, 2H), 3.22-3.12 (m, 16H), 2.91 
(d, J = 7.5 Hz, 4H), 2.18-2.09 (m, 8H), 2.00 (sept, J = 6.5 Hz, 2H), 1.82-1.64 (m, 5H), 
1.32-1.01 (m, 6H), 0.98 (d, J = 6.5 Hz, 12H). 13C NMR (125 MHz, D2O) δ 159.7, 133.2, 
123.6, 117.6, 74.6, 55.1, 51.0, 45.0, 44.9, 44.3, 37.1, 29.4, 26.2, 25.8, 25.4, 22.8, 22.7, 19.2. 








(butylamino)propyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 MHz, 
D2O) δ ppm 7.91 (s, 2H), 7.85-7.82 (m, 2H), 7.65-7.62 (m, 2H), 7.57-7.56 (m, 1H), 4.42 
(s, 4H), 4.39 (s, 2H), 3.30-3.14 (m, 24H), 3.07 (t, J = 7.5 Hz, 6H), 2.24-2.10 (m, 12H), 1.66 
(t, J = 7.5 Hz, 6H), 1.39 (hex, J = 8.0 Hz, 6H), 0.92 (t, J = 7.5 Hz, 9H).  13C NMR (125 
MHz, D2O) δ 141.9, 140.0, 132.4, 131.5, 130.6, 130.3, 130.0, 129.8, 128.8, 128.6, 51.4, 
51.1, 47.8, 44.9, 44.4, 44.3, 27.7, 22.9, 22.8, 19.3, 12.9. LRMS calculated for C45H85N9 
m/z 753.2 [M+H]+, Obsd. 376.7 [M+H]+/2. 
 
CZ-01-127: N1,N1',N1''-([1,1'-biphenyl]-3,3',5-triyltris(methylene))tris(N3-(3-
((cyclohexylmethyl)amino)propyl)propane-1,3-diamine), hydrochloride salt:  1H 
NMR (500 MHz, D2O) δ 7.92 (s, 2H), 7.86-7.83 (m, 2H), 7.67-7.64 (m, 2H), 7.58-7.57 (m, 
1H), 4.43 (s, 4H), 4.40 (s, 2H), 3.31-3.14 (m, 24H), 2.94 (d, J = 7.0 Hz, 6H), 2.25-2.12 (m, 
12H), 1.73-1.64 (m, 17H), 1.31-0.98 (m, 16H).  13C NMR (125 MHz, D2O) δ 141.9, 140.0, 
133.4, 131.5, 130.6, 130.3, 130.0, 129.8, 128.8, 128.6, 53.9, 51.4, 51.1, 44.9, 44.9, 44.5, 





Obsd. 436.8 [M+H]+/2. 
 
CZ-01-128: N1,N1',N1''-([1,1'-biphenyl]-3,3',5-triyltris(methylene))tris(N3-(3-
(octylamino)propyl)propane-1,3-diamine): 1H NMR (500 MHz, D2O) δ 7.91 (s, 2H), 
7.85-7.82 (m, 2H), 7.66-7.63 (m, 2H), 7.58 (t, J = 7.5 Hz, 1H), 4.42 (s, 4H), 4.39 (s, 2H), 
3.30-3.13 (m, 24H), 3.06 (t, J = 7.5 Hz, 6H), 2.24-2.10 (m, 12H), 1.68 (pent, J = 7.0 Hz, 
6H), 1.38-1.27 (m, 30H), 0.86 (t, J = 7.0 Hz, 9H) 13C NMR (125 MHz, D2O) δ 141.9, 
140.0, 132.5, 131.5, 130.6, 130.3, 130.0, 129.8, 128.8, 128.6, 51.4, 51.1, 48.1, 44.9, 44.5, 
44.4, 44.3, 31.2, 28.3, 28.3, 25.8, 25.6, 22.9, 22.8, 22.1, 13.6. LRMS calculated for 








diyl))bis(azanediyl))bis(propane-3,1-diyl))bis(3-isopropylurea), hydrochloride salt: 
1H NMR (500 MHz, D2O) δ ppm 7.16 (s, 2H), 7.15 (s, 1H), 4.26 (s, 4H), 3.93 (d, J = 6.0 
Hz, 2H), 3.68 (pent, J = 6.5 Hz, 2H), 3.22-3.18 (m, 8H), 3.13 (t, J = 7.5 Hz, 4H), 3.07 (t, J 
= 7.5 Hz, 4H), 2.17-2.10 (m, 4H), 1.87-1.65 (m, 11H), 1.32-1.15 (m, 4H), 1.09 (d, J = 6.5 
Hz, 12H). 13C NMR (125 MHz, D2O) δ 160.2, 159.6, 133.2, 123.6, 117.5, 74.6, 50.9, 45.3, 









diyl))bis(azanediyl))bis(propane-3,1-diyl))bis(3-(tert-butyl)urea), hydrochloride salt: 
1H NMR (500 MHz, D2O) δ ppm 7.13 (s, 3H), 4.24 (s, 4H), 3.90 (d, J = 6.5 Hz, 2H), 3.19-
3.09 (m, 12H), 3.03 (t, J = 7.5 Hz, 4H), 2.13-2.10 (m, 4H), 1.82-1.61 (m, 11H), 1.22 (s, 
18H) 1.15-0.97 (m, 4H). 13C NMR (125 MHz, D2O) δ 160.4, 159.7, 133.2, 123.6, 117.6, 
74.6, 50.9, 50.3, 45.4, 44.6, 44.3, 37.1, 36.1, 29.4, 28.8, 26.7, 26.2, 25.5, 22.9. LRMS 




hydrochloride salt: 1H NMR (500 MHz, D2O) δ ppm 7.89 (s, 2H), 7.84-7.79 (m, 2H), 
7.60 (t, J = 8.0 Hz, 2H), 7.54-7.52 (m, 1H), 4.38 (s, 4H), 4.35 (s, 2H), 3.27-3.04 (m, 24H), 
2.21-2.14 (m, 6H), 1.82 (pent, J = 7.0 Hz, 6H), 1.23 (s, 27H). 13C NMR (125 MHz, D2O) 
δ ppm 160.3, 141.8, 140.0, 132.4, 131.5, 130.7, 130.3, 130.0, 129.8, 128.9, 128.6, 51.3, 









diamine), hydrochloride salt: 1H NMR (500 MHz, D2O) δ ppm 7.88 (s, 2H), 7.74-7.72 
(m, 2H), 7.60 (s, 1H), 7.56 (t, J = 8.0 Hz, 2H), 7.50-7.47 (m, 1H), 4.43 (s, 4H), 3.62-3.56 
(m, 8H), 3.28 (t, J = 8.0 Hz, 4H), 3.17 (t, J = 8.5 Hz, 4H), 3.06 (t, J = 7.5 Hz, 4H), 2.20-
2.14 (m, 4H), 1.68 (pent, J = 8.0 Hz, 4H), 1.41-1.26 (m, 12H), 0.88-0.85 (m, 6H). 13C NMR 
(125 MHz, D2O) δ ppm 142.6, 138.8, 132.0, 130.3, 130.0, 129.5, 128.7, 127.3, 51.4, 48.1, 
45.3, 44.4, 43.5, 43.0, 30.6, 25.6, 25.5, 22.9, 21.9, 13.5. LRMS calculated for C36H64N6 
m/z 581.5 [M+H]+, Obsd. 581.3. 
 
CZ-01-138: N1,N1'-(1,3-phenylenebis(methylene))bis(N3-isobutyl-N1-(3-





for C36H72N6 m/z 589.6 [M+H]+, Obsd. 589.4. 
 
CZ-01-140: N1,N1',N1''-([1,1'-biphenyl]-3,3',5-triyltris(methylene))tris(N3-(3-
(hexylamino)propyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 MHz, 
D2O) δ ppm 7.90 (s, 2H), 7.86-7.81 (m, 2H), 7.65-7.62 (m, 2H), 7.56-7.55 (m, 1H), 4.41 
(s, 4H), 4.38 (s, 2H), 3.29-3.12 (m, 24H), 3.05 (t, J = 8.0 Hz, 6H), 2.23-2.09 (m, 12H), 1.67 
(t, J = 7.5 Hz, 6H), 1.38-1.29 (m, 18H), 0.86 (t, J = 7.0 Hz, 9H). 13C NMR (125 MHz, D2O) 
δ ppm 141.7, 139.9, 132.4, 131.4, 130.6, 130.2, 130.0, 129.8, 128.8, 128.5, 51.4, 51.0, 48.1, 
44.8, 44.4, 44.2, 30.5, 25.6, 25.4, 22.8, 21.8, 13.4. LRMS calculated for C51H97N9 m/z 







(isobutylamino)propyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 MHz, 
D2O) δ ppm 7.33 (s, 1H), 7.31 (s, 2H), 4.93 (d, J = 1.5 Hz, 2H), 4.38 (s, 4H), 3.32-3.22 (m, 
16H), 3.08 (t, J = 2.0 Hz, 1H), 3.00 (d, J = 7.5 Hz, 4H), 2.28-2.19 (m, 8H), 2.10 (sept, J = 
7.0 Hz, 2H), 1.06 (d, J = 7.0 Hz, 12H).  13C NMR (125 MHz, D2O) δ ppm 157.7, 133.1, 




hydrochloride salt: 1H NMR (500 MHz, D2O) δ ppm 7.34 (s, 2H), 7.32 (s, 1H), 5.08 (s, 
2H), 4.36 (s, 4H), 4.23 (d, J = 6.0 Hz, 1H), 4.14-3.83 (m, 4H), 3.69-3.46 (m, 4H), 3.32-
3.20 (m, 16H), 2.98 (d, J = 7.5 Hz, 4H), 2.41 (oct, J = 6.0 Hz, 1H) 2.27-2.17 (m, 8H), 2.09 





124.5, 117.9, 86.8, 77.3, 65.2, 63.5, 56.2, 54.9, 50.7, 44.8, 44.7, 44.6, 44.3, 27.3, 25.6, 22.6, 
22.5, 19.0, 19.0, 16.4. 
 
CZ-01-150:  N1,N1'-([1,1'-biphenyl]-4,4'-diylbis(methylene))bis(N3-(3-
(isobutylamino)propyl)propane-1,3-diamine): 1H NMR (500 MHz, D2O) δ ppm 7.87 (d, 
J = 7.5 Hz, 4H), 7.67 (d, J = 8.0 Hz, 4H), 4.40 (s, 4H), 3.32-3.19 (m, 16H), 2.98 (d, J = 7.5 
Hz, 4H), 2.28-2.16 (m, 8H), 2.07 (sept, J = 7.0 Hz, 2H), 1.05 (d, J = 6.5 Hz, 12H). 13C 
NMR (125 MHz, D2O) δ ppm 140.9, 130.5, 130.1, 127.7, 54.9, 50.9, 44.7, 44.6, 44.0, 25.6, 








(isobutylamino)propyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 MHz, 
D2O) δ ppm 7.87-7.85 (m, 4H), 7.67 (t, J = 7.0 Hz, 2H), 7.59-7.58 (m, 2H), 4.42 (s, 4H), 
3.32-3.19 (m, 16H), 2.98 (d, J =7.5 Hz, 4H), 2.28-2.17 (m, 8H), 2.07 (sept, J = 7.0 Hz, 
2H), 1.05 (d, J = 6.5 Hz,  12H). 13C NMR (125 MHz, D2O) δ ppm 140.6, 131.2, 130.0, 
129.2, 128.5, 128.3, 54.9, 51.2, 44.8, 44.7, 44.0, 25.6, 22.6, 22.5, 19.1. LRMS calculated 
for C34H60N6 m/z 553.5 [M+H]+, Obsd. 553.4. 
 
CZ-01-152: N1,N1'-([1,1':2',1''-terphenyl]-3,3''-diylbis(methylene))bis(N3-(3-
(isobutylamino)propyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 MHz, 
D2O) δ ppm 7.64-7.58 (m, 4H), 7.43-7.38 (m, 6H), 7.30-7.28 (m, 2H), 4.23 (s, 4H), 3.24-
3.13 (m, 16H), 2.97 (d, J = 7.5 Hz, 4H), 2.22-2.14 (m, 8H), 2.06 (sept, J = 6.5 Hz, 2H), 
1.04 (d, J = 7.0 Hz, 12H).  13C NMR (125 MHz, D2O) δ ppm 142.0, 139.4, 131.2, 131.1, 
130.5, 130.4, 128.9, 128.4, 128.1, 54.9, 51.0, 48.9, 44.7, 44.6, 43.8, 25.6, 22.6, 22.5, 19.0. 







(isobutylamino)propyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 MHz, 
D2O) δ ppm 7.94-7.90 (m, 3H), 7.81-7.80 (m, 2H), 7.75-7.60 (m, 6H), 4.44-4.43 (m, 6H), 
3.36-3.06 (m, 24H), 2.98-2.97 (m, 6H), 2.29-2.03 (m, 15H), 1.05 (d, J = 6.5 Hz, 18H). 13C 
NMR (125 MHz, D2O) δ ppm 142.5, 140.9, 140.2, 140.1, 131.3, 131.2, 130.7, 130.3, 130.0, 
129.4, 128.5, 128.4, 127.7, 127.1, 54.9, 51.2, 48.0, 44.8, 44.6, 44.7, 44.5, 44.3, 44.2, 44.1, 








(isobutylamino)propyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 MHz, 
D2O) δ ppm 7.63-7.58 (m, 4H), 7.41 (d, J = 8.0 Hz, 4H), 7.33 (d, J = 8.5 Hz, 4H), 4.29 (s, 
4H), 3.26-3.18 (m, 16H), 2.97 (d, J = 7.5 Hz, 4H), 2.23-2.13 (m, 8H), 2.08 (sept, J = 7.0 
Hz, 2H), 1.05 (d, J = 7.0 Hz, 12H). 13C NMR (125 MHz, D2O) δ ppm 142.5, 139.4, 130.6, 
130.5, 129.5, 128.9, 128.3, 54.9, 50.9, 44.8, 44.6, 43.9, 25.6, 22.6, 22.5, 19.0. LRMS 
calculated for C40H64N6 m/z 629.6 [M+H]+, Obsd. 629.5. 
 
CZ-01-155: N1,N1'-([1,1':2',1''-terphenyl]-3,3''-diylbis(methylene))bis(N3-(3-
(hexylamino)propyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 MHz, 
D2O) δ ppm 7.63-7.58 (m, 4H), 7.44-7.38 (m, 6H), 7.29 (d, J = 7.0 Hz, 2H), 4.24 (s, 4H), 
3.27-3.11 (m, 20H), 2.22-2.16 (m, 8H), 1.74 (pent, J = 7.0 Hz, 4H), 1.45-1.36 (m, 12H), 
0.93 (t, J = 6.0 Hz, 6H). 13C NMR (125 MHz, D2O) δ ppm 142.0, 139.4, 131.2, 131.1, 
130.6, 130.4, 128.9, 128.4, 128.1, 51.0, 47.9, 44.7, 44.6, 44.2, 43.8, 30.4, 25.4, 25.3, 22.6, 







(hexylamino)propyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 MHz, 
D2O) δ ppm 7.92-7.88 (m, 3H), 7.81-7.78 (m, 2H), 7.74-7.66 (m, 3H), 7.63-7.60 (m, 3H), 
4.45-4.43 (m, 6H), 3.37-3.06 (m, 30H), 2.31-2.06 (m, 12H), 1.76-1.71 (m, 6H), 1.44-1.34 
(m, 18H), 0.92 (t, J = 6.5 Hz, 9H). 13C NMR (125 MHz, D2O) δ ppm 142.5, 140.9, 140.2, 
140.0, 131.3, 131.2, 130.8, 130.7, 130.4, 130.0, 129.8, 129.4, 129.3, 128.5, 128.3, 127.6, 
127.1, 51.2, 51.2, 48.0, 47.9, 44.7, 44.7, 44.5, 44.3, 44.2, 44.2, 44.1, 30.4, 25.4, 25.3, 22.7, 








(isobutylamino)propyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 MHz, 
D2O) δ ppm 7.97 (s, 1H), 7.86 (d, J = 8.0 Hz, 4H), 7.77 (d, J = 7.5 Hz, 2H), 7.68-7.64 (m, 
5H), 4.38 (s, 4H), 3.31-3.17 (m, 16H), 2.96 (d, J = 7.5 Hz, 4H), 2.25-2.15 (m, 8H), 2.06 
(sept, J = 7.0 Hz, 2H), 1.03 (d, J = 6.5 Hz, 12H). 13C NMR (125 MHz, D2O) δ ppm 141.5, 
140.4, 130.5, 129.9, 129.8, 127.7, 126.6, 125.4, 54.9, 50.9, 44.8, 44.6, 43.9, 25.6, 22.6, 
22.5, 19.0. LRMS calculated for C40H64N6 m/z 629.5 [M+H]+, Obsd. 629.4. 
 
CZ-01-158: N1,N1'-(1,3-phenylenebis(methylene))bis(N3-(3-((2-
ethylhexyl)amino)propyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 
MHz, D2O) δ ppm 7.65 (s, 4H), 4.39 (s, 4H), 3.31-3.16 (m, 16H), 3.07 (d, J = 7.0 Hz, 4H), 





12H). 13C NMR (125 MHz, D2O) δ ppm 131.5, 131.3, 131.1, 130.2, 51.4, 50.9, 44.9, 44.7, 
44.7, 44.1, 36.2, 29.5, 27.6, 22.9, 22.6, 22.5, 22.1, 13.3, 9.4. LRMS calculated for C36H72N6 
m/z 589.6 [M+H]+, Obsd. 589.3. 
 
CZ-01-159: N1,N1'-([1,1'-biphenyl]-3,5-diylbis(methylene))bis(N3-(3-((4-(tert-
butyl)benzyl)amino)propyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 
MHz, D2O) δ ppm 7.92 (s, 2H), 7.80 (d, J = 7.5 Hz, 2H), 7.66-7.62 (m, 7H), 7.56 (t, J = 
7.0 Hz, 1H), 7.50 (d, J = 8.5 Hz, 4H), 4.45 (s, 4H), 4.30 (s, 4H), 3.33-3.15 (m, 16H), 2.77-
2.12 (m, 8H), 1.37 (m, 18H). 13C NMR (125 MHz, D2O) δ ppm 153.6, 142.6, 138.9, 132.2, 
130.0, 129.8, 129.6, 129.3, 128.5, 127.4, 127.1, 126.3, 50.8, 50.8, 44.6, 44.3, 43.6, 36.6, 







butyl)benzyl)amino)propyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 
MHz, D2O) δ ppm 7.63-7.61 (m, 8H), 7.49-7.48 (m, 4H), 4.35 (s, 4H), 4.28 (s, 4H), 3.28-
3.14 (m, 16H), 2.33-2.11 (m, 8H), 1.35 (s, 18H). 13C NMR (125 MHz, D2O) δ ppm 153.5, 
131.6, 131.2, 131.1, 129.8, 127.5, 126.3, 50.9, 50.7, 44.6, 44.1, 43.7, 34.1, 30.4, 22.6, 22.6. 
LRMS calculated for C42H68N6 m/z 657.6 [M+H]+, Obsd. 657.4. 
 
CZ-01-161: N1,N1'-([1,1':3',1''-terphenyl]-4,4''-diylbis(methylene))bis(N3-(3-((2-





MHz, D2O) δ ppm 8.06 (t, J = 1.5 Hz, 1H), 7.91 (d, J = 8.0 Hz, 4H), 7.84-7.82 (m, 2H), 
7.72 (t, J = 7.5 Hz, 1H), 7.68 (d, J = 8.0 Hz, 4H), 4.41 (s, 4H), 3.30 (t, J = 8.0 Hz, 4H), 
3.26-3.17 (m, 12H), 3.04 (d, J = 7.0 Hz, 4H), 2.25-2.18 (m, 8H), 1.76 (sept, J = 6.0 Hz, 
2H), 1.48-1.33 (m, 16H), 0.94-0.91 (m, 12H).  13C NMR (125 MHz, D2O) δ ppm 141.4, 
140.3, 130.5, 129.8, 129.7, 127.7, 126.6, 125.4, 51.3, 50.8, 44.8, 44.5, 43.8, 36.1, 29.4, 
27.5, 22.8, 22.5, 22.4, 22.1, 13.2, 9.3. LRMS calculated for C48H80N6 m/z 741.6 [M+H]+, 
Obsd. 371.3. [M+H]+/2. 
 
CZ-01-163: N1,N1'-(1,3-phenylenebis(methylene))bis(N3-(3-((2-
ethylhexyl)amino)propyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 
MHz, D2O) δ ppm 7.57 (s, 4H), 4.30 (s, 4H), 3.23-3.12 (m, 16H), 2.99 (d, J = 7.0 Hz, 4H), 
2.18-2.09 (m, 8H), 1.71(sept, J = 6.0 Hz, 2H), 1.41-1.25 (m, 16H), 0.86 (t, J = 7.5 Hz, 
12H). 13C NMR (125 MHz, D2O) δ ppm 131.4, 131.2, 131.0, 130.1, 51.3, 50.8, 44.8, 44.6, 
44.6, 44.0, 36.1, 29.4, 27.5, 22.8, 22.4, 22.1, 13.2, 9.3. LRMS calculated for C36H72N6 m/z 







ethylbutyl)amino)propyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 
MHz, D2O) δ ppm 7.97 (t, J = 1.5 Hz, 1H), 7.83 (d, J = 8.0 Hz, 4H), 7.75-7.73 (m, 2H), 
7.64 (t, J = 7.0 Hz, 1H), 7.60 (d, J = 8.0 Hz, 4H), 4.33 (s, 4H), 3.23 (t, J = 8.0 Hz, 4H), 
3.19-3.10 (m, 12H), 2.97 (d, J = 7.0 Hz, 4H), 2.19-2.08 (m, 8H), 1.64 (sept, J = 6.5 Hz, 
2H), 1.37 (p, J = 7.0 Hz, 8H), 0.85 (t, J = 7.5 Hz, 12H). 13C NMR (125 MHz, D2O) δ ppm 
141.5, 140.4, 130.4, 129.8, 129.7, 127.7, 126.6, 125.5, 50.9, 50.8, 44.8, 44.5, 43.8, 37.6, 









ethylbutyl)amino)propyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 
MHz, D2O) δ ppm 7.59 (s, 4H), 4.33 (s, 4H), 3.25-3.16 (m, 16H), 3.01 (d, J = 7.0 Hz, 4H), 
2.20-2.11 (m, 8H), 1.67 (sept, J = 7.0 Hz, 2H), 1.40 (p, J = 7.5 Hz, 8H), 0.87 (t, J = 7.0 Hz, 
12H). 13C NMR (125 MHz, D2O) δ ppm 131.6, 131.5, 131.3, 130.4, 51.2, 51.1, 45.1, 44.8, 
44.8, 44.3, 37.8, 22.9, 22.7, 22.6, 9.7. LRMS calculated for C32H64N6 m/z 533.5 [M+H]+, 
Obsd. 533.4 [M+H]+. 
 
CZ-01-166: N1,N1'-([1,1':3',1''-terphenyl]-4,4''-diylbis(methylene))bis(N3-(3-((2-
methylbutyl)amino)propyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 
MHz, D2O) δ ppm 7.86 (t, J = 1.5 Hz, 1H), 7.78 (d, J = 8.5 Hz, 4H), 7.71-7.67 (m, 2H), 
7.63-7.58 (m, 6H), 4.36 (s, 4H), 3.31-3.18 (m, 16H), 3.07 (dd, J = 6.0, 12 Hz, 2H), 2.93 
(dd, J = 8.5, 12.5 Hz, 2H), 2.26-2.17 (m, 8H), 1.89-1.82 (m, 2H), 1.52-1.44 (m, 2H), 1.34-
1.25 (m, 2H), 1.03 (d, J = 6.5 Hz, 6H), 0.95 (t, J = 8.0 Hz, 6H). 13C NMR (125 MHz, D2O) 
δ ppm 141.4, 140.3, 130.5, 129.8, 129.7, 127.7, 126.6, 125.4, 53.5, 50.9, 44.8, 44.6, 43.9, 
31.8, 26.2, 22.6, 22.5, 16.0, 10.1. IR (neat): 3342 (bs), 2963, 2766, 1457 (all s) cm-1. mp 








methylbutyl)amino)propyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 
MHz, D2O) δ ppm 7.66 (s, 4H), 4.39 (s, 4H), 3.32-3.21 (m, 16H), 3.10 (dd, J = 6.0, 12.0 
Hz, 2H) 2.96 (dd, J = 8.0, 12.0 Hz, 2H), 2.27-2.18 (m, 8H), 1.88 (oct, J = 7.0 Hz, 2H), 1.50 
(sept, J = 8.0 Hz, 2H) 1.31 (sept, J = 7.5 Hz, 2H), 1.05 (d, J = 7.0 Hz, 6H), 0.96 (t, J = 7.5 
Hz, 6H). 13C NMR (125 MHz, D2O) δ ppm 131.5, 131.3, 131.1, 130.2, 53.5, 50.9, 44.9, 
44.7, 44.7, 44.1, 31.8, 26.2, 22.6, 22.5, 16.0, 10.1. LRMS calculated for C30H60N6 m/z 







(isopentylamino)propyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 
MHz, D2O) δ ppm 7.97 (s, 2H), 7.91-7.88 (m, 2H), 7.72-7.69 (m, 2H), 7.64-7.62 (m, 1H), 
4.48 (s, 4H), 4.45 (s, 2H), 3.37-3.20 (m, 24H), 3.15 (t, J = 8.5 Hz, 8H), 2.30-2.17 (m, 14H), 
1.72 (sept, J = 6.5 Hz, 3H),  1.66-1.61 (m, 7H), 0.98 (d, J = 6.5 Hz, 18H). 13C NMR (125 
MHz, D2O) δ ppm 141.7, 139.9, 132.3, 131.4, 130.5, 130.1, 129.8, 129.6, 128.6, 128.5, 
51.2, 50.9, 46.4, 44.7, 44.3, 34.2, 25.2, 22.7, 22.7, 21.4. IR (neat): 3390 (bs), 2951, 2742, 
1450 (all s) cm-1. mp decomposition (256-257 °C).  LRMS calculated for C48H91N9 m/z 
794.7 [M+H]+, Obsd. 397.8 [M+H]+/2. 
 
CZ-01-169: N1,N1',N1''-([1,1'-biphenyl]-3,3',5-triyltris(methylene))tris(N3-(3-((2-
methylbutyl)amino)propyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 
MHz, D2O) δ ppm 7.97 (s, 2H), 7.91-7.87 (m, 2H), 7.71-7.69 (m, 2H), 7.63-7.62 (m, 1H), 





= 7.5, 12.0 Hz, 3H), 2.30-2.18 (m, 12H), 1.87 (oct, J = 6.5 Hz, 3H), 1.49 (sept, J = 6.0 Hz, 
3H), 1.32 (sept, J = 6.5 Hz, 3H), 1.04 (d, J = 7.0 Hz, 9H), 0.95 (t, J = 7.5 Hz, 9H). 13C 
NMR (125 MHz, D2O) δ ppm 141.7, 139.8, 132.3, 131.3, 130.4, 130.1, 129.8, 129.6, 128.6, 
128.4, 53.5, 51.2, 50.9, 44.9, 44.7, 44.3, 44.1, 31.8, 26.2, 22.7, 22.5, 16.0, 10.1. LRMS 
calculated for C48H91N9 m/z 794.7 [M+H]+, Obsd. 397.8 [M+H]+/2. 
 
CZ-01-170: N1,N1',N1''-([1,1'-biphenyl]-3,3',5-triyltris(methylene))tris(N3-(3-((2-
ethylbutyl)amino)propyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 
MHz, D2O) δ ppm 7.97 (s, 2H), 7.91-7.88 (m, 2H), 7.72-7.69 (m, 2H), 7.64-7.62 (m, 1H), 
4.48 (s, 4H), 4.45 (s, 2H), 3.36-3.21 (m, 24H), 3.07 (d, J = 7.0 Hz, 6H), 2.30-2.18 (m, 12H), 
1.73 (p, J = 6.5 Hz, 3H), 1.46 (p, J = 7.0 Hz, 12H), 0.94 (t, J = 7.5 Hz, 18H). 13C NMR 
(125 MHz, D2O) δ ppm 141.7, 139.9, 132.3, 131.4, 130.4, 130.1, 129.8, 129.6, 128.6, 
128.4, 51.0, 44.9, 44.7, 44.7, 44.3, 44.1, 37.6, 22.7, 22.5, 22.5, 9.5. IR (neat): 3457 (bs), 





m/z 836.8 [M+H]+, Obsd. 418.8 [M+H]+/2. 
 
CZ-01-171: N1,N1',N1''-(benzene-1,3,5-triyltris(methylene))tris(N3-(3-
(isobutylamino)propyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 MHz, 
D2O) δ ppm 7.77 (s, 3H), 4.44 (s, 6H), 3.34-3.20 (m, 24H), 2.99 (d, J = 7.5 Hz, 6H), 2.28-
2.18 (m, 12H), 2.08 (sept, J = 7.0 Hz, 3H), 1.05 (d, J = 6.5 Hz, 18H). 13C NMR (125 MHz, 
D2O) δ ppm 132.6, 54.9, 50.5, 44.8, 44.7, 44.7, 44.4, 25.6, 22.7, 22.5, 19.1. LRMS 








methylpentyl)amino)propyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 
MHz, D2O) δ ppm 7.90-7.52 (m, 8H), 4.38 (s, 4H), 4.36 (s, 2H), 3.27-3.06 (m, 24H), 3.02 
(t, J = 7.5 Hz, 6H), 2.20-2.06 (m, 12H), 1.66 (t, J = 7.5 Hz, 6H), 1.55 (sept, J = 6.5 Hz, 
3H), 1.22 (q, J = 8.5 Hz, 6H), 1.15 (tt, J = 1.0, 7.0 Hz, 6H),  0.85 (d, J = 6.5 Hz, 18H). 
 
CZ-01-174: N1,N1-((pyrimidine-2,4-diylbis(4,1-phenylene))bis(methylene))bis(N3-(3-
(isopentylamino)propyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 
MHz, D2O) δ ppm 8.91 (d, J = 5.5 Hz, 1H), 8.36 (d, J = 8.0 Hz, 2H), 8.27 (d, J = 7.5 Hz, 
2H), 7.96 (d, J = 5.5 Hz, 1H), 7.72 (d, J = 7.0 Hz, 4H), 4.43 (s, 2H), 4.42 (s, 2H), 3.35-3.20 
(m, 16H), 3.14 (t, J = 8.0 Hz, 4H), 2.28-2.16 (m, 8H), 1.72 (sept, J = 6.5 Hz, 2H), 1.65-
1.60 (m, 4H), 0.97 (d, J = 6.5 Hz, 12H). 13C NMR (125 MHz, D2O) δ ppm 164.5, 163.4, 
157.7, 137.6, 136.9, 133.8, 133.4, 130.5, 130.4, 129.0, 128.4, 116.4, 50.8, 50.8, 46.4, 44.7, 
44.6, 44.2, 44.2, 44.1, 34.1, 25.2, 22.6, 21.3. LRMS calculated for C40H66N8 m/z 659.5 







(isobutylamino)propyl)butane-1,4-diamine) , hydrochloride salt: 1H NMR (500 MHz, 
D2O) δ ppm 7.89 (s, 2H), 7.84-7.80 (m, 2H), 7.65-7.55 (m, 3H), 4.38 (s, 4H), 4.36 (s, 2H), 
3.22-3.14 (m, 24H), 2.93 (d, J = 7.5 Hz, 6H), 2.16-2.13 (m, 6H), 2.02 (sept, J = 6.5 Hz, 
3H), 1.89-1.76 (m, 12H), 0.99 (d, J = 7.0 Hz, 18H). LRMS calculated for C48H91N9 m/z 
794.7 [M+H]+, Obsd. 397.9 [M+H]+/2.  
 
CZ-01-176: N1,N1'-((pyrimidine-4,6-diylbis(4,1-phenylene))bis(methylene))bis(N3-(3-
(isobutylamino)propyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 MHz, 





4.39 (s, 4H), 3.28 (t, J = 8.5 Hz, 4H), 3.23-3.15 (m, 12H), 2.93 (d, J = 7.0 Hz, 4H), 2.23-
2.12 (m, 8H), 2.02 (sept, J = 7.0 Hz, 2H), 1.00 (d, J = 6.5 Hz, 12H). 13C NMR (125 MHz, 
D2O) δ ppm 164.6, 157.6, 136.9, 133.7, 130.6, 128.4, 115.6, 54.8, 50.7, 44.7, 44.6, 44.6, 





hydrochloride salt: 1H NMR (500 MHz, D2O) δ ppm 7.78 (d, J = 7.5 Hz, 4H), 7.74 (d, 
2H), 7.71 (s, 1H), 7.60 (d, J = 8.0 Hz, 4H), 4.34 (s, 4H), 3.28-3.14 (m, 16H), 2.93 (d, J = 
7.0 Hz, 4H), 2.22-2.12 (m, 8H), 2.02 (sept, J = 7.0 Hz, 2H), 1.39 (s, 9H), 1.00 (d, J = 6.5 
Hz, 12H). 13C NMR (125 MHz, D2O) δ ppm 153.4, 141.8, 140.5, 130.4, 129.7, 127.8, 
123.8, 122.9, 54.9, 50.9, 44.7, 44.6, 43.9, 34.5, 30.5, 25.5, 22.6, 22.5, 19.0. LRMS 









hydrochloride salt: 1H NMR (500 MHz, D2O) δ ppm 7.65 (d, J = 7.5 Hz, 4H), 7.59 (s, 
2H), 7.57-7.52 (m, 5H), 4.27 (s, 4H), 3.22-3.09 (m, 16H), 2.98 (dd, J = 6.0, 12.0 Hz, 2H), 
2.84 (dd, J = 8.5, 12.0 Hz, 2H), 2.18-2.09 (m, 8H), 1.77 (hex, J = 6.0 Hz, 2H), 1.39 (sept, 
J = 7.0 Hz, 2H), 1.27 (s, 9H), 1.23-1.19 (m, 2H), 0.94 (d, J = 6.0 Hz, 6H), 0.86 (t, J = 7.5 
Hz, 6H). 13C NMR (125 MHz, D2O) δ ppm 153.2, 141.7, 140.2, 130.4, 129.6, 127.7, 123.6, 
122.8, 53.4, 50.9, 48.8, 44.8, 44.6, 43.9, 34.4, 31.7, 30.5, 26.2, 22.6, 22.5, 15.9, 10.0. 








hydrochloride salt: 1H NMR (500 MHz, D2O) δ ppm 7.78-7.69 (m, 7H), 7.61 (bs, 4H), 
4.38 (s, 4H), 3.26-3.20 (m, 16H), 3.01 (s, 4H), 2.17 (bs, 8H), 1.67 (bs, 2H), 1.38 (bs, 17H), 
0.88 (s, 12H). 13C NMR (125 MHz, D2O) δ ppm 153.4, 141.8, 140.4, 130.4, 129.7, 127.8, 
123.8, 122.9, 50.9, 50.9, 44.9, 44.6, 43.9, 37.6, 34.4, 30.5, 22.6, 22.4, 22.4, 9.4. IR (neat): 
3334 (bs), 2963, 2766, 1457 (all s) cm-1. mp decomposition (180-184 °C). LRMS 
calculated for C48H80N6 m/z 741.6 [M+H]+, Obsd. 370.7 [M+H]+/2. 
 
CZ-01-180:  N1,N1'-([1,1':3',1''-terphenyl]-4,4''-diylbis(methylene))bis(N3-(3-
(hexylamino)propyl)propane-1,3-diamine), hydrochloride salt: 1H NMR (500 MHz, 
D2O) δ ppm 8.62-8.55 (m, 1H), 8.50 (d, J = 8.5 Hz, 4H), 8.39 (d, J = 7.5 Hz, 2H), 8.34-
8.29 (m, 5H), 4.87 (s, 4H), 3.77 (t, J = 7.5 Hz, 4H), 3.72-3.64 (m, 12H), 3.57 (t, J = 7.5 Hz, 
4H), 2.75-2.62 (m, 8H), 2.28-2.22 (m, 4H), 1.99-1.88 (m, 12H), 1.53 (t, J = 6.5 Hz, 6H). 









hydrochloride salt: 1H NMR (500 MHz, D2O) δ ppm 7.86-7.82 (m, 6H), 7.63 (t, J = 7.5 
Hz, 2H), 7.53 (d, J = 7.5 Hz, 2H), 4.37 (s, 4H), 3.26-3.05 (m, 20H), 2.20-2.07 (m, 8H), 
1.65 (sept, J = 6.5 Hz, 2H), 1.57-1.53 (m, 4H), 1.43 (s, 9H), 0.90 (d, J = 7.0 Hz, 12H). 13C 
NMR (125 MHz, D2O) δ ppm 153.6, 141.5, 140.8, 131.1, 129.8, 128.9, 128.6, 128.5, 123.8, 
123.1, 51.2, 46.3, 44.5, 44.1, 43.9, 34.5, 34.1, 30.5, 25.1, 22.6, 22.6, 21.2. IR (neat): 3367 
(bs), 2957, 1457 (all s) cm-1. mp decomposition (218-220 °C). LRMS calculated for 









4H), 4.32 (s, 4H), 3.24-3.13 (m, 16H), 2.99 (d, J = 6.5 Hz, 4H), 2.18-2.14 (m, 8H), 1.66 
(pent, J = 5.5 Hz, 2H), 1.38 (s, 17H), 0.87 (t, J = 6.5 Hz, 12H). 13C NMR (125 MHz, D2O) 
δ ppm 153.4, 141.4, 140.5, 131.0, 129.8, 128.9, 128.5, 128.3, 123.6, 122.9, 51.2, 50.9, 44.8, 
44.6, 43.9, 37.6, 34.5, 30.5, 22.6, 22.4, 22.4, 9.4. LRMS calculated for C48H80N6 m/z 741.6 




hydrochloride salt: 1H NMR (500 MHz, D2O) δ ppm 7.75 (s, 2H), 7.71-7.67 (m, 4H), 
7.63 (s, 1H), 7.54 (t, J = 8.0 Hz, 2H), 7.46 (d, J = 6.5 Hz, 2H), 4.28 (s, 4H), 3.23-3.10 (m, 
16H), 2.89 (d, J = 7.0 Hz, 4H), 2.19-2.08 (m, 8H), 1.98 (sept, J = 6.5 Hz, 2H), 1.34 (s, 9H), 
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